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The doctor of the future will give no medicine, but will interest her or his 
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prevention of disease. 
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US inventor (1847 - 1931) 
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1 Introduction 
Colorectal cancer is the second most prevalent cancer form in both men and women in the 
Europe. In 2002, alimentary cancer (oesophagus, stomach, intestines) made up 26% of the 
annual incident cases of cancer amongst males in Europe, whereby about half of those were 
cancers of the colon and rectum (Eurostat 2002). Epidemiological evidence accumulating 
over the last decades indicates that besides a genetic disposition, diet plays a strong epigenetic 
role in the genesis of cancer. It is generally assumed that diet is causal for up to 80% of 
colorectal cancer (Bingham 2000). With the prospect of an approximated 50% rise in global 
cancer incidence over the first two decades of the 21st century, the World Health Organisation 
(WHO) has emphasized the need for an improvement in nutrition. Indeed there is increasing 
public health awareness with respect to nutrition. Today, living healthily is associated with 
less consumption of animal fats and red (processed) meat, moderate or no consumption of 
alcohol coupled with increased physical activity, and frequent intake of fruits, vegetables and 
whole grains (Bingham 1999; Johnson 2004). This idealogy partly stems from scientific 
epidemiological evidence supportive of an inverse correlation between the consumption of 
fruits and vegetables and the development cancer. Besides fibre and essential micro-nutrients 
like ascobate, folate, and tocopherols, the anti-carcinogenic properties of fruits and vegetables 
are generally thought to be rooted in the bioactivity of secondary plant components like 
flavonoids (Johnson 2004; Rice-Evans and Miller 1996; Rice-Evans 1995).  
Along with the increased public health awareness, has also come a burgeoning and lucrative 
dietary supplement industry, which markets products based on polyphenols and other 
potentially healthy compounds, sometimes with questionable promises of better health and 
increased longevity. These claims are based on accumulating in vitro and in vivo evidence 
indicating that flavonoids and polyphenols in fruits and vegetables can hinder proliferation, 
induce apoptosis of cancerous cells (Kern et al. 2005; Kumar et al. 2007; Thangapazham et al. 
2007), act as antioxidants (Justino et al. 2006; Rice-Evans 1995) and influence cell signalling 
pathways (Marko et al. 2004; Joseph et al. 2007; Granado-Serrano et al. 2007), all of which 
are potential mechanisms proposed for their anti-carcinogenic activity. However, not only is 
the vast variety of supplements worrisome, but also problematic, is their easy accessibilty 
(just a click away on the internet) and the amount that can potentially be consumed. Such 
supplements are usually offered in pharmaceutical form (tablets, capsules, powder, 
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concentrates) containing concentrations well beyond what is normally comsumable from the 
diet. For example, quercetin’s recommended intake is about 1g daily. However, estimates 
portend a possible daily increase of upto 1000 fold of the daily intake of quercetin (Hertog et 
al. 1995). Mindful of the concept of dose coined from the words of swiss scientist Paracelsus 
“What is it that is not poison? All things are poison and nothing is without poison. The right 
dose differentiates a poison and a remedy.” (“Alle Dinge sind Gift und nichts ist ohn’ Gift; 
allein die Dosis macht, dass ein Ding kein Gift ist”), it is thus conceivable that such high 
concentrations may not only reverse the acclaimed positive effects of flavonoids and 
polyphenols but also have negative effects thereby representing a health risk. The fact that 
direct evidence of the beneficial effects of flavonoids and polyphenols remains wanting, if not 
entirely lacking, coupled with the afore-mentioned marketing trend demands for a thorough 
examination of the possible adverse effects that may arise from increased consumption of 
flavonoids and polyphenols.  
The genesis and progression of cancer is usually accompanied by dysfunctional signalling of 
certain cell signalling pathways. Typical for colon carcinogenesis is the malfunctioning of the 
Wnt-signalling pathway, a pathway, which is crucial for the growth and development of 
normal colonocytes. The dysfunction of the Wnt-signalling pathway occurs in a manner that 
culminates in a proliferation stimulus of colonocytes, while differentiation is increasingly 
minimized. Hence, tumourigenesis is promoted. Interupting the proliferation stumuli by 
intervening in the actions of components of the Wnt-signalling pathway is one potential 
mechanism for the anti-carcinogenic action of flavonoids and polyphenols (Pahlke et al. 2006; 
Dashwood et al. 2002; Park et al. 2005). However, as previously hinted, the indulgence in the 
consumption of flavonoids and polyphenols based supplements could instead lead to a 
proliferation stimulus and provoke or promote carcinogenesis in normal cells or pre-cancerous 
cells respectively.  
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2 Theory 
2.1 Colon, Wnt-signalling and Colorectal Cancer 
2.1.1 Colon 
The intestinal tract consists of the small intestine (duodenum, jejunum and ileum) and the 
large intestine (colon, rectum). A single layer of epithelium cells lines the surface of the small 
and large intestines. The epithelium of the small intestine is arranged in two functional and 
morphological distinct compartments: flask-shaped submucosal invaginations known as 
crypts of Lieberkühn, and finger-shaped luminal protrusions termed villi. Differentiated cells 
(enterocytes, enteroendocrine cells and goblet cells) occupy the villi (figure 1). A fourth 
differentiated type, the Paneth cell (Porter 2002; Reya and Clevers 2005), resides at the 
bottom of the crypts and secretes antimicrobial agents. The remainder of the crypts constitutes 
the stem/progenitor compartment (figure 1). While the cells of the crypts that form the 
proliferative unit are monoclonal, the differentiated cells of the villi originate from different 
crypts and are polyclonal.  
 
 
 
 
Figure 1: Architecture of the small intestine showing the 
putative stem cells (blue) directly placed above the paneth cells 
(yellow), which reside at the bottom of the crypt. 
Differentiated cells (green) consisting of enterocytes, goblet 
cells, and enteroendocrine cells populate the villi (Reya and 
Clevers 2005). 
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The colonic epithelium has larger crypts than the small intestines and there are no villi 
present. Instead the mucosa of the colon has a flat surface epithelium (figure 2). Proliferative 
stem and precursor cells occupy the bottom two-thirds of the crypts, whereas differentiated 
cells constitute the surface epithelium and top third of the crypts.  
 
 
Figure 2: Tissue anatomy of the adult large intestine. Putative 
stem cells (dark blue) populate the bottom of the crypt. 
Proliferating progenitor cells (light blue) occupy two thirds of the 
crypt. Differentiated cells make up the rest one third and surface 
of the epithelium, which in contrast to the small intestine is a flat 
surface (Reya and Clevers 2005). 
 
The life cycle of the cells in the small intestine starts from the multipotent stem cells located 
in the crypt, which divide and morph in to the fast dividing transit-amplifying cells (TA). The 
TA cells (progenitor cells), with a division rate of approx. 150 cells every 12h, expand into 
non-proliferating daughter cells, which accumulate in the medium third (figure 1) of the crypt 
to subsequently differentiate into the four cell lineages; enterocytes (90% of villus-associated 
cells) (Pinto and Clevers 2005), enteroendocrine cells (secrete hormones like serotonin) 
(Hocker and Wiedenmann 1998), paneth cells (secrete antibacterial peptides) (Porter 2002), 
and the goblet cells (mucous secreting) (Pinto and Clevers 2005). Differentiation of the cells 
is completed as the cells (enterocytes, goblet cells, enteroendocrine cells) migrate, upwards to 
the tip of the villi and in the case of the paneth cells, toward the base of the crypt, where they 
reside for about 20 days (Garabedian et al. 1997; Bry et al. 1994). The epithelium of the small 
intestine is renewed in man every 5 days (Wright and Irwin 1982). This corresponds to the 
time it takes for a differentiated cell to reach the tip of the villi where it dies and is exfoliated 
into the lumen (about 1400 dead cells on a daily basis) (Potten and Loeffler 1990). The 
canonical Wnt-signalling pathway controls the homoeostasis of the intestinal epithelium. In 
the next section, the crux of the pathway (which is most crucial for colon cancer initiation) is 
presented. 
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2.1.2 Wnt-signalling 
The Wnt-signalling pathways encompass three different molecular pathways, namely; the 
Wnt/β-catenin pathway also referred to as canonical Wnt-pathway, the Wnt/Ca2+ pathway and 
lastly, the Wnt/JNK pathway. The last two pathways both make up the non-canonical Wnt-
pathway (Janssens et al. 2006; Kuhl et al. 2000). Signal transduction via the Wnt-pathways is 
initiated when a Wnt ligand protein engages a cognate frizzled (Fz) trans-membrane receptor. 
Which of the three pathways is subsequently activated depends upon which Wnt ligand and 
Fz receptor is present and interacts. Twenty different Wnt ligands (Reya and Clevers 2005), 
classified in two functional groups, have been identified in mammals. The transforming 
group, also called the proto-oncogenic group or Wnt1 class, consists of Wnt1, -3A, -8, -8B 
and act via the Wnt-β-catenin pathway, whereas the Wnt proteins of the second group 
(Wnt5A class) e.g., Wnt4, -5A, and -11) stimulate transduction through the non-canonical 
pathways and act also to antagonize the canonical pathway (Du 1995; Kuhl 2002; Torres 
1996.) 
In the following section, only the Wnt/β-catenin pathway will be discussed in detail because 
of its immediate relevance to cancer.  
 
2.1.2.1 Canonical Wnt-signalling Pathway in normal Intestine Cells 
The canonical Wnt pathway regulates fundamental aspects of maintenance of intestinal and 
colonic cells. It is intricate in the regulation of processes like cell fate, proliferation, 
differentiation and apoptosis by controlling the intra-cellular levels of free cytoplasmic β-
catenin (Cadigan and Nusse 1997; Malbon 2005).  
At the bottom of the crypt, the Wnt proteins promote the proliferation of progenitor cells by 
accumulating β-catenin. The presence of an appropriate Wnt protein stimuli, causes the Fz 
receptors binding to the obligate low density lipoproteins receptor protein (LRP5/6)   5/6 co-
receptors forming a trimeric complex (Tamai et al. 2000; Pinson et al. 2000). As a result 
dishevelled (Dvl) becomes phosphorylated. Phosphorylated Dvl associates with the  
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Figure 3: The Wnt-signalling pathway. APC, adenomatous polyposis coli; Dvl, dishevelled; GSK-3, 
glycogen synthase kinase-3; PKA, protein kinase A; PKB, protein kinase B; PI3K, 
phosphatidylinositol 3-kinase; Tcf/Lef, T-cell factor-lymphoid enhancer factor. 
 
adenomatous polyposis coli (APC)/axin protein complex, where it acts in concert with Frat to 
interupt the phosphorylation of β-catenin by casein kinase Iα (CK Iα) and glycogen synthase 
kinase-3 (GSK-3) from (figure 3). The result is the dissociation of the APC complex and the 
subsequent breakdown of axin. Due to the failure of the phosphorylation of β-catenin, it 
escapes degradation because it is not recognized by β-transducin repeat containing protein (β-
Trcp), a component of an E3 ubiquitin ligase complex that initiates the destruction of 
phosphorylated β-catenin. Consequentially, β-catenin accumulates in the cytoplasm from 
where it translocates in to the nucleus and engages T-cell factor-4 (TCF-4) DNA binding 
protein and co-activators, like CREB binding protein (CBP) and the chromatin-remodelling 
protein Brg-1 to induce the expression of pro-proliferation steering proteins like COX-1, c-
myc, cyclin D1 and the tyrosine kinase guidance receptors ephrinB2 and ephrinB3 (Hecht A 
2000; Hsu et al. 1998; van Noort and Clevers 2002).  
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Halfway up the crypt, Wnt protein actions in the progenitor cells are repressed so that free β-
catenin is actively targeted for degradation. Various secreted factors, such as cerberus and 
frizzled-related proteins, bind to Wnt ligands and block their interaction with Fz. Dickkopf-1 
(Dkk-1) secreted protein potently and specifically antagonizes canonical Wnt action by 
blocking access to the LRP5/6) co-receptors. Dkk-1 can induce LRP5/6 internalization and its 
subsequent removal from the plasma membrane, by cooperating with kremen 1/2 
transmembrane proteins (Kawano and Kypta 2003). In the absence of Wnt signal stimulus, β-
catenin is sequentially phosphorylated within the APC multi-protein complex composed of 
APC, axin, GSK-3, CK-Iα and β-catenin (figure 3). Within the stabilized APC-axin complex, 
β-catenin phosphorylation is mediated by CK Iα and GSK-3 in this order. The 
phosphorylation of β-catenin permits its recognition by β-Trcp, and subsequent proteasomal 
degradation. The intra-nuclear β-catenin levels are consequently reduced so that Tcf-β-catenin 
complex formation is held below the threshold required to stimulate Wnt-target gene 
expression. Concomitantly, proteins of the Groucho family interact and bind Tcf/lef 
transcriptional factors to repress the expression Wnt target genes. At this stage in the 
development/migration of the progenitor cells (Halfway up the crypt), differentiation of the 
cells into the various functional cell types commences (Hurlstone and Clevers 2002; Cavallo 
et al. 1998; Waltzer and Bienz 1999; Brantjes et al. 2001). 
The Wnt signalling pathway is potentially influenced by crosstalk from other signalling 
pathways. Protein kinase A (PKA) of the cAMP signalling pathway and protein kinase B 
(PKB), of the insulin phosphatidylinositol-3-kinase pathway are able to phosphorylate GSK-3 
(figure 3) and cause its inactivation (Du 1995; Jensen et al. 2007; Liu et al. 2006). 
 
2.1.2.2 Canonical Wnt-signalling in Colorectal Cancer 
There is strong evidence that dysregulation of Wnt-signalling is crucial for cell transformation 
in different human diseases including cancer. Germline or somatic mutations of genes 
encoding components of the Wnt-signalling pathway like APC or axin, or site specific 
substitutions in the N-terminus of β-catenin, are mutations which have been found to be 
prominent in some cancer types, including colorectal cancer (Liu et al. 2000; Fukushima 
2001; Kim et al. 2003b; Ilyas et al. 1997; Smith et al. 1993). APC mutations (most of which 
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are truncation mutations) with approximately 85% occurrence, are the most frequent form of 
mutation in sporadic colorectal cancer (Waterman 2004). 10% of sporadic tumours, which do 
not harbor an APC aberration, have a mutation in the β-catenin gene (CTNNB1) (Smith et al. 
1993). Over 70 β-catenin mutations have been reported in colorectal cancers, most of which 
are mis-sense mutations (Kim et al. 2003a). These mutations (APC, β-catenin, axin) preclude 
the degradation of β-catenin (described in chapter 2.1.2.1). The result is a shift in the 
homeostasis of β-catenin towards stabilization, leading to surge in cytoplasmic and nuclear 
levels of free β-catenin (Maruyama 2000; Hao 1997) and the constitutive expression of Wnt 
target genes. As a result, the termination of proliferation and the onset of differentiation of the 
progenitor cells into functional progeny is prevented (figure 4, right) a process, which 
normally occurs half-way up the crypt axis is prevented (figure 4, left).  
Figure 4: Schematic depiction of a colonic crypt, 
the left side is wild type and the right side shows 
the diseased condition. Left side: Wnt signal at the 
bottom of the crypt blocks β-catenin degradation, 
thereby activating target genes that maintain the 
cells in a proliferating state (green). Halfway up 
the crypts, β-catenin is downregulated and the 
progenitor crypt cells start to differentiate (blue). 
Right side: Mutations of APC and β-catenin 
causes the cells of the crypt to maintain their 
progenitor state and continuously proliferate (red) 
(R. Städeli 2006).  
In today’s proposed multi-step genetic model for colon carcinogenesis (figure 5) (Fearon and 
Vogelstein 1990; Vogelstein and Kinzler 1993), it is hypothesized that, the loss of 
heterozygosity at the APC loci (leading to inactivating mutations of both APC alleles) as well 
as mutations of β-catenin and axin are events that happen early in the adenoma-carcinoma 
sequence and are prerequisited to initiate transformation of normal epithelium cells into the 
aberrant crypts foci. Subsequent progression towards malignancy in colon carcinogenesis is 
accompanied by genomic instability (which leads to the formation of an early adenoma) and 
sequential mutations in K-ras (formation of an intermediate adenoma), SMAD4, (formation of 
the late adenoma), p53 (transition to carcinoma), as well as other unknown genes (figure 5). 
Several studies have led to the conclusion that tumour progression in the intestine is promoted 
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by the selection of specific genetic and epigenetic alterations that accumulate in strict order. 
Though mutation events are generally stochastic, the order in which they accumulate is non-
random and certain mutations are needed to confer a selective advantage.  
Normal 
Epithelium
Metastasis
Abberrant
crypts foci
Early
adenoma
Intermediate
adenoma
Late
adenoma Carcinoma
First hit; germline inactivating
mutation in one APC allele
Germline mutation (FAB)
First hit; somatic inactivating
mutation in one APC allele
somatic mutation (FAB)
Second hit; 
Inactivation of second APC allele
somatic mutation needed for tumour intiation
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Beta-catenin
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Other alterations
p53Smad4K-ras
genomic
instability
 
Figure 5:  Genetic model of colorectal carcinogenesis adapted from (Fearon and Vogelstein 1990). FAP, 
familial adenomatous polyposis (Vogelstein and Kinzler 1993). 
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2.1.3 Key Components of the Wnt-signalling Pathway involved in 
Cancer  
2.1.3.1 Adenomatous Polyposis Coli (APC) 
The APC gene is located on chromosome 5q21 and encodes for a protein with a molecular 
weight of 310kDa. The APC protein (figure 5) comprises 2843 amino acids and encompasses 
numerous domains like conserved regions, such as the Armadillo repeats, and regions that 
interact with at least 10 protein partners, including axin, and β-catenin (Fodde et al. 2001). 
The N-terminus carries an oligomerisation domain followed by the Armadillo repeats. The 
arm repeats are highly conserved and can react with several proteins like ASEF (APC 
stimulated guanine nucleotide exchange factor), KAPS (Kinesin superfamily-associated 
protein 3A) and PPA2 (protein phosphatase 2). The central region of APC contains three 15-
amino acid (aa) repeats and seven 20-aa repeats which extends into the C terminus. Both 15 
and 20 aa repeats can bind β-catenin. Within the 20-aa repeat region, there are three SAMP 
motifs (Ser-Ala-Met-Pro), which mediate the binding of APC to axin. 
Figure 6: Structure of the APC gene, showing regions encoding binding sites for components of the Wnt 
pathway. aa, amino acid; SAMP, Ser-Ala-Met-Pro; P, phosphorylation site (Bright-Thomas 
and Harvest 2003) 
The best-characterized function of APC is its role in the negative regulation of β-catenin in 
the Wnt-signalling pathway. APC is also involved in processes that regulate apoptosis, cell 
adhesion and migration, cell cycle and organisation of the cytoskeleton (Giles et al. 2003; 
Buda and Pignatelli 2002). 
Mutations in the APC gene were initially identified as the basis for familial adenomatous 
polyposis coli (FAP), a heritable predisposition to colorectal cancer. Individuals with FAP 
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invariably develop hundreds to thousands of polyps in the colon at a very early age, which can 
grow in to cancer if they are not surgically removed (Bright-Thomas and Hargest 2003). 
Mutations in APC have also been identified in the majority of sporadic colorectal tumours 
where they appear early in the progression to cancer. Over 300 different APC germline 
mutations in FAP kindred have been identified whereby the most severe and common occur 
between codons 1055 and 1039 (Bright-Thomas and Hargest 2003). In sporadic cancer APC 
mutations are common between codons 1286 and 1513 (Bright-Thomas and Hargest 2003). 
These mutations result in a protein that is truncated at the C-terminus, eliminating five or 
more of the 20-aa repeats and the SAMP motifs necessary for β-catenin binding. As at least 
three of the 20-aa repeats are needed in order to downregulate β-catenin, these mutations 
ensure that β-catenin is able to accumulate and cause expression of proliferation stimulating 
genes. The 15 aa repeats, which are not required for the negative regulation of β-catenin are 
mostly retained in cancers. 
 
2.1.3.2 Glycogen Synthase Kinase 3 
Mammalian cells have three closely related forms of the serine/threonine kinase, GSK-3, 
namely, GSK-3α (51kDa), GSK-3β (47kDa), and the minor splice variant GSK-3β2, encoded 
by 2 separate genes that are located on chromosomes 19q13.2 and 3q13.3 respectively. The 
GSK-3 isoforms display 84% overall identity (98% within their catalytic domains) with the 
main difference being an extra glycine rich stretch (63 residues) in the N-terminal domain of 
GSK-3α (figure 7) (Woodgett and Cohen 1984; Woodgett 1990, 1991). The splicing variant 
of GSK-3β contains a 13-amino-acid insertion in the catalytic domain (Meijer et al. 2004).  
Kinase Domain
Kinase Domain
Y 216 (facultative)
Y 279 (facultative)S 21 (inhibitory)
S 9 (inhibitory)
C
CN
NGSK-3α
GSK-3β
1 483
4201
51kDa
47kDa
 
Figure 7:  Scheme of the α- and β-isoforms of glycogen synthase kinase-3 indicating the serine inhibitory 
sites and tyrosine activating sites (Woodgett and Cohen 1984). 
Theory/Wnt-signalling  GSK-3 
 
 ▓ PAGE 12 ▓ 
GSK-3 belongs to the superfamily of MAP-kinases (mitogen-activated protein) (Hanks and 
Hunter 1995). Like the other members of the MAP kinase family, GSK-3 has a small N-
terminal lobe that consists mostly of β-sheets and a large C-terminal lobe, which is formed 
essentially of α-helices (Noble et al. 2004). The ATP-binding pocket is located between the 
two lobes. Arg96, Arg180 and Lys205 on the catalytic site form a pocket into which the 
phosphate group of a primed substrate binds (Lee and Kim 2007). 
Under basal conditions, GSK-3 is active. The mechanisms by which GSK-3 activity is 
regulated in the cell include post translational reversible phosphorylation of GSK-3, binding 
to scaffold proteins, as well as the sub-cellular localization of GSK-3 and its substrates, (Lee 
and Kim 2007; Patel et al. 2004). The phosphorylation of GSK-3α on Ser21 and GSK-3β on 
Ser9 of the N-terminus leads to the inhibition of kinase activity. Upon phosphorylation, the N-
terminus acts as a pseudo-substrate by folding back on itself and forming electrostatic 
interactions with the residues (Arg96, Arg180 and Lys205) of the catalytic site, thus 
occluding access of primed substrates to the catalytic site (Dajani et al. 2001; Bax et al. 2001; 
Frame et al. 2001). The inhibiting phosphorylation of the α-(Ser21), and β-(Ser9) isoforms of 
GSK-3 is mediated by several kinases including Akt (protein kinase B) of the insulin 
pathway, PKA of the cAMP-signalling pathway and PKC (Jensen et al. 2007; Liu et al. 2006; 
Du SJ 1995.; Liu et al. 2003; Wang et al. 2006). Conversely, tyrosine phosphorylation at the 
residue Y279 and Y216 in the activation loop of GSK-3α and GSK-3β respectively, enhances 
kinase activity. Whether the tyrosine phosphorylation is mediated by a kinase or is a result of 
autophosphorylation, still remains elusive (Cole et al. 2004). 
Little is known about the isoform specific functions of GSK in the cell, however studies 
indicate that, despite their close structural similarities, they are not functionally redundant to 
each other (Lee and Kim 2007). GSK-3’s function was initially associated with the regulation 
of glycogen synthase, the rate-determining enzyme for glycogen deposition (Frame and 
Cohen 2001). However, a plethora of GSK-3 substrates, about forty so far (Jope and Johnson 
2004), have been identified, which now implicate GSK-3 in a broad range of cellular 
processes, including cell-division cycle, stem-cell renewal and differentiation, apoptosis, cell 
survival, transcription, neuronal functions, protein synthesis and even circadian rhythm 
(Meijer et al. 2004). With a few exceptions, like axin for example, GSK-3 generally requires 
‘primed’ phosphorylation of its substrates by other kinases before it can phosphorylate them. 
GSK-3 will then phosphorylate the serine or threonine residue four amino acids N-terminal to 
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the primed residue. The minimal recognition motif for phosphorylation by GSK-3 is 
S/TXXXS/T(p), where “X” is any amino acid and “p” denotes the phosphorylated residue.  
In view of the manifold substrates of GSK-3 and the wide variety of their cellular functions, 
GSK-3 has been implicated in a variety of human pathologies including cancer (Manoukian 
and Woodgett 2002; Hill and Hemmings 2002), type II diabetes, alzheimer’s disease (Jope 
1999; Kozlovsky et al. 2002), schizophrenia (Jope and Roh 2006; Li et al. 2007), and bi-polar 
mood disorder (Bhat et al. 2004). Its value as a target for type II diabetes and bi-polar disorder 
is widely discussed in the literature (Jope 1999; Patel et al. 2004). However, its therapeutic 
value is still shrouded in uncertainty over the Wnt-mimetic potential of GSK-3 antagonists, to 
promote other pathologies like tumorigenesis. GSK-3 inhibition stabilizes three cell-cycle 
regulators, namely cyclin D1, cyclin E and c-Myc, the overexpression of which is linked with 
tumorigenesis. Addressing this concern is necessary for each GSK-3 inhibitor. However, long 
term use of lithium chloride, a known inhibitor of GSK-3 used for the therapy of bi-polar 
mood disorder (Jope 1999) is not associated with increased cancer morbidity in patients 
(Cohen et al. 1998). Furthermore, lithium treatment does not significantly increase the number 
of tumors in a mutant adenomatous polyposis coli mouse model (Gould et al. 2003). Other 
examples of GSK-3 inhibitors are shown below in table 1. 
Table 1:  Pharmacological inhibitors of GSK-3 (Meijer et al. 2004). 
Inhibitor Class 
Flavopyridol Flavone 
SB216763, SB415268 Arylindolemaleimide 
CHIR98014, CT20026 Aminopyrimidine 
Compound 8b Triazole 
Beryllium, Zinc, Lithium Atom 
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Figure 8: Structure of the GSK-3 specific inhibitor SB216763 (Meijer et al. 2004). 
 
2.1.3.3 Beta Catenin 
The β-catenin gene (CTNNB1) is located on chromosome 3p22 of the human genome and 
encodes a 92kDa large protein with 781 amino acids (aa). Beta-catenin is divided in to three 
structural domains: (figure 9) (Peifer et al. 1994). 
− An N-terminal domain, which bears the phosphorylation and thus 
recognition sites for the β-catenin degradation machinery of the proteasome.  
− A centrally placed 550 aa armadillo repeat domain (arm), with 12 armadillo 
repeats of 42 imperfect aa. The arm motifs harbor binding sites for APC, 
axin and E-cadherin. 
− Lastly, a highly acidic 100 aa C-terminal domain imperative for the 
transcriptional co-activation of Tcf/Lef. 
N C
Armadillo  repeats
7811
Axin
TCF-LEF
APC
GSK-3
Amino acid residue phosphorylated by GSK-3:
33 37 41 47
D  S  G  S  G   T  T  SI  H   A  T  A  P 
 
Figure 9: Scheme of the β-catenin protein showing the Wnt-relevant domains (Peifer et al. 1994). 
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Like APC, β-catenin belongs to the armadillo super-family of proteins, which all share as a 
common hallmark, a central domain with a minimum of 6 sets of repeated aa sequences called 
the arm motifs (Bright-Thomas and Hargest 2003). Like the other members of the armadillo 
family, β-catenin has been shown to typically combine structural functions such as cell 
contact and cytoskeletal-associated molecules with signalling functions. Indeed, β-catenin was 
initially discovered for its role in cell-adhesion (Kemler 1993). As a component of the 
adherens junctions, it binds directly to the cytoplasmic portion the transmembrane E-cadherin 
(Ca2+-dependent homotypal adhesion molecules) and, by associating with α-catenin acts as an 
interfacing link between actin cytoskeleton and cell-cell junctions (Knudsen et al. 1995).  
As described in chapter 2.2.1.1, β-catenin is the key mediator in the Wnt-signal pathway, 
where, upon stabilization in response to Wnt signals, it acts in conjunction with Tcf/Lef to 
promote the transcription of Wnt target genes. In normal unstimulated cells, i.e. in the absence 
of Wnt-signals, β-catenin levels are often low as a consequence of its destabilization in the 
Wnt signalling pathway. For the successful cytosolic destabilization of β-catenin, it has to be 
phosphorylated within the APC complex. This is accomplished by the serine (Ser)/threonine 
(Thr) kinases; CK-1α or CK-Iε and GSK-3 acting as a tag team, whereby CK-1 acts as the 
priming kinase for GSK-3. Only in the event of a previous phosphorylation of β-catenin by 
CK-1α or CK-Iε on the residue Ser45, can GSK-3 recognize and serially phosphorylate β-
catenin on the residues Thr41, Ser37 and Ser 33 in this order. The phosphorylation of the last 
two residues, Ser37 and Ser 33 earmarks β-catenin for proteasomale degradation. Besides the 
GSK-3-regulated degradation of β-catenin, a second APC dependent, but Siah-1 regulated 
pathway for β-catenin degradation has been identified (Matsuzawa and Reed 2001). In 
addition, an APC independent pathway involving the retinoid X receptor (RXR) has also been 
implicated in the regulation of cellular β-catenin levels (Xiao et al. 2003).  
 
2.1.3.4 T-Cell Factor-Lyphoid Enhancer Factor Transcription Factors 
(Tcf/Lef)  
The mammalian Tcf/Lef family of transcriptional factors consists of four member proteins, 
TCF-1, TCF-3, TCF-4 and LEF-1 which each share a similar structure of four basic functional 
domains (figure 10) (Waterman 2004): 
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− An N-terminal β-catenin binding domain, a central transcription repression 
domain, a high mobility group (HMG) DNA binding domain and  lastly, a C-
terminal tail  
dnLEF-1
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Figure 10: Structure and alignment of the isoform subtypes of the human T-cell factor/lymphoid 
enhancer factor (Tcf/Lef) family. Percent amino acid identity in select domains is shown 
relative to the amino acids sequence of LEF-1. Italicized names in parenthesis refer the official 
HUGO name of each of the genes. High mobility group: HMG, nuclear localization signal: 
NLS, dominant negative: dn (Waterman 2004). 
The β-catenin binding domain (figure 10) is the second most highly conserved feature within 
the Tcf/Lef family. It binds β-catenin in a fashion that promotes interactions with the 
armadillo repeats of β-catenin (Waterman 2004). Independently, the Tcf/Lefs can bind DNA 
but lack the ability to activate target gene transcription because they have a weak transcription 
activation domain. This deficiency is remedied by binding β-catenin, which possesses a potent 
transcription activation domain but on its own cannot bind DNA. Together they complement 
one another to form a potent transcription regulatory complex. Flanking the β-catenin binding 
domain is a transcription repression domain (figure 10), which possesses a weak gene 
transcription suppressing activity and so recruits co-repressor proteins of the groucho family 
(Giese et al. 1995; Grosschedl et al. 1994). Sandwiched between the transcription repressor 
domain and the C-terminus is the highest conserved feature of the Tcf/Lefs, the DNA binding 
domain (figure 10) with a sequence identity between 93-99%. It contains an HMG-Box (high 
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mobility group) and a nuclear localization signal (Bustin and Reeves 1996). This domain has 
the function of recognizing, binding and bending (90°-130°) target DNA (consensus sequence 
YCTTTGWW), so as to maximize productive interactions between the DNA and the 
activating or repressing complex (Giese et al. 1992; Giese et al. 1991). The last notable 
feature of the Tcf/Lefs is the multiple C-termini generated from alternate splicing (figure 10). 
Alternate splicing increases the diversity of the Tcf/Lefs by producing C- termini of variable 
lengths, denoted with the letters A, B, C, E, and N (figure 10) (van de Wetering 1996; 
Hovanes et al. 2000; Duval et al. 2000). Although the definite function of each the alternative 
C-termini still remains at large, evidence points to the fact that the E tail could be involved the 
regulation of transcriptional activity (Hecht and Stemmler 2003; Atcha et al. 2003).  
Promoter 1 Promoter 2 Compete for gene
transcription sites
Transcription starting from here
produces truncated proteins
Transcription starting from here
produces full-length Lef-1 and Tcf-1
Beta-Catenin
Gene encoding
Lef-1 or Tcf-1
Repressor
Proteins  
Figure 11: Different forms of Tcfs. Transcription starting at alternate promoters on Tcf genes can 
produce either full-length or truncated proteins. The full-length proteins tend to activate 
transcription of target genes, whereas truncated proteins will block transcription (Doucas et 
al. 2005).  
Some of the Tcf/Lef family members, specifically, Tcf-1 and Lef-1 are expressed in two 
variations; as a full-length protein and in a shorter truncated form. This is possible because the 
genes that encode for Tcf-1 (TCF-7) and Lef-1 (LEF-1) each have 2 different promoters for 
transcription (figure 11) (Hovanes et al. 2001; Giese et al. 1991). Activation of the first 
promoter in each gene leads to the expression of the full-length protein while the second 
promoter, located in the second intron, favours the expression of the truncated protein. 
Truncated Tcf/Lef proteins lack the β-catenin binding domain and hence are incapable of 
transmitting Wnt signals. Since they can however still recruit the co-repressors of the groucho 
Theory/Wnt-signalling  Tcf/Lef 
 
 ▓ PAGE 18 ▓ 
family, they act in a dominant negative fashion, by competing for DNA regulatory sites with 
the full-length forms, and hence can suppress Wnt-signalling (Molenaar 1996 ; Hovanes et al. 
2001). 
Tcf/Lefs are normally expressed during embryogenesis (Oosterwegel et al. 1993), but in most 
tissues, they are down regulated once the tissues become terminally differentiated. However, 
in sites of continual cell growth and differentiation, some members of the family continue to 
be expressed (examples are listed in table 2). One site of continual Tcf/Lef expression is the 
crypts of the colon, where TCF-4 is expressed as the sole representative of the Tcf/Lef family. 
However, when colon cells turn cancerous, TCF-1 and LEF-1 are additionally expressed 
(Hovanes et al. 2001). While the expression pattern of TCF-1 i.e. the truncated form against 
full-length protein, in cancer is still unclear, TCF-4 and LEF-1 are expressed exclusively as 
full-length proteins (Hovanes et al. 2001). The physiological role of TCF-1 and LEF-1 in 
cancer development is still unknown, even though there is evidence that speaks for the fact 
that TCF-1 might rather function normally as a Wnt-linked tumour suppressor than a Wnt-
linked tumour promoter. In vivo studies with TCF-7 (encodes for TCF-1) deficient mice, 
which lacked of the TCF-1 protein showed that the absence of TCF-1 provoked the 
development of intestinal and mammary adenoma (Roose J 1999 ).  
Table 2: Table listing the adult tissues of continual growth that express proteins of the Tcf/Lef family, 
the respectively expressed protein. 
Tissue Tcf/Lef Family Members Literature 
Intestinal mucosa TCF-1, TCF-4 (Hovanes et al. 2001; Roose J 1999 ) 
Colon TCF-4 (Hovanes et al. 2001) 
Thymus LEF-1, TCF-1 (Reya et al. 2000) 
Mammary epithelia TCF-1, TCF-4 (Roose J 1999 ; Barker et al. 1999)  
Bone marrow LEF-1 (Reya et al. 2000) 
Testes LEF-1 (Porfiri et al. 1997) 
Skin and dermal papillae at the 
base of the hair follicles LEF-1, TCF-3 (Zhou et al. 1995; Merrill et al. 2001) 
. 
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2.2 Glucose-Glycogen Homeostasis 
2.2.1 Key regulatory Elements of the Glucose/Glycogen 
Homeostasis 
2.2.1.1 Glycogen Synthase (EC 2.4.1.11) 
As can be inferred from its name, glycogen synthase (GS, EC 2.4.1.11) is involved in the 
synthesis of glycogen. It catalyzes the rate limiting step in the formation of glycogen in the 
cell by linking a glucose molecule from uridine diphosphate (UDP)-glucose via an α-1,4-
glycosidic bond to an already existing glycogen molecule. It belongs to the 3rd family of 
retaining glycosyltransferase (Campbell et al. 1997; Henrissat and Davies 2000). There are 
two isoforms in mammals encoded by separate genes. The first, muscle GS (MGS) is 
expressed predominantly in skeletal tissues and several other tissues (heart, fat, kidney, brain) 
and the second, liver GS (LGS), is expressed exclusively in the liver (Nuttall et al. 1994; 
Browner et al. 1989). Human LGS and MGS share an approximately 70% amino acid identity 
with the most divergence located on the N- and C-terminals. In comparison to the human 
MGS, which has 737 amino acids and weighs 85kDa, human LGS (80.9kDa) is with 703 
amino acids, 34 amino acids shorter (Nuttall et al. 1994; Browner et al. 1989). 
The N-terminal of GS has 2 phosphorylation sites, site 2 (ser7) and site 2a (ser10), whereby 
site 2 is phosphorylated in vitro by kinases like, the cyclic AMP-dependent protein kinase A 
(Huang and Krebs 1977), AMP-activated protein kinase (Carling and Hardie 1989), and 
phosphorylase kinase (Roach et al. 1978). Phosphorylation of site 2 is prerequisite for the 
subsequent phosphorylation of site 2a by casein kinase 1 (Flotow and Roach 1989; Flotow et 
al. 1990), which reduces GS activity in vitro. However, in vivo, the relevance of this 
phosphorylation site still remains to be substantiated. 
The C-terminal of GS contains 7 phosphorylation sites in MGS (figure 12) and 5 sites in LGS, 
which lacks the C-terminal sites 1a (ser697) and 1b (ser710). In vivo, the phosphorylation of 
sites 3a (ser640) and 3b (ser644) (figure 12) is most influential on GS activity (Wang and 
Roach 1993). The phosphorylation of these sites, which is mediated by GSK-3, occurs 
likewise the phosphorylation of the N-terminal sites (2 and 2a) in a hierarchal fashion, 
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whereby CK-2 acts as the priming kinase for GSK-3. CK-2 phosphorylated site 5 (ser 656) 
creating a recognition site for GSK-3, which then phosphorylates site 4 (ser652), 3c (ser648), 
3b and 3a in this order (figure 12) (Poulter et al. 1988; Wang and Roach 1993). An unknown 
kinase has been identified in vitro that in addition to GSK-3 targets site 3a (Poulter et al. 
1988). 
2   2a
578     590
1   1a3a  3b  3c  4  5
CamK
PhK
PKA
Glycogen
AMPK Novel site-3a Kinase PKAGSK3 CK2
CK1
N C
 
Figure 12: Schematic of the rabbit muscle glycogen synthase showing the nine serine residues, whose 
phosphorylation regulates the activity of glycogen synthase. All nine serine residues are 
conserved in the human MGS. AMPK, AMP-activated protein kinase; CaMK, calmodulin 
dependent protein kinase; CK 1 and 2, casein kinase 1 and 2; Phk, phosphorylase kinase; 
PKA, protein kinase A. 
Active control of GS activity is mediated by allosteric ligands (Piras et al. 1968), kinase-
mediated reversible phosphorylation (Roach 1990), which inactivates the enzyme, and also by 
feedback inhibition by glycogen (Laurent et al. 2000; Danforth and Harvey 1964; Piras and 
Staneloni 1969) via an unknown mechanism.  
GS can assume two conformational states in vivo: A GSa-conformation, in which the enzyme 
is unphosphorylated and more active, and a GSb-conformation assumed upon phosphorylation 
that renders GS lesser active. The switch from GSb to GSa i.e. the dephosphorylation and 
activation of GS, is mediated in response to insulin stimulation of muscle GS by type 1 
protein phosphatases (PP-1) with a type 1 catalytic subunit (Ragolia and Begum 1998; Roach 
2002). In cell models, the dephosphorylation of all phosphorylation sites depicted in figure 12 
is needed for full activation of GS (Skurat et al. 2000).  
As mentioned above, GS activity is also regulated by the actions of allosteric ligands. While 
physiological concentrations of ATP, ADP, AMP and Pi bring about an inhibition of GS 
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activity, glycogen-6-phosphate (G-6-P) causes an activation of GS activity by binding and 
prompting a conformational change of GS so that PP-1 has better access to the 
phosphorylation sites of GS. The region between amino acids 578-590 has been shown to 
confer sensitivity to activation by G-6-P (figure 12) (Roach 2002). 
Mutations in both of the GS genes have been observed. Several mutations of GYS2, encoding 
the liver form, lead to a disorder called glycogen storage disease 0, which is characterized by 
hypoglycemia, low glycogen levels in the liver and low GS activity. Mutant alleles of GYS1, 
encoding the MGS, have also been detected. While some studies correlate this mutation with 
type II diabetes development, it is yet to be fully substantiated (Roach 2002). In some cancer 
types, GS is overexpressed.  
 
2.2.1.2 Glycogen Phosphorylase (EC 2.4.1.1) 
Glycogen phosphorylase (EC 2.4.1.1) is a member of the 35th family of glycosyltransferases. 
It plays a central role in the mobilization of carbohydrate reserves in man by acting in 
conjunction with the debranching enzyme (EC 3.2.1.68) to degrade glycogen. During 
degradation, GP stalls four residues from an α-1, 6-branchpoint, from where the branching 
enzyme takes over. GP exists as a homodimer containing two identical subunits of molecular 
mass 97,500 (Hudson et al. 1993; Newgard et al. 1989). Three isoforms of GP, encoded by 
separate genes, exist in mammals. The brain GP (BGP) is the predominant isoenzyme in adult 
brain and most fetal tissues, whereas adult liver and muscle tissues are known to express 
primarily, the liver (LGP) and muscle isoforms (MGP), respectively (Hudson et al. 1993; 
Newgard et al. 1989). BGP is made up of 862 amino acids (AA), and shares more sequence 
similarity with MGP (841) than with LGP (841).  
Like GS, GP activity is regulated by reversible phosphorylation and allosteric interactions. 
The phosphorylation of GP is mediated by GP-kinase, which in turn is activated in response 
to glucagon by the cAMP-dependent protein kinase or as a result of increased cellular Ca2+ 
levels (muscle contraction). Dephosphorylation is mediated in response to insulin by PP-1. 
Depending on the interaction with intracellular allosteric ligands or the state of 
phosphorylation, each of the GP isozymes can assume two interchangeable forms; an active 
GPa form and an inactive GPb form, which in turn can assume two interchangeable 
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conformations; an active relaxed conformation (R-conformer) and an inactive tensed 
conformation (T-conformer) (figure 13). In resting muscle cells, the lesser active form, GPb, 
becomes phosphorylated on ser14 and is converted to a more active GPa. Intracellular ligands, 
such as AMP and glycogen activate MGP by promoting formation of the active R conformer, 
while glucose, G-6-P purines and purine nucleosides stabilize the inactive T-conformer of 
MGP (figure 13). The liver isoform has generally similar properties as MGP. However it 
exhibits differential regulatory properties especially with regard to its response to allosteric 
ligands. For example, LGP experiences a significantly lesser activation by AMP than MGP. 
Moreover, it is insensitive to inhibition by G-6-P and ATP (Newgard et al. 1989).  
 
Figure 13:  Regulation of muscle glycogen phosphorylase by phosphorylation and allosteric ligands. AMP, 
adenosine monophosphate; ATP, adenosine triphosphate; G-6-P, glucose-6-phosphate; GPa, 
glycogen phosphorylase a; GPb, glycogen phosphorylase b; IMP, inosine monophosphate; P, 
phosphate functional group; PhK, phosphorylase kinase; PP-1, protein phosphatase-1; R, 
relaxed; T, tensed. 
Each GP isozyme fulfills different physiological requirements even though all forms catalyze 
the phosphorolysis of glycogen. While the muscle enzyme provides metabolic fuel for 
muscular contraction, the liver form plays a central role in the maintenance of blood glucose 
homeostasis, and the brain type is associated primarily with the provision of an emergency 
glucose supply during periods of anoxia or hypoglycemia.  
Hyperglycemia is a hallmark of diabetes. Since LGP catalyzes the breakdown of glycogen 
stores and thus contributes to increase glucose levels of the bloodstream, GP is a potential 
pharmacological target for therapy of type 2 diabetes. However, due to the high similarities in 
the regulatory sites of the GP isoforms, isotype specific inhibitors are hard to synthesize. 
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Since MGP activity is crucial for normal skeletal functioning, fatigue may be a plausible side 
effect and so pose a major development hurdle for such a therapeutic strategy. Examples of 
GP-inihibitors include CP-91149 and CP-316819 (Lerin et al. 2004), which both principally 
bind the less active GPb on the glucose inhibitory site, so preventing the conformational 
change to the the more active GPa form. 
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2.2.2 Regulation of Glucose/Glycogen Homeostasis 
Blood glucose homeostasis is determined by the factors that are rate limiting for glycogen 
anabolism and catabolism. Three set of events potentally determine the regulation of glycogen 
anabolism in skeletal muscle, adipose tissue and liver cells. First, the rate of glucose 
transportation in these cells, second, the subsequent phosphorylation of glucose by hexose 
kinase in muscle tissue and glucokinase in the liver, and lastly the activation state of glycogen 
synthase (Roach 2002). The activity of glycogen phosphorylase on the other hand is 
considered rate determining for the breakdown of glycogen, hence for the release of glucose 
molecules and rise in plasma glucose levels (Roach 2002). 
 
Figure 14: Schematic of the signalling pathways involved in the metabolism of glycogen. IP3, 3, 4, 5 
phosphatidyl inositol-3-phosphate;  
In mammals, after a meal, elevated plasma insulin, induced by high blood glucose levels, 
stimulates the transport of glucose into the cell by the glucose transporter proteins (figure 14) 
(GLUT4 in muscle and adipose tissue and SGLT2 in the liver) (Scheepers et al. 2004; 
Bornemann et al. 1992; Handberg et al. 1992).  Simultaneously, insulin initiates the relay of a 
signal via the phosphatidylinositol-3-kinase (PI3-kinase) signalling pathway (Petersen et al. 
2001; Vanhaesebroeck and Alessi 2000) resulting in the activation of protein kinase B (PKB), 
the deactivation of GSK-3 and eventually the dephosphorylation and activation of GS (figure 
14). This results in reduced plasma glucose levels and the synthesis and accumulation of 
glycogen. However, not all of insulin dependent control of GS is explainable by the regulation 
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of GSK-3, considering that the key regulatory sites of GS (site 3a and 3b) (figure 12) are not 
solely phosphorylated by GSK-3 (Poulter et al. 1988; Skurat and Roach 1996; DePaoli-Roach 
et al. 1983). Moreover, insulin stimulus causes the dephosphorylation of both amino and 
carboxy termini of GS (Parker et al. 1983; DePaoli-Roach et al. 1983), including sites not 
phosphorylated by GSK-3. In the liver, glucose rather than insulin plays a superior role in the 
acute stimulation of glycogen synthesis. Insulin is involved more in the control of gene 
expression (O'Brien and Granner 1996). The acute rise in blood glucose correlates with 
increased glucose in hepatocytes and the allosteric activation of GS. Meanwhile, GP activity 
is simultaneously shut down by the allosterical actions of glucose and increased 
dephosphorylation by PP-1 (Roach 2002; Ragolia and Begum 1998) 
In periods of hunger (figure 14), the GP-mediated breakdown of glycogen stores to glucose-1-
phosphate is the primary response of the liver in order to maintain blood glucose levels at 
concentrations between 800-1200mg/l (van de Werve and Jeanrenaud 1987; Stalmans 1976), 
before gluconeogenesis can set in if hunger periods prolong into fasting. Glucagon is secreted 
into the bloodstream as a response to falling blood glucose levels where it gains ascendancy 
over insulin. In the liver, glucagon binds to a G-protein coupled receptor (GPCR) and initiates 
the cAMP signalling pathway leading to increased cytosolic cAMP levels and the subsequent 
activation of protein kinase A (PKA) (figure 14). Active PKA phosphorylates and activates 
GP-kinase, which in turn phosphoryates and activates GP (Hayes and Mayer 1981). GP then 
catalyzes the breakdown of glycogen. While relaying the signal that leads to the activation of 
GP, PKA also concurrently phosphorylates and inactivates GS. Altogether, decreased liver 
glucose levels cause the reversal of the glucose-mediated activation of GS hence precluding 
glycogen synthesis. In addition to glucagon, adrenaline can elicit similar effects through 
cAMP or Ca2+ signals but this is of higher relevance in muscles (Roach 2002). 
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2.3 Flavonoids and Polyphenols 
Polyphenols constitute secondary metabolic products that arise biosynthetically from 
phenylalanine via two main pathways in plants: the shikimic pathway and the acetate pathway 
(Heller 1986). Flavonoids are the most abundant sub-class of polyphenols with over 5000 
different structures identified. They all share a common nucleus (figure 15) consisting of a 
benzene ring A, condensed with a member ring C to which a phenyl benzene ring is 
connected at position 2. Flavonoids can be further divided into 6 sub-classes on account of the 
variations in the heterocyclic C-ring. Ring C may be a heterocyclic pyran, which yields 
flavanols (catechins) and anthocyanidins, or pyrone, which yields flavonols, flavones, 
isoflavones and flavanones (Kuhnau 1976). The patterns of substitution on the flavan nucleus 
include hydrogenation, hydroxylation, malonylation, methylation, and sulfation (Harborne 
1986). Flavonoids occur richly in seeds, olive oil, fruits, tea, herbs, and wine where they 
provide much of the flavour and colour that accompany these products (Middleton et al. 
2000). While most flavonoids occur naturally attached to sugar moieties (glycosides) such as 
glucose, rhamnose, galactose, arabinose, and thus tend to be water-soluble, a small fraction do 
not carry any sugar group and are termed aglygones. 
O
A C
B
 
Figure 15: Flavan nucleus commonly shared by all flavonoids  
2.3.1 Structure, Occurrence in Food and Intake 
Information on the daily consumption of flavonoids in food is incomplete and often 
contradictory in the literature. This is because there still are some unresolved issues as far as 
overcoming the challenges that come with the task of determining intake is concerned. First, 
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there is the fact that flavonoid content can vary over wide ranges in the same food. For 
example, cherry tomatoes contain six times more quercetin per gram fresh weight than do 
normal tomatoes (Duthie and Crozier 2000). Flavonoid content is determined, not only by 
natural factors like climate, season, degree of ripeness, and plant genetics, but also by 
artificial factors such as variations in food preparation, food processing and storage 
conditions. A study by Ross et al. showed significant differences in the flavonoid content in 
nine commercial brands of grapefruit juice (Ross et al. 2000). Another difficulty with respect 
to determining flavonoid intake resides in the fact that there is a lack of agreement on an 
appropriate method to analyze polyphenols contents in general. Lastly, there is also the aspect 
of cultural and individual feeding habits that have to be considered.  
Quercetin and EGCG ((-) Epigallocatechine-3-gallate) are the two central flavonoids relevant 
for the studies presented in this work. In the following subsection, mainly the flavonoid sub-
classes, flavonols and catechins, to which these two substances belong respectively, are 
introduced. Also discussed will be the adsoption, metabolism and dietary relevance of 
flavonoids in cancer prevention.  
2.3.1.1 Flavonols 
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Figure 16: Structure of the most prevalent flavonols in the human diet. 
Flavonols are the most ubiquitously spread member of the flavonoid family in the plant 
kingdom, hence in food of plant origin. They belong to the group of 4-oxo-flavonoids, which 
carry a carbonyl group on position 4 of the C-ring (figure 16). Flavonols occur in food usually 
as O-glycosides, preferably on C-3 position and, less frequently on the C-7 position. D-
glucose is the most usual sugar residue (Kuhnau 1976).  
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Prominent representatives of flavonols in the diet include quercetin, myricetin and kaempferol 
(figure 16) with quercetin being the most abundant. Major dietary sources for flavonols 
include beverages like tea (10-25mg/l) and red wine, onions, broccoli, kale, and fruits like 
cherries and apples. There exists little information on the daily intake amounts for flavonols. 
Three independent reseach groups estimated the daily intake to be 23mg/day (flavonols and 
flavones), 28 mg/day (flavonols, flavanones and flavones) and 115mg/day (flavonols and 
flavones), in the Netherlands, Denmark and the USA respectively (Leth 1998 ; Hertog et al. 
1993; Kuhnau 1976). However, Hollman et al. (1997) advanced that the results by Kuhnau 
might be inflated because of the relatively unreliable methods of analysis back in the 1970s. 
Van der Woude et al. (2003) stated that the concentration of free quercetin can reach up to 
100μM in the intestinal lumen after ingestion of a quercetin supplement (250–500 mg) (van 
der Woude et al. 2003). 
2.3.1.2 Flavan-3-ols (Catechins) 
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Figure 17: Structure of the prominent members of the catechin class of flavonoids in tea 
Major dietary sources of catechins include tea (Camellia sinensis), apples, grapes (red wine), 
and cacao (chocolate) (Ross and Kasum 2002). Catechins of tea are mostly galloylated on 
position 3, whereas flavan-3-ols in chocolate and grapes are (-)-epicatechin and (+)-catechin. 
Grapes (seeds) also contain condensed flavanols (4-11 units) called proanthocyananidins. Due 
to varying processing techniques, grape juice has lesser catechins than red wine because the 
wine making process extracts some flavonoids from seeds and the skin of grapes as well 
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(Yang et al. 2006). The total daily intake of catechins is rated between 200-800mg for tea 
drinkers (1-4 cups of green tea) (Yang et al. 2006). 
Flavan-3-ols are by virtue of the vicinal dihydroxy or trihydroxy structures liable to air 
oxidization under alkaline and neutral pH (Yang et al. 2006). EGCG for example can 
autooxidize to generate a superoxide anion, H2O2, and dimers (figure 18) such as 
theasinensins. This reactions occur also during cell culturing, probably catalyzed by trace 
metals like Ca2+ and Fe3+(Yang et al. 2006).  
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Figure 18: Proposed mechanism for the autooxidation of EGCG under neutral or slightly alkaline pH 
(Yang et al. 2006). 
2.3.2 Resorption and Bioavailability 
Although many answers have been provided over the years, the issue as to how flavonoids get 
past the gastrointestinal tract (GIT) into systemic circulation is still not totally understood. 
Kuhnau J initially postulated in the 1970s that flavonoids in glycosidized form (the form in 
which they mostly occur in foods) are not absorbed because the sugar moeities, which 
otherwise, render them water-soluble, hinder passive diffusion in the small intestine. He 
argued that, for these flavonoids to be absorbed, they have to be present as aglycones i.e. their 
sugar moeities needed to be cleaved. And since the human gut lacked the necessary enzymes, 
glycosides should pass the small intestines unchanged to be hydrolized by the microflora of 
the colon where absorption is minimal (Kuhnau 1976). In recent years however, there is rising 
evidence of a hydrolysis of glycosidized flavonoids as high up in the GIT as the oral cavity 
(Walle 2003). In the mammalian small intestine two enzymes are involved in the hydrolysis 
of glycosides: Lactase phloridzin hydrolase (LPH), located in the brushborder membrane and 
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the broad-specific β-glucosidase (BSβG), located within enterocytes, which may hydrolize 
glycosides should they gain assess into the cells (Day et al. 2003; Ioku et al. 1998). Indeed 
there is evidence, that some glycosides can intactly be absorbed via the actions of apical 
transporter proteins of the small intestines. The sodium dependent glucose transporter SGLT1 
has, for example, been shown to transport quercetin glycosides across the brushborder 
membrane (Walgren et al. 2000; Wolffram et al. 2002; Gee et al. 1998). In another study, the 
tea catechin epicatechin gallate (ECG) was shown to be a substrate of the monocarboxylate 
transporter (MCT). Apically located multidrug-resistant associated proteins (MRP2) have 
been shown to also transport some flavonoid glycosides, however they act in opposition to 
SGLT 1 by ejecting the glycosides out of the enterocytes back to the luminal tract (Walgren et 
al. 2000; Vaidyanathan and Walle 2003), which is probably one factor that contributes to the 
low systemic concentrations generally seen for flavonoids in in vivo studies. ECG's 
bioavailabilty determined in rats lay between 1-3% for the doses of 12.5-50mg/kg (Takizawa 
et al. 2003). Bioavailability studies have shown that the concentrations of intact flavonoids in 
human plasma rarely exceed 1µM when the quantities of polyphenols ingested do not exceed 
those commonly ingested with the diet (Scalbert and Williamson 2000). Another factor that 
influences flavonoid absorption and bioavailability is the food source (food matrix). The 
recovery rate for quercetin for example, has been reported to be two fold higher from onions 
than from black tea (de Vries 1998). 
2.3.3 Biotransformation and Excretion 
After ingestion, metabolism of flavonoids occurs at the level of the brushborder membrane, 
the colon and beyond, in the circulatory system (liver), where flavonoids and polyphenols are 
subjected to hydrolysis and mostly conjugative metabolism leading to their glucuronidation, 
methylation, and sulfatation. The sequence and extent of metabolism depends on: the 
substrate specificity of the enzyme, which in turn determines the reactivity and position of the 
conjugation, the availability of conjugation enzymes and cofactors and lastly the 
concentration of the polyphenol. 
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2.3.3.1
2.3.3.2
2.3.3.3
 Hydrolysis 
Following ingestion, flavonoid metabolism starts in the oral cavity with the hydrolysis of 
glycosides and release of the aglycone (Walle 2003). As described in the previous chapter, the 
enzymes, LPH and BSβG also catalyse the hydrolysis of flavonoid glycosides in the small 
intestine. Five percent of Europeans and 90% of Africans and Asians have LPH deficiency in 
adulthood (Scalbert and Williamson 2000). For this set of people, the microflora of the colon 
is assumed to be the main source of glycoside hydrolysis. Phase I metabolism of flavonoids 
by cytochrom-P450 (CYP450) is also thought to occur. Experiments using rat and human 
liver microsomes have been used to show that CYP450 isoforms can catalylze the hydrolysis 
and demethylation of polyphenols. However, these findings are as yet unsubstantiated in 
intact cells or in vivo (Walle 2003). If CYP450 mediated hydrolysis occurs in the intestine, the 
isoforms CYP1A2 and CYP3A4 should predominantly be involved, given that they are the 
active isoforms in the small intestines (Breinholt et al. 2002). 
 Glucuronidation 
UDP glucuronosyltransferase (UDPGT) catalyzes the conjugation of flavonoids and 
polyphenols to glucuronic acid, which increases water solubility and renal excretion. UDPGT 
is situated in the endoplasmic reticulum and exists as a large family of related enzymes. 
Glucuronidation of polyphenols is predominantly by the UGT1A family, which occurs in 
intestine, liver and kidney. Of all tissues, the liver has the greatest capacity for  
glucuronidation (Strassburg 1999; Mojarrabi 1998; Strassburg 1998). UDPGT isoforms 
demonstrate regioselectivity in the glucuronidation of flavonoids. In the case study of luteonin 
and quercetin, Boersma et al. (2002) showed that preferentially glucuronidated were positions 
7-, 3-, 3'-, or 4'-hydroxyl moiety. They concluded that regioselectivity is dependent on the 
model flavonoid of interest and also on the isoenzyme of UDPGT involved, since 
glucuronidation of luteolin and quercetin did not following the same pattern, (Boersma 2002) 
 O-Methylation 
Catechol-O-methyltransferase (COMT, EC 2.1.1.6), that otherwise plays a crucial role in the 
metabolism of dopamine, catalyzes the transfer of a methyl group to polyphenols from S-
adenosylmethionine (SAM). COMT is expressed in a wide range of tissues. Which hydroxyl 
group is methylated by COMT is determined by specificity of the polyphenol (Scalbert and 
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Williamson 2000). A genetic polymorphism in the COMT gene in humans, leads to the 
expression of gene products with a three to fourfold difference in enzyme activity (Tiihonen 
et al. 1999). 
2.3.3.4
2.3.3.5
 Sulfatation 
Phenol sulfotransferases (P-PST, SULT; EC 2.8.2.1) are a small group of cytosolic enzymes 
that are widely distributed. The isoform, SULT1A3, is highly expressed in the colon and has a 
high activity on catechol groups found in flavonoids and polyphenols, whereas SULT1A3 is 
predominant in the liver (Scalbert and Williamson 2000). Generally, sulfotransferases utilize 
3’-phosphoadenosine 5’-phosphosulfate (PAPS) as sulfate donor for the sulfatation reactions. 
Some sulfotransferases are inhibited by polyphenols (Burchell and Coughtrie 1997). 
Other phase II metabolism enzymes like N-Acetyl transferase which catalyzes the acetylation 
of amines, glutathione transferases, and epoxide hydrolases generally are thought to play a 
minor role in flavonoid and polyphenol metabolism (Scalbert and Williamson 2000). 
 Contribution of the Intestinal Microflora 
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Figure 19: Possible routes for polyphenols in humans proposed by Scalbert and Williamson, 2000 
An estimate 1013 bacteria of 400 different species colonize the human GIT, whereby 101 
reside in the stomach in comparison to 108 and 1012 in the small and large intestines 
respectively. Over 99% of the bacteria are strict anaerobes with a small fraction being 
facultatively anaerobic. The microbiota of the GIT contribute to digestion by fermenting 
dietary compounds that are refractory to absorption and enzymatic breakdown in the stomach 
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and upper bowel. Their actions lead to the formation of short-chain fatty acids, acetate, 
propionate, butyrate, and of gases like carbon dioxide, methane and hydrogen (Blaut et al. 
2003). When polyphenols are absorbed, some enter the enterohepatic circulation. This means, 
after absorption in the small intestine or colon; they are reintroduced into these organs in bile 
secretions as conjugated metabolites after passage and metabolism in the liver. Some of these 
metabolites are again absorbed and some pass on to reach the colon (figure 19).  
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Figure 20:  Degradation of quercetin by bacteria Eubacterium ramulus of the gut microflora (Scalbert and 
Williamson 2000). 
Also reaching the colon are dietary polyphenols that escape absorption in the upper 
gastrointestinal tract. In the colon, they are broken down by the hydrolytic and catalytic 
activity of the microbiota. For example, quercetin, its 3-glycoside and rutin, have been shown 
to be broken down by Eubacterium ramulus and Enterococcus casseliflavus, whereby the 
latter only hydrolyzes the glycosidic bond whereas the former, not only mediates a cleavage 
of the glycosidic bond but also splits open the flavonoid ring converting quercetin to 3, 4-
dihydroxy-phenylacetic acid and pholoroglucinol. Taxifolin and amphitonin are intermediate 
products in the breakdown of quercetin (figure 20). By-products of the reaction include 
carbon dioxide, butyrate and acetate. Generally, E. ramulus is thought to degrade flavonoids 
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devoid of the 3 hydroxyl group in the C-ring (flavones and flavanones) to the corresponding 
phenylpropionic acid, while flavonoids with a 3 hydroxyl group (flavonols and flavanols) are 
converted to the corresponding phenylacetic acid (Blaut et al. 2003). 
2.3.4 Flavonoids, Nutrition and Colorectal Cancer  
There is an increased incidence of (colorectal) cancer in developed nations compared to 
developing nations. The World Health Organisation (WHO), estimates that the rate of 
incidence of colorectal cancer in males in developing countries is one quarter the average rate 
in developed countries (Ferlay 2001; Doll and Peto 1981; Parkin et al. 2005). For example the 
age-standardised rate of incidence of colorectal cancer among males in Bangladesh is about 1 
case per 100,000, compared to approximately 50 per 100,000 in Australia and New Zealand, 
and 60 per 100,000 in some Eastern European countries (Ferlay 2001). 
Inferred from epidemiological studies (case-control and prospective), as well as by examining 
and comparing associations between dietary patterns and cancer rates in different populations 
around the world, the differences in consumed diet and in life style have been advanced as 
possible explanations for the demographic disparity in colorectal cancer and some other 
cancer types. It is generally assumed that diet is causal, in one way or the other, for up to 80% 
of colorectal cancer (Bingham 2000). However, the mechanisms underlying the 
epidemiological relationship between diet and cancer remains unclear (Johnson 2004).  
The frequent consumption of red and processed meat, and a diet rich in animal fats and poor 
in micronutrients, which in effect is reflective of the western style diet, are generally viewed 
in combination with other factors like low energy expenditure, and obesity (Carroll 1998), as 
high risk factors for getting colorectal cancer. In one prospective study for example, the risk 
for consumers of processed red meat over non-consumers to get colorectal cancer was 
estimated at approximately 51% (Giovannucci 1994). The potential formation of known 
mutagens like heterocyclic amines and polycyclic aromatic hydrocarbons during high 
temperature cooking of red meat (Gooderham et al. 1997; Kazerouni et al. 2001), and also, the 
possible micro flora-dependent colonic conversion of nitrites (cured meat) to carcinogenic N-
nitroso compounds (NOC) are being proposed as possible mechanism for the increased 
carcinogenic risk of red (processed) meat (Bingham 1999). In addition, high iron levels in the 
colon may increase the formation of mutagenic free radicals (Lund et al. 2001; Lund et al. 
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1999). On the other hand, the consumption of a diet rich in micronutrients i.e. a diet 
complemeted with fruits and vegetables as well as whole grains and tea for example, has been 
proposed to potentially inhibit the genesis of colorectal cancer in particular and cancer as a 
whole. It is thought that the non-nutritive bioactive components, flavonoids and polyphenols 
present in fruits, vegetables and tea are responsible for the inverse association seen between 
consumption of fruit, vegetables and tea with cancer.  
Several mechanisms, based on in vitro and in vivo studies, have been suggested as to how 
flavonoids might act as anticarcinogens. These include: inhibition of protein kinases, 
induction of phase II enzyme activity, acting as antioxidants, inhibition of cyclooxygenase 
activity, modulating β-catenin signalling, inhibiting cell proliferation and inducing apoptosis 
(Johnson 2004). Flavonoids reportedly can inhibit cell proliferation in cancerous cell lines of 
colonic origin. Studying the effect of flavonoids on cell proliferation and apoptosis in the 
human colonic cell line (HT29), Daskiewicz et al. (2005) suggested the contribution of a 
positive apoptotic response to the observed flavonoid-dependent growth inhibition of HT29 
cells. Generally, flavones and flavonols have been shown to possess greater antiproliferative 
activity than chalcones and flavanones (Daskiewicz et al. 2005). In vivo (rodents), quercetin 
and its glycosides, (3-O-glycoside and 3-O-rutinoside) have been demonstrated to suppress 
crypt cell mitosis and inhibit abberant crypt foci formation at diet relevant concentrations 
(Gee et al. 2002; Depeint et al. 2002). Also, tea which contains high levels of flavanols, 
especially EGCG, has been shown to have chemopreventive properties in mouse models of 
colorectal cancer. Orner and coworkers showed that tea at diet relevant concentrations, 
inhibited heterocyclic amine-initiated colonic aberrant crypt formation in rats, and reduced 
tumour incidence in APCmin/+ mice (Orner et al. 2002; Orner et al. 2003). The 
chemopreventive potential of tea is ascribed to the down regulation of β-catenin expression in 
the intestines by catechins. Ju et al. (2005) reported of an EGCG-induced reduction in the 
formation of intestinal tumour (37%-47%) in the APCmin/+ mouse model (Ju et al. 2005). In 
addition, the fermentation of flavonoids (see chapter 2.3.3.5) in the large intestine may 
generate short chain fatty acids such as butyrate (figure 20), which have potential 
anticarcinogenic properties by promoting differentiation, inducing apoptosis and/or inhibiting 
the production of secondary bile acids by reducing luminal pH (Hague et al. 1995; Nagengast 
et al. 1995). 
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3 Objectives and Problem Formulation 
The World Health Organisation has prognosed a 50% rise in cancer incidences by 2020. 
Scientific data has been published supporting the epigenetic role of diet in the development of 
cancer. These factors coupled with public appreciation that getting cancer often 
commensurates a death sentence have fueled the race in the identification of the food 
components that might promote/prevent cancer. This led to the discovery and emergence of 
flavonoids and polyphenols as bioactive compounds with anti-carcinogenic potential. 
This dissertation was performed within the scope of the project entitled “Impact of 
flavonoids/polyphenols on transporters and enzymes involved in glucose/glycogen 
homeostasis in different cells types and in humans”. The project was supported by the 
“Deutsche Forschungsgemeinsschaft (DFG)” and was performed as part of the “Flavonet” 
network called “Plant flavonoids and polyphenols: Toward a better understanding of the 
molecular mechanisms of action relevant towards benefit/risk evaluation”. The main goal of 
the network was to establish an objective scientific foundation that permits an improved 
judgemental assessment of the risks and benefits of human flavonoid and polyphenol 
consumption.  
As an integral part of the glucose/ glycogen homeostasis, GSK-3 influences the glucose to 
glycogen flux by regulating the activity of glycogen synthase (GS). In this light, GSK-3 is a 
potential pharmacological target for diabetes therapy. GSK-3 also plays a pivotal role within 
the Wnt signalling pathway where it acts as part of the machinery regulating cellular β-catenin 
activity (Jope and Johnson 2004). In the event of the inactivation of GSK-3, β-catenin 
accumulates in the cell and is translocated in to the nucleus where by associating with other 
transcription factors (Tcf/Lef), it promotes the expression of proliferation stimulating genes. 
For cancerous cells or pre-malignant cells, such an event constitutes a proliferation stimulus 
that leads to increased growth and thus, increased tumourigenesis or carcinogenesis. Hence, 
while the inhibition of GSK-3, might lead to the abatement of blood glucose concentrations, it 
might concomitantly pose the risk of increased tumour growth formation by activation of β-
catenin in the Wnt-signalling pathway. In view of the fact that high intake of flavonoid-based 
supplements might dramatically increase the load of flavonoids and because such high 
concentrations might inhibit GSK-3 kinase activity, the potential adverse effects of flavonoids 
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might outweigh the beneficial effects. The effects of flavonoids on GSK-3 in colon carcinoma 
cells was hence determined in order to provide more insight into the molecular-level 
understanding of mechanisms involved in the flavonoid-dependent modulation of the Wnt-
signalling pathway.  
To elucidate the impact of flavonoids on GSK-3 in HT29 cells, GSK-3 activity, expression 
and mRNA level was determined. SB216763, a specific GSK-3 inhibitor was employed as the 
positive control. Since the influence on GSK-3 activity should directly influence β-catenin 
cellular levels, potential modulating effects of flavonoids on cellular and nuclear β-catenin 
levels as well as the state of phosphorylation of β-catenin was determined. Also, the 
flavonoid-dependent modulation of mRNA transcripts for β-catenin was determined. 
Methodically, western blot analysis and quantitative TaqMan RT-PCR were employed to the 
end of achieving these goals.  
To determine if the modulation of GSK-3 by the flavonoids and polyphenols culminates in a 
proliferation stimulus, a dual luciferase reporter gene assay tailored to the experimental 
question was validated and optimized in the immortalized human embryonal kidney cells, 
HEK293 (DMSZ) as well as the colon carcinoma cell lines HT29 and HCT116. The 
experimental plasmid of choice was TOPflash from Upstate Biotechnology. FOPflash was 
employed for negative control experiments. 
Besides its β-catenin regulating role in the Wnt signalling pathway, GSK-3 also influences 
glycogen metabolism indirectly by regulating GS activity. In vivo experiments have shown 
that some flavonoids and polyphenols are potentially anti-diabetic, mimicking the hormonal 
effects of insulin, i.e. causing a reduction of level blood sugar levels. One possible mechanism 
of action may be via inactivation of GSK-3 and thus activating glycogen synthase (GS) and 
hence speeding up the flux of glucose to glycogen and uptake of glucose in the cells. To 
therefore determine if possible flavonoid-dependent modulations of GSK-3 in HT29 cells 
commensurately influence glycogen metabolism, time-course effects of flavonoids on GS 
activity in HT29 cells were investigated using the method described by Thomas et al. (1968). 
Another possible mechanism for the anti-diabetic properties of flavonoids may be via 
inhibition of glycogen phosphorylase (GP), responsible for the catalytic breakdown of 
glycogen to phosphorylated glucose. EGCG, for example, has been shown to potently inhibit 
the activity of isolated glycogen phosphorylase, the rate limiting enzyme in the breakdown of 
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glycogen (Jakobs et al. 2006). Using methods described by Layzer et al. (1967) and Kaiser et 
al. (2001), the GP activity in HT29 cells was determined. In addition the flavonoid-dependent 
modulation of GS and GP expression levels and mRNA transcripts was determined in HT29 
cells using western blot analysis and quantitative TaqMan RT-PCR. Finally, as an overall 
parameter summing the effects of flavonoids on GS and GP, the glycogen content in HT29 
cells was determined using a modification of the assay (Anthron assay) described by Pflüger 
et al. (1905). Since the liver is the principal organ responsible for regulating acute changes in 
the blood sugar level, a second cell line, derived from the liver, namely the hepatoma cell line 
HepG2 was employed to determine the time and concentration related effects of flavonoids on 
mRNA transcripts of GP and GS. 
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4 Results and Discussion 
4.1 Optimization and Validation of TOPflash Luciferase 
Reporter Gene Assay  
One goal of this thesis was to optimize and validate a dual luciferase reporter gene assay in 
human embyonal kidney cells (HEK293 cells) and human colon carcinoma cells (HCT116 
cells). This kind of the luciferase reporter gene assay combines the differential biochemistries 
of two luciferase proteins; a firefly (Photinus pyralis)-derived luciferase protein and a sea 
pansy (Renilla reniformis)-derived luciferase protein. The aim was to establish an assay with 
the possibility of normalizing transfection efficiency, which is capable of detecting potential 
flavonoid-dependent stimulations of the β-catenin/Tcf/Lef-mediated transcription of Wnt 
target genes.  
The TOPflash TCF plasmid from Upstate Biotechnology, which contains 2 sets of 3 copies of 
the Tcf binding site located upstream of a thymidin kinase (TK) promoter was the 
experimental plasmid of choice. Upon occupation of the Tcf binding sites by a β-catenin/Tcf 
complex, the TK promoter initiates the expression of a downstream to the TK promoter 
located open reading frame for the firefly luciferase protein (figure 21). FOPflash, which 
carries mutated Tcf binding sites was used a negative control. For normalization of the firefly 
luciferase expression, a second plasmid; pRL-TK-Renilla vector that constitutively expresses 
low levels of the renilla luciferase protein was also employed.  
 
 
 
Figure 21: Schematic of the luciferase 
reporter gene assay with TOPflash 
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4.1.1 Optimization of the dual luciferase reporter gene assay in 
HEK293 cells (24 well plate format) 
Log Phase Growth 
The transfection of cells is most efficient when the cells are in the log phase of growth 
represented by a cell confluency between 60-70%, thus seeding experiments with HEK293 
cells in 24 well dishes were performed using varying starting populations between 10,000 - 
40,000 cells per well. The starting cell number of 40,000 cells per well, grown for 48h yielded 
the required cell confluency between 60-70%. Claudia Handrich performed the optimization 
of the starting cell population in the course of her Diploma thesis (Handrich 2004) 
Ratio of Transfection reagent to DNA concentration 
Next the optimal transfection reagent (FuGENE 6) to DNA concentration was determined 
with the optimal starting cell population of 40,000 HEK293 cells per well (24 well plate). In 
accordance with the recommendations of the producer’s protocols (Promega-(7/01)), 
TOPflash and pRL-TK-renilla vector were transiently co-tranfected at a weight ratio of 10:1. 
At a starting plasmid concentration of 300ng TOPflash and 30ng pRL-TK-renilla vector, 
transfection experiments were performed in HEK293 cells at FuGENE 6 to DNA ratios of 
3:1, 3:2 and 6:1 (w/v). The cells were harvested 24h post transfection and the luciferase 
activity determined with the dual luciferase assay kit from promega. The FuGENE 6 to DNA 
ratio 3:1 (FuGENE 6: DNA) evinced the highest transfection efficiency 24h post transfection 
as evidenced in the highest relative luciferase activity (figure 22).  
Figure 22: Determination of the optimal 
transfection efficiency in HEK293 cells with 
FuGENE6 at the FuGENE 6 to DNA ratios of 3:1, 
3:2, 6:1. The cells were transfected with 300ng 
TOPflash/FOPflash and 30ng. Transfection 
efficiencies were determined 24h post transfection 
and expressed as the mean ± SD of the ratio of 
firefly luciferase activity to renilla luciferase activity 
of three independently performed experiments  
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Optimal Plasmid Concentration for TOPflash and FOPflash 
Using the optimal FuGENE 6 to DNA ratio of 3:1, HEK293 cells were transiently transfected 
with increasing amounts of plasmid DNA (110ng and 550ng) (TOPflash: pRL-TK vector; 
10:1) to determine the DNA concentration leading to a maximum luciferase expression. The 
increase in transfected DNA amount led to a linear increase in luciferase activity of both 
TOPflash and FOPflash transfected cells (figure 23). A plot of the data of luciferase activity 
against DNA concentration produced 2 curves for TOPflash and FOPflash divergent from the 
DNA concentration of 110ng (figure 23). The rate of increase of luciferase activity in 
TOPflash transfected cells was higher than that in FOPflash transfected cells as evidenced by 
the steeper nature of the TOPflash curve. Viewing the data, the DNA concentration of 
440ng/well was thus selected for further tranfection reactions, because at this concentration, a 
maximal difference between TOPflash and FOPflash expression is evident.  
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Figure 23:  Transient transfection of HEK293 cells with TOPflash and FOPflash DNA using FuGENE 6 
at the FuGENE 6 to plasmid DNA ratio of 3:1 with increasing concentrations of plasmid DNA. 
Transfection efficiencies are expressed normalized to renilla luciferase activity and are plotted 
as mean ± SD of three independently performed experiments. 
 
Optimal Plasmid Concentration for pRL-TK-renilla 
To determine the optimal pRL-TK-renilla plasmid concentration, transient transfection 
experiments were performed using the pRL-TK-renilla vector at varying concentrations 
between 40ng and 60ng DNA with increasing intervals of 5ng DNA. The TOPflash/FOPflash 
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plasmid concentration was kept constant at 400ng. The increase in pRL-TK-vector amount led 
to a drop of the transfection efficiencies for TOPflash and FOPflash from 45ng pRL-TK-
renilla plasmid concentration (figure 24). The comparison of the relative luciferase activities 
at 40ng and 45ng pRL-TK plasmid concentrations showed an insubstantial change in activity, 
hence, for cost-effective reasons, 40ng pRL-TK plasmid/ well was employed for subsequent 
experiments.  
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Figure 24:  Determination of the optimal pRL-TK-vector DNA concentration. TOPflash and FOPflash 
transiently transfected into HEK293 cells at increasing pRL-TK-vector quantities (FuGENE 6 
to plasmid DNA ratio of 3:1). Transfection efficiencies for TOPflash/FOPflash are expressed 
normalized to renilla luciferase activity plotted as mean ± SD of three independently 
performed experiments. 
 
With the objective in mind to establish a reporter gene assay sensitive enough to detect 
increasing intracellular β-catenin levels, HEK293 cells were transiently co-transfected with 
pFLAG-CMV5a-Δ45-β-Catenin encoding a constitutively active mutant of β-catenin to 
determine if luciferase activity will be increased. pFLAG-CMV5a-Δ45-β-catenin carries the 
cDNA sequence a β-catenin protein mutated at Ser45. This mutation prevents the degradation 
of β-catenin so that an accumulation in HEK293 cells is expected. Theoritically, an increase 
in cellular β-catenin should lead to increased engagement of the Tcf binding sites on 
TOPflash and FOPflash by the β-catenin/Tcf complex. While for TOPflash-transfected cells, 
an increase in luciferase activity is expected, no change should be registered in FOPflash-
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transfected cells owing to the mutated Tcf binding sites in FOPflash. To establish if the 
reporter gene assay is sensitive enough to capture increases in β-catenin levels, HEK293 cells 
were sequentially co-transfected with pFLAG-CMV5a-Δ45-β-Cateninbetween 5ng and 30ng 
per well at a TOPflash/FOPflash concentration of 400ng per well. The normalization plasmid, 
pRL-TK renilla, was also co-transfected at a concentration of 40ng per well. Luciferase 
activity was analysed 24h post transfection. 
The serial increase of pFLAG-CMV5a-Δ45-β-catenin led to a dose dependent increase in 
luciferase activity of TOPflash-transfected cells that climaxed at 30ng with an approximately 
80 fold increase (figure 25). As expected, no change in luciferase activity was registered in 
FOPflash-transfected cells. These results are in accordance with the findings of Ishitani et al. 
(1999) who reported a 25 fold increase of luciferase actvity when HEK293 cells were co-
transfected with TOPflash and β-catenin that lacked the entire N-terminal region. No increase 
in luciferase activity was also detected when FOPflash was co-transfected with β-catenin 
(Ishitani 1999). In view of the stimulated increase of luciferase activity by the transient 
tranfection of pFLAG-CMV5a-Δ45-β-catenin, the reporter gene assay was thus considered 
validated. 
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Figure 25: Transient co-transfection of HEK293 cells with TOPflash/FOPflash (400ng) and pFLAG-
CMV5a-Δ45-β-catenin at the FuGENE 6: plasmid DNA ratio of 3:1. 40ng pRL-TK-vector was 
also co-tranfected as the normalization plasmid. TOPflash n=4; FOPflash n = 2 
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4.1.2 Optimization of Transfection Efficiency for Reporter Gene 
Assay in HEK293 cells (10cm Petri dish format) 
Transfection optimization experiments were then performed only when cell confluency was 
between 60-70%. To obtain the optimal seeding cell number, seeding experiments were 
performed in 10cm (55cm2) tissue culture dishes with varying amounts (500,000, 750,000 and 
1.0 x 106) of HEK293 cells for 48 and 72h. 500,000 or 1.5 x 106 HEK293 cells grown for 72h 
and 48h respectively yielded cell confluencies between 60-70%. HEK293 cells were hence 
seeded in 10cm Petri dishes (55cm2) at a density of 500,000 cells per dish and subsequently 
grown for 72 hours. Transfection was performed at varying FuGENE 6 volumes and a 
constant plasmid DNA concentration of 5µg. (FuGENE 6: DNA; 3:1, 6:1, 9:1). 
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Figure 26: Determination of (A) the optimal FuGENE 6 to plasmid DNA ratio (TOPflash/FOPflash = 
5µg) and (B) the optimal pFLAG-CMV5a-Δ45-β-catenin for co-transfection experiments with 
TOPflash/FOPflash.  
Similar to the transfection experiments performed in 24 well plates, the transfection of 
HEK293 cells in 10cm plates at the FuGENE 6/DNA ratio of 3:1 produced the highest 
transfection efficiency when 5µg plasmid DNA was employed (figure 26A). When pFLAG-
CMV5a-Δ45-β-catenin was serially co-transfected with 5µg TOPflash at the optimal 
FuGENE 6/DNA ratio of 3:1, luciferase activity was increased in a concentration dependent 
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manner (figure 26B). All tested concentrations of pFLAG-CMV5a-Δ45-β-catenin 
substantially increased luciferase activity. 1µg pFLAG-CMV5a-Δ45-β-catenin, which caused 
an approximately 400 fold surge in luciferase activity was arbitrarily selected for further 
incubation experiments. 
4.1.3 Optimization of Transfection Efficiency for Reporter Gene 
Assay in HT29 cells and HCT116 cells (10cm Petri dish 
format) 
Aim of the reporter gene assay was to establish an assay in a human colon carcinoma cell line, 
preferentially in HT29 cells since most experiments on the impact of flavonoids performed 
within the work group were carried out with HT29 cells.  
All attempts to transiently tranfect HT29 cells with TOPflash or FOPflash remained 
unsuccessful. As many as 4 different transfection reagents namely; Fugene 6 from ROCHE, 
Gene jammer from Qiagen as well as Effectene and Superfect from Strategene were tested but 
none yielded successful results. 
Transfection optimization experiments in HCT116 cells were performed when the cells had 
attained a confluency between 60-70%. This was attained when HCT116 cells (0.3 x 106 cells) 
were seeded in a 10cm Petri dish (55cm2) and grown for 72h. Transfection optimization 
experiments were then performed using FuGENE 6 at the following FuGENE 6 to DNA 
combinations: 3:1, 6:1 and 9:1 whereby different DNA concentrations between 1-5µg per dish 
were employed. 24h after incubation the cells were lysed in cell culture lysis buffer (Promega) 
and the luciferase activity determined. The combination 9:1 (FuGENE 6: DNA) produced the 
highest transfection efficiency in HCT116 cells (figure 27) at all plasmid concentrations 
tested. Luciferase activities were normalized to protein concentration and are represented in 
figure 27 as luciferase activity per mg protein since initial experiments with pRL-TK-renilla 
in HEK293 cells showed that renilla expression was influenced by the test compounds. For 
subsequent incubation experiments, HCT116 cells were transfected at a FuGENE 6 to plasmid 
DNA ration of 9:1 using 5µg plamid DNA since this concentration yielded the highest 
transfection efficiency.  
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Figure 27  Determination of the optimal FuGENE 6 to plasmid DNA ratio for transient transfection of 
HCT116 cells with TOPflash at different concentrations. 
4.1.4 Discussion of Optimization of the Tcf/Lef Reporter gene 
Assay  
Washing steps with PBS in experiments with HEK293 cells were always accompanied with a 
tremendous loss of cells since HEK293 cells easily detach due to their semi-adherent nature. 
The consequence was an uneven distribution of cells in the wells leading to fluctuations in the 
transfection efficiencies from well to well and hence reduced experimental consistency. To 
circumvent this problem, the reporter gene assay in the 24 well format was modified. First the 
cells were seeded in a 10cm Petri dish. After attaining the needed confluency they were 
transiently transfected and allowed to acclimitize and stabilize for 24h. Thereafter the cells 
were treated with typsin/EDTA (10s) to promote efficient separation during counting. The 
cells were plated anew, this time in 12 well dishes (HEK293 cells: 200,000 cells per well, 
HCT116 cells: 150,000 cells per well) and grown for 24h before being subjected to incubation 
experiments. Because HEK293 cells were washed away during medium replacement, 
incubation occurred without removal of medium by adding a 2 fold concentrated dilution of 
the test substance to the well. Replatting the cells after transfection guaranteed higher and 
same transfection efficiencies in each well per experiment thus improving reproducibility and 
data consistency. This approach also reduced the number of handling steps and was time-
effective since less time was spent per well during transfection. This experimental sequence 
was also employed for tranfection experiments with HCT116 cells with the difference that the 
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experimental steps were interjected with washing steps as HCT116 cell grow adherent and do 
not wash away easily.  
Some flavonoids such as quercetin are known to bind to serum proteins contained in the 
culturing medium and thus influence their cellular bioavailabilty (Kitson 2004). A possible 
remedy for this problem would be to perform incubation experiments in a serum free medium. 
However incubation under serum-free conditions for long periods was not applicable for 
HEK293 cells, since they could not survive in serum free medium. Serum starvation of 
HEK293 cells led to increased cell detachment and death observable by visual and 
microscopic inspection of the cell culture. This phenomenom was also evidenced in a reduced 
luciferase activity in tranfection experiments with HEK293 cells (5µg TOPflash and 0.5µg 
pRL-TK-renilla) cultivated in a serum void medium versus a serum-containing medium 
(10%, 20%). The relative luciferase activity of serum-starved cells was reduced by 50% 
compared to cells grown in 10% and 20% FCS for 19h (figure 28). For this reason, reporter 
gene assays with HEK293 cells were carried out in serum containing medium (10% fetal calf 
serum). For cost-effective reasons 10% FCS was chosen over 20% FCS since both 
concentrations had similar effects on luciferase activity (figure 28). Data on HCT116 cells 
indicated that, in contrast to HEK293 cells, HCT116 cells are still viable after long periods of 
serum starvation. Incubation with flavonoids was hence performed in medium void of serum. 
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Figure 28: Effect of serum on the transfection efficiency in HEK293 cells measured 19h post transfection 
(with 5µg TOPflash/FOPflash). The results are expressed as mean ± SD of the relative 
luciferase activity (Firefly: Renilla) (TOPflash n>3, FOPflash n=1) 
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As described in the previous chapter pRL-TK-renilla-vector was employed for normalization 
in the dual luciferase reporter gene assay. In order to function as an efficient normalization 
tool, the expression of renilla luciferase protein, which occurs constitutively, must be 
indifferent to stimulus by the test compounds. However, early data from orienting incubation 
experiments with transiently transfected HEK293 cells could not unambiguously dismiss the 
contingency of a modulation of renilla luciferase expression by the test substances. As an 
alternative method of normalization, the luciferase activity was normalized to protein levels of 
the cells. This constituted a deviation from the initially intended dual luciferase reporter gene 
assay. To compare these two methods of normalization, HEK293 cells transfected with 10µg 
TOPflash and 1µg pRL-TK-renilla were incubated with two compounds; LiCl and SB216763 
known to inhibit GSK-3 kinase activity in vitro (Rao et al. 2005; Rochat et al. 2004). 
Theoretically the inhibition of GSK-3 should provoke increased β-catenin levels in HEK293 
cells and hence increase luciferase activity. In figure 29 the shaded bars represent results 
normalized to renilla expression and the red coloured bars represent data normalized to 
protein concentration. Normalization to protein indicated an about 3 fold increase of 
luciferase activity by 10mM LiCl, which is in line with literature observations (Rao et al. 
2005). On the other hand normalization to renilla suggests no inhibition of GSK-3 by LiCl. It 
was hence conjectured that the differences in the effects produced by LiCl might derive from 
fluctuation in renilla expression. Both methods of normalization resulted in similar results for 
SB16763 at both tested concentrations suggesting no effect on renilla expression. 10µM 
SB216763 caused an approximately 14 fold increase of luciferase activity compared to a circa  
 
Figure 29: Effect of LiCl and SB216763 on 
the transcriptional activity of Tcf/Lef diven 
luciferase activity in HEK293 cells after 19h 
incubation. The results are represented as test 
over control (control = HEK293 cells treated 
with DMSO (1%)) of the mean ± SD of at least 
three independent experiments  
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3 fold increase at 5µM (figure 29). 10µM SB216763 was therefore employed for subsequent 
experiments as a positive control for GSK-3 inhibition since SB216763 seemed to potently 
inhibit GSK-3 at this concentration, a result consistent with literature descriptions of 
SB216763 as a potent inhibitor of GSK-3 (Meijer et al. 2004). These results also led to the 
choosing of the protein normalization method over the renilla method as the principal method 
of normalization for reporter gene assay results. 
In summary, it has been shown that the optimized firefly reporter gene assay is a suitable 
model for measuring the inducing effects of substances on the β-catenin/Tcf/Lef 
transcriptional activity in HEK293 cells and HCT 116 cells. To verify the functionality and 
hence validate the luciferase reporter gene assay, potent inhibitors of GSK-3, (LiCl, 
SB216763) were employed. These inhibitors successfully increased the β-catenin dependent 
induction of Tcf/Lef drive luciferase activity in HEK293 cells. In addition, the transient co-
transfection of HEK293 cells with a mutated form of β-catenin, strongly increased luciferase 
activity (figure 25). Table 3 summarizes the conditions optimized for the reporter gene assays 
in HEK293 and HCT116 cells 
Table 3: Parameters for the firefly reporter gene assay in HEK293 cells and HCT116 cells 
 HEK293 cells HCT116 cells  
Seeding amount/ 10cm dish 500,000 cells 300,000 cells 
Growth incubation after 
seeding in 10cm dish 72h 72h 
Transfetion 
5µg TOPflash/FOPflash alone 
or with 1µg pFLAG-CMV5a-
Δ45-β-Catenin 
5µg TOPflash/FOPflash 
Acclimitization length 24h 24h 
Seeding amount/12 well plate 200,000 cells  150,000 cells  
Growth incubation after 
seeding in 12 well dish 24h 24h 
Incubation 24h                       (in serum containing medium)
24h                       
(in serum free medium) 
Normaliszation of results Protein content Protein content 
. 
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4.2 Modulation of the Wnt-signalling Pathway by 
Flavonoids 
4.2.1 Effects on the β-Catenin/Tcf/Lef Mediated Transcriptional 
Activity 
The β-catenin/Tcf/Lef mediated transcriptional activity is measured as a cumulative parameter 
that sums up the effects of the tested flavonoid on the upstream elements of the Wnt-
signalling cascade. Free β-catenin in the cytosol is transduced in to the nucleus where it 
associates with the transcription factors of the Tcf/Lef family. To investigate whether the 
effects flavonoids on the level of cellular and, in particular, on nuclear β-catenin would 
prompt a transcriptional response mediated by the β-catenin/Tcf/Lef transcriptional complex, 
the optimized luciferase reporter gene assay was employed. The expression of the luciferase 
reporter gene after transient transfection of the reporter plasmid TOPflash represents the 
expression of a Tcf/Lef driven gene. 
Both HEK293 cells and HCT116 cells were incubated with the polyphenols of interest 
(quercetin, (-) epigallo catechin gallate (EGCG), epicatechin, pholretin, phloridzin, and the 
extract (AE02) of a consumer relevant apple juice) for 24h after transient transfection with the 
experimental plasmid. While HEK293 cells were transfected either with TOPflash only 
(HEK293-TOP cells) (chapter 6.3.5.3) or with TOPflash in combination with pFLAG-
CMV5a-Δ45-β-catenin (HEK293-TOP-CAT cells) (chapter 6.3.6.3), HCT116 cells were 
transfected with only TOPflash. FOPflash transfected cells (chapter 6.3.5.3) were used as a 
negative transfection control to determine leakages of luciferase expression. The maleimide 
SB-216763, a GSK-3β specific inhibitor served as the positive control substance. The results 
are presented in percentage as test over control (T/C (%)) with the control being cells treated 
with the solvent DMSO (100%). 
4.2.1.1 Effect of Flavonoids on β-catenin/Tcf/Lef driven transcriptional 
Activity in HEK 293 Cells  
In HEK293 cells transfected with TOPflash (5µg) only, 10µM of the positive control 
compound (SB216763) potently increased luciferase activity up to 21 fold above that of the 
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DMSO solvent control cells (figure 30A) after 24h. In comparison to the positive control, the 
flavonol quercetin also increased luciferase activity, albeit moderately. The effect was 
nevertheless significant at 50µM (figure 30A), thus indicating a possible induction of the β-
catenin/Tcf/Lef-driven gene transcription. The green tea catechin EGCG did not affect β-
catenin/Tcf/Lef-communicated luciferase expression up to 50µM (figure 30B). 
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Figure 30: Impact of flavonoids on the Tcf/Lef mediated transcriptional activity in HEK 293 cells 
(TOPflash (5µg)) measured as luciferase activity after 24h incubation with (A) quercetin and 
(B) EGCG. The results are presented as test over control of the mean ± SD of at least three 
independent experiments. Significance calcultations were performed with the student’s t-test 
(* = p < 0.05; *** = p < 0.001). SB, SB216763. 
 
In comparison to the singly tested flavonoids, the effect of a polyphenol-rich extract of a 
consumer-relevant apple juice blend AE02 on the β-catenin/Tcf driven transcriptional activity 
was investigated (Schaefer et al. 2006). The juice of AE02 was prepared from a mixture of 
table apples (20%) and cider apple types harvested in the year 2002, which included, Topaz 
(25%), Bohnapfel (17.5%), Winterrambour (22.5%), and Bittenfelder (15%). The polyphenol 
fraction of the juice was seperated as described in Schaefer et al. (2005) and about 50% of the 
polyphenol composition was identified as listed in table 4 
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Table 4: Polyphenolic composition of the apple juice extract AE02 (Schaefer et al. 2006) (1g/l) Total 
polyphenolic amount; 576.4 mg 
Compound  [mg] 
Procyanidin B1 7.0 
Procyanidin B2 15.1 
Epicatechin 19.2 
Phloretinglycoside 1 24.7 
Phloretinglycoside 2 9.0 
Phloretinxyloglucoside 138.9 
Phloridzin 27.9 
Chlorogenic acid 181.5 
3-Coumaroyl-quinic acid 9.5 
Caffeic acid 4.8 
4-Coumaroyl-quinic acid 77.3 
5-Coumaroyl-quinic acid 10.4 
Quercetin-3-rutinoside 2.6 
Quercetin-3-galactoside 0.8 
Quercetin-3-glucoside 1.4 
Quercetin-3-rhamnoside 4.1 
 
AE02 had no effect on the luciferase activity in HEK293 cells transfected with TOPflash, 
after 24h incubation at concentrations between 100µg/ml and 500µg/ml AE02, suggesting no 
influence on the β-catenin/Tcf driven transcriptional activity (figure 31A), hence no 
proliferation stimulus. 
Incubation of HEK293 (transiently transfected with TOPflash only) with the aglycones 
phloretin (10µM, 50µM), and phloridzin (10µM, 50µM), whose glycosides richly occur in 
AE02 extract (table 4) yielded no change in luciferase activity compared to DMSO treated 
cells (figure 31B). Epicatechin (50µM, 100µM), another polyphenol represented in the AE02 
had no effect on the luciferase activity (figure 31B). 
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Figure 31: Effect on the Tcf/Lef mediated transcriptional activity in HEK 293 cells (TOPflash (5µg)) 
measured as luciferase activity after 24h incubation with (A) apple juice extract AE02 and (B) 
phloretin, phoridzin and epicatechin. The results are represented as test over control of the 
mean ± SD of at least three independent experiments.  
 
Most tumours of colonic origin are hallmarked by an elevated cellular β-catenin level (Bright-
Thomas and Hargest 2003). To emulate the situation in colon tumour cells, β-catenin (1µg), 
mutated at Ser45 was transiently co-transfected with TOPflash (5µg) into HEK293 cells. This 
mutation precludes the phosphorylation and hence the degradation of β-catenin so that β-
catenin accumulates in the cell.  
When in addition to TOPflash HEK293 cells were co-transfected with mutated β-catenin 
(HEK293-TOP-CAT), The GSK-3 inhibitor (10µM) SB216763 caused an approximately 1.4 
fold increase in luciferase activity (figure 32A). Quercetin concentration-dependently 
increased luciferase activity in HEK293-TOP-CAT cells overexpressing mutated β-catenin 
after 24h of incubation. The induction of luciferase activity was significant from 25µM and 
attaining an approximately 2 fold increase at 50µM compared to solvent control (figure 32A). 
EGCG affected HEK293-TOP-CAT cells similarly as HEK293-TOP inducing no change in 
luciferase activity up to 50µM EGCG following a 24h (figure 32B). 
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Figure 32: Impact of (A) quercetin and (B) EGCG on the β-catenin/Tcf/Lef driven luciferase expression 
in HEK393 cells after 24h incubation. The cells were co-transfected with TOPflash (5µg) and 
pFLAG-CMV5a-Δ45-β-catenin (1µg). The results are presented as test over control of the 
mean ± SD of at least three independent experiments. Significance calcultations were 
performed with the student’s t-test (* = p < 0.05; ** = p < 0.01; *** = p < 0.001).  
 
4.2.1.2 Effect of Flavonoids on β-catenin/Tcf driven transcriptional Activity 
in HCT116 Cells  
The serum free incubation of HCT116 cells, known to possess one mutated allele for (Ser45) 
β-catenin, with quercetin (1µM, 10µM, 25µM) lead to a concentration dependent stimulation 
of luciferase expression, significant from 10µM (approximately 2 fold increase). SB216763 at 
a concentration of 10µM caused a marginal but significant increase in luciferase activity after 
24h while EGCG, phloretin and epicatechin caused no substantial change of the luciferase 
activity in HCT116 cells after 24h of serum free incubation (figure 33B). 
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Figure 33: Effect on the Tcf/Lef mediated transcriptional activity in HCT116 cells (TOPflash (5µg)) 
measured as luciferase activity after 24h incubation with (A) quercetin and (B) phloretin, 
phoridzin and epicatechin. SB16763 served as a positive control for the induction of luciferase 
expression. The results are presented as test over control of the mean ± SD of two or more 
experiments. 
 
In summary, it has been shown that quercetin might influence the β-catenin/Tcf/Lef driven 
transcriptional activity. Quercetin concentration-dependently upregulated luciferase 
expression in HEK293 cells reaching a significant increase of 182 ± 12.4% of control at 
50µM (figure 30A). However compared to the positive control, SB216763, with over 2000% 
induction of luciferase activity, quercetin is a weak inducer of luciferase activity at 50µM 
(figure 30A). When mutated β-catenin (Ser45) was co-expressed in emulation of the situation 
in some colon cancer cells, quercetin still significantly increased luciferase expression in 
HEK293 cells, this time at a lower concentration (25µM quercetin) (figure 32A)  in 
comparison to cells expressing only the Tcf/Lef binding sites. In the human colon carcinoma 
cell line HCT116, which is heterozygous for β-catenin and hence overexpresses β-catenin 
mutated at Ser45, quercetin also caused concentration-dependent increases of luciferase 
activity significant at even as low as 10µM. At 25µM quercetin, luciferase activity in 
HCT116 cells was increased upto about 5 fold compared to the solvent control (figure 33A). 
These results show that quercetin was a more potent inducer of Tcf/Lef driven luciferase 
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activity in HCT116 cells than in HEK293 cells co-expressing mutated β-catenin. Taken 
together, the results suggest that quercetin might act via the Wnt signalling pathway, 
modulating β-catenin/Tcf/Lef dependent gene expression probably causing a stronger 
proliferation stimulus in tumour cells. Indeed this hypothesis borrows support from the 
findings of van der Woude et al. (2003) who reported a cell type- and concentration-
dependent biphasic influence of querectin on the growth of tumour cells. The growth of 
HCT116 cells was promoted by quercetin up to the concentration of 30µM, beyond which, 
cell growth became inhibited (van der Woude et al. 2003). Van der Woude and colleagues 
further posited in a follow-up paper that the proliferative effects of quercetin might be 
mediated via the estrogen receptor (ER) (van der Woude et al. 2005). Cumulatively, the 
results of this thesis suggest that in addition to the ER pathway, the Wnt pathway may also be 
involved in mediating quercetin’s dependent proliferation stimulus.  
The apple juice extract AE02 had no effect on the β-catenin-dependent transcriptional activiy 
in HEK293 cells up to a concentration of 500µg/ml suggesting that AE02 does not cause a 
stabilization of β-catenin. Indeed, experiments with AE02, performed in HT29 cells by Dr. 
Melanie Kern during her PhD fellowship, indicated that AE02 did not influence cellular β-
catenin levels up to 250µg/ml. In contrast AE02 at 500µg/ml significantly reduced the cellular 
and phosphorylated levels of β-catenin after a 24h challenge (Kern et al. 2006). It is 
interesting that quercetin, when tested as an aglycone caused a dose dependent increase of 
luciferase acivity in HEK293 cells and HCT116 cells, yet within AE02, no effect on 
luciferase activity was registered. Apparently, quercetin at the concentration present in AE02 
did not affect β-catenin homoestasis. Furthermore quercetin has been detected in AE02 
mainly as glycosides. Identified in AE02 are the rhamnoside, glucoside, rutinoside, and 
galactoside of quercetin with a total concentration of 9µM (table 4.4-1). Given that, these 
quercetin glycosides have been shown in several test systems to be either inactive or at most 
bioactively less potent than the quercetin aglycone (Shen et al. 2003; Veeriah et al. 2006; 
Kern et al. 2005), it is hence conceivable that these quercetin glycosides are too low to 
increase the mediating potential of AE02. 
The other characteristic compounds of AE02, phloretin, phloridzin and epicatechin did not 
influence luciferase expression, neither in HEK293 cells nor in HCT116 cells. The tea 
catechin, EGCG also had no effect on luciferase activity, hence on Tcf/Lef driven 
transcriptional activity neither in HEK293 cells nor HCT116 cells.  
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The GSK-3 inhibitor, SB216763, at 10µM, significantly induced luciferase activity in the cell 
models tested (figures 30A/32A&33A) indicating an induction of Tcf/lef driven 
transcriptional activity. In HEK293 cells, with a high expression of the Tcf binding sites, 
owing to the transfection of TOPflash (HEK293-TOP cells), SB216763 had the highest 
impact causing a significant near 22 fold increase of luciferase activity (figure 30A). 
However, when HEK293 cells and HCT116 cells expressing high levels of mutated β-catenin 
in addition to Tcf-binding sites were incubated with SB216763, the potent induction of 
luciferase activity observed in HEK293-TOP cells became much less potent, with a 12-14 
fold reduction, yet to levels still significantly higher than the solvent control (figures 
32A&33A). The lesser potency of SB216763 in HEK293-TOP-CAT cells and HCT116 cells 
than in HEK293-TOP cells may result from an exhaustion of the Tcf/Lef transcriptional 
factors by the overexpression of β-catenin so that luciferase activity plateaus leaving little 
room for further increase. Cumulatively, these results lend support to the thesis that 
SB216763 can inihibit GSK-3 kinase activity within the APC complex and that such 
inhibition might lead to the accumulation of β-catenin in the cell with the result that the Tcf-
transcriptional activity is augmented constituting a proliferation stimulus. 
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4.2.2 Effects on Glycogen Synthase Kinase 3 
The results obtained from the Tcf/Lef reporter gene assay identified quercetin, the most 
abundant flavonoid in the human diet as an inducer of Tcf/Lef driven luciferase activity, 
suggesting potential induction of proliferation stimulating genes. Thus the impact of quercetin 
on GSK-3α and GSK-3β upstream of the β-catenin-dependent gene transcription were 
investigated by western blot analysis in order to elucidate its mechanism of action. Because of 
its lack of influence on the Tcf/Lef transcription combined with its lack of influence of 
isolated GSK-3 (kinase assay) (schreiner 2004), the most abundant tea catechin EGCG was 
included in the studies as a negative control substance. SB216763 was employed at a 
concentration of 10µM as a control for GSK-3 inhibition. HT29 cells were incubated with the 
respective flavonoid for 24h under serum-free conditions.  
4.2.2.1 Activity and Expression of GSK-3α/β 
The phosphorylation of residues Ser21 or Ser9 of GSK-3α or GSK-3β respectively potentiates 
the inhibition of the respective enzyme activity. Hence, the phosphorylation status of GSK-3 
was determined, using antiphospho-GSK-3α/β (Cell Signaling) by Western blot analysis as a 
barometer for flavonoid-dependent inhibition of GSK-3 in human colon cancer cells. The 
overall expression of GSK-3 was also determined using anti-GSK-3α/β antibodies (Santa 
Cruz).  
Intracellular levels of phosphorylated GSK-3α (figure 34A/C) and phosphorylated GSK-3β 
(figure 34B/C) in HT29 cells were indifferent to treatment with up to 75µM quercetin (figure 
indicative of an insubstantial inhibition of GSK-3α and GSK-3β enzyme activity by quercetin. 
However, quercetin caused a marginal, yet significant reduction in the protein level of GSK-
3α, which was not concentration dependent. At a concentration of 75µM quercetin GSK-3α 
protein levels experienced a remission to control levels (figure 34A/C). 
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Figure 34: Western blot analysis of (A) GSK-3α and (B) GSK-3β in HT29 cells after 24h treatment with 
quercetin. SB216763 (SB) was employed as a control for the inhibition of GSK-3 activity. The 
data are presented as test over control (%) with the control being cells treated with 1% 
DMSO. The data are the mean ± SD of at least 3 independent experiments with similar 
outcome with (C) showing a respective representative Western blot with C as control (solvent-
treated cells). The significances indicated are calculated compared to the solvent control using 
student’s t-test (*** = p < 0.001). 
 
In contrast to quercetin, the treatment of HT29 cells with EGCG for 24h resulted in the 
increase of GSK-3α/β (figure 35C) phosphorylation, which is indication of decreased enzyme 
activity of GSK-3α and GSK-3β (figure 35A/B). Phosphorylated GSK-3α levels increased 
significantly at a concentration of 0.5µM EGCG and peaked at 25µM EGCG (figure 35A). 
EGCG increased the levels of phosphorylated GSK-3β significantly from the concentration 
0.5µM of EGCG (figure 35B), although less pronounced than for the GSK-3α isoform. 
Concomitantly, the protein level of total GSK-3α and -β was not affected by treatment of 
HT29 cells with EGCG (figure 35A/B). 
Interestingly, incubation of HT29 cells with the potent GSK-3 inhibitor, SB216763 had 
different outcomes on the phosphorylation of the two GSK-3 isoforms (figure 35A/B). 
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Whereas the intracellular level of phosphorylated GSK-3α in HT29 cells was significantly 
enhanced (up to 174 ± 27%) by SB216763 (10µM) (figure 35A/C) indicating inhibition of the 
enzyme activity, the amount of phosphorylated GSK-3β in HT29 cells was notably 
diminished by about 60%, suggesting the presence of active GSK-3β enzyme (figure 35B/C). 
The protein levels of both GSK-3 isoenzymes were marginally yet significantly increased by 
this compound (figure 35A/B/C). 
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Figure 35: Western blot analysis of (A) GSK-3α and (B) GSK-3β in HT29 cells after 24 h treatment with 
EGCG. SB216763 was included in the tests as a control for the inhibition of GSK-3 activity. 
The data are presented as test over control (%) with the control being cells treated with 1 % 
DMSO. The data are the mean ± SD of at least 3 independent experiments with similar 
outcome, with (C) showing a respective representative Western blot (C=control (solvent-
treated cells)). The significances indicated are calculated compared to the solvent control 
using student’s t-test (*** = p < 0.001). 
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In summary, EGCG was identified as a potent inhibitor of both the α- and β-isoform of GSK-
3 in the colon cancer cell line HT29. Sequential treatment with concentration of EGCG up to 
50µM for 24h resulted in a significant increase of phosphorylation of GSK-3α and GSK-3β at 
Ser21 and Ser9 respectively, consistent with inactivation of the kinase (figure 35A/B/C). The 
inhibition of GSK-3α/β raises the question of the mode of action of EGCG. GSK-3α/β protein 
levels were not affected by EGCG up to 50µM (figure 35A/B/C) dismissing the possible 
upregulation of enzyme activity due to increased protein expression. In contrast to the potent 
inhibition of GSK-3 in HT29 cells, isolated GSK-3α/β has been shown to be indifferent to 
treatment with up to 100µM EGCG (Schreiner 2004). Although EGCG is readily taken up by 
HT29 cells with a predominant localization in the cytosol (Lambert et al. 2006; Hong et al. 
2002), these results collectively suggest that the inhibition of GSK-3α and GSK-3β may 
primarily be based, on the interference of EGCG with other signalling cascades that target 
GSK-3 rather than on a direct targeting of the enzyme. Protein kinase A (PKA) of the cAMP 
pathway or protein kinase B (PKB) of the insulin/PI3 kinase cascade or Protein kinase C 
(PKC) all of which have been shown in vitro to target the Ser21 and Ser9 phosporylation sites 
of the α- and β-isoforms of GSK (Fang et al. 2000; Cross et al. 1995), are potential candidates 
involved in the communication of EGCG’s inhibition of the GSK-3 isoenzymes. In 
accordance with this argument are the findings Lorenz and co-workers showing in endothelial 
cells that EGCG stimulates the activity of PKB and PKA at the same concentrations range 
employed in this work (1-50µM) (Lorenz et al. 2004). 
Recently, it has been shown that dependent on cell type and cell culture conditions the 
autooxidation of EGCG can generate substantial amounts of H2O2 (figure 18) (Yang et al. 
2006). Thus it is argued that the cellular effects attributed to EGCG might be totally or at least 
in part owed to the generated H2O2 (Dashwood et al. 2002). Hydrogen peroxide (100µM and 
500µM) has however been reported to activate GSK-3β in HEK293 and in other cell lines 
(Shin et al. 2006). In contrast to the reported effect of H2O2, EGCG effectively inhibited 
GSK-3α and GSK-3β in HT29 cells (figure 35A/B/C). Furthermore, Dashwood et al. (2002) 
reported that upto 20µM H2O2 did not influence Tcf/Lef transcriptional activity in HEK293 
cells. Finally, even at 0.5µM EGCG (figure 35A/B/C), a concentration far below the reported 
concentrations of EGCG that usually generate substantial amounts of H2O2, GSK-3β  
phosphorylation (Ser9) indicative of the inhibition of enzyme activity was already 
significantly increased (Dashwood et al. 2002). Cumulatively, these facts permit the 
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conclusion that H2O2 production by EGCG is likely of no substantial relevance for the 
biological effects observed in this work on key elements of the Wnt pathway.  
Quercetin, employed at concentrations up to 75µM did not influence the phosphorylation 
status of either isoform of GSK-3 (figure 34A/B/C) indicating no influence on enzyme 
activity. Although the protein levels of both isoforms were marginally reduced, no 
consequences for the enzyme phosphorylation were evident. The lack of concentration 
dependency, coupled with the limited nature of the effects on protein expression levels argues 
for a non-specific mechanism, rather than a specific targeting of the respective enzyme in the 
cell. As a plausible explanation might be quercetin’s postulated influence on protein 
synthesis. Quercetin has been shown to repress protein synthesis by activating eIF2alpha 
kinases (Ito et al. 1999). Conclusively, these results suggest that no inhibition of GSK-3 is 
expected from treatment of HT29 cells with quercetin.  
Interestingly, SB216763 (10µM) had opposing outcomes on the phosphorylation of the two 
GSK-3 isoforms (figure 35A/B/C) in HT29 cells. The intracellular level of phosphorylated 
GSK-3α was significantly enhanced (up to 174 ± 27% of control) (figure 35A/C) indicating 
effective inhibition of the enzyme activity. On the other hand, the amount of phosphorylated 
GSK-3β was notably diminished, suggesting the presence of active GSK-3β enzyme (figure 
35B/C). However, SB216763 is highly cell permeable (Meijer et al. 2004) and has been 
shown to indiscriminately bind to and block the active ATP binding sites of both GSK-3 
isoforms (Coghlan et al. 2000; Meijer et al. 2004), thus inhibiting kinase activity. It is 
therefore unlikely that in HT29 cells GSK-3β will be active. The decreased phosphorylation 
might most probably be due to a concurrent inactivation of a kinase by SB216763 that targets 
GSK-3β at Ser9. The protein levels of both GSK-3 isoenzymes were marginally yet not 
significantly increased by this compound (figure 35A/B/C). This probably might be due to 
increased protein synthesis of the cells to compensate for the inhibition of GSK-3 activity. 
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4.2.3 Effect on β-Catenin 
The impact of quercetin and EGCG on the activity and expression of GSK-3α/β raised the 
question whether the homeostatsis of β-catenin in HT29 cells is equally influenced by these 
flavonoids. Western blot experiments using polyclonal antibodies against total β-catenin 
(92kDA) and β-catenin phosphorylated at Ser33, Ser37 and Thr41 (92kDA) was performed in 
that respect. The incubation of the cells occurred in serum-free medium for 24h and the GSK-
3 inhibitor SB216763 (10µM) was included in the experiments as a positive control. 
4.2.3.1 Phosphorylation and Protein Level of cellular β-Catenin 
Quercetin did not significantly affect the level of phosphorylated β-catenin at concentrations 
ranging from 10µM to 75µM quercetin (figure 36A/B). Total β-catenin level in HT29 cells 
remained unaffected as well (figure 36A/B).  
As depicted in figure 36C, treatment of HT29 cells with the GSK-3 inhibitor SB216763 
(10µM) for 24h yielded a strong reduction in the immuno-reactivity of anti-phospho-β-catenin 
(figure 36B) indicating that SB216763 potently reduced phosphorylated β-catenin (figure 
36A). In line with this result, total β-catenin levels rose appreciably (figure 36A), as indicated 
by the increase in immuno-reactivity of the anti-β-catenin antibody (figure 36B). These results 
are supportive of the result that SB216763 effectively inhibits GSK-3 in the APC complex. 
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Figure 36: Effect of quercetin on phosphorylated and total β-catenin in HT29 cells with (A) showing a 
chart representation of the results after treatement for 24 h and (B) showing respective 
western blots for quercetin and SB216763. The results, plotted as test over control (T/C (%)), 
are presented as the mean ± SD of at least 3 independent experiments with similar outcome. 
Cells treated with 1% DMSO were employed as control while a GSK-3 selective inhibitor 
SB216763 served as the positive control. The significances indicated are calculated compared 
to the solvent control using student’s t-test (*** p < 0.001). 
 
EGCG effectively diminished the immno-reactivity of anti-phospho-β-catenin in a 
concentration dependent manner from 10µM with an IC50 value of 24 ± 7 µM, which is 
indicative of a reduction in the amount of phosphorylated β-catenin in HT29 cells (figure 
37A/B). EGCG also caused a concentration dependent reduction in the amount of total β-
catenin (figure 37A/B). The observed effect of EGCG on phosphorylated and total β-catenin 
in HT29 cells stands at variance with what would be expected, considering that with the 
inhibition of GSK-3 activity, non-phosphorylated β-catenin should escape proteasomal 
degradation and accumulate in the cell as was seen with SB216763 (figure 37A/B). 
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Figure 37: Effect of EGCG on phosphorylated and total β-catenin in HT29 cells with (A) showing a chart 
representation of the results after treatement for 24 h and (B) showing respective western 
blots for quercetin and SB216763. The results, plotted as test over control (T/C (%)), are 
presented as the mean ± SD of at least 3 independent experiments with similar outcome. Cells 
treated with 1% DMSO were employed as control while a GSK-3 selective inhibitor SB216763 
served as the positive control. The significances indicated are calculated compared to the 
solvent control using student’s t-test (*** p < 0.001). 
 Effect on the nuclear Level of β-Catenin  4.2.3.2
In view of the fact that intra-nuclear β-catenin levels crucially contribute to the Tcf/Lef-
dependent transcriptional response (Hurlstone and Clevers 2002; van Noort and Clevers 2002) 
and that EGCG markedly diminished total β-catenin levels while quercetin did not; it was of 
interest to study whether the nuclear β-catenin levels were similarly influenced in response to 
treatment with quercetin and EGCG. For this purpose, the nuclear fraction of HT29 cells was 
isolated after a serum free incubation with these flavonoids for 24h. The β-catenin levels were 
detected by Western blot analysis using polyclonal antibodies against β-catenin. 
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Quercetin caused no significant impact on nuclear β-catenin level in HT29 cells (figure 
38A/B). In contrast, EGCG diminished nuclear β-catenin an effect significant (50% T/C) at 
the concentration of 50µM (figure 38A/B), suggesting a suppression of Tcf/Lef driven gene 
transcription. The GSK-3 inhibitor SB216763 used as a positive control caused a strong 
increase of β-catenin in HT29 nuclei (figure 38A/B), in line with the effect of SB216763 on 
total β-catenin levels (figure 37A/B). 
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Figure 38: Effect of quercetin, EGCG and SB216763 on nuclear β-catenin in HT29 with (A) depicting a 
chart representation and (B) showing an exemplary picture representation after treatment for 
24h. The GSK-3 selective inhibitor SB216763 served as positive control. The data are plotted 
as test over control (%) with the control being cells treated with 1% DMSO. The data are the 
mean ± SD of at least three independent experiments. The significances indicated are 
calculated in relation to the solvent control using student’s t-test (*** = p < 0.001). 
 
4.2.3.3 Effect on the β-catenin mRNA Transcript Level  
The effect of EGCG on phosphorylated and total β-catenin (chapter 4.2.3.1) stands at variance 
with what was expected, considering the inhibitory properties of EGCG on GSK-3. 
Furthermore the reduction in phosphorylated β-catenin (figure 37A/B) did not provoke the 
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anticipated accumulation of total and nuclear β-catenin in the cell. Rather, the reduced 
phosphorylation of β-catenin was concomitantly accompanied by a reduction of total β-
catenin (figure 37A/B). This raised the question whether the reduced β-catenin level might 
result from a reduction in the expression of β-catenin. Therefore transcripts of β-catenin were 
quantified after 24h incubations of HT29 cells with EGCG under serum-free conditions using 
a pre-developed assay reagent (Hs99999168_m1) for β-catenin (Applied Biosystems). The 
transcript level of the endogenous control gene β-Actin was determined for normalization. 
EGCG appreciably suppressed the levels β-catenin transcripts in HT29 cells in a 
concentration-dependent manner (figure 39) after 24h incubation. An initial marginal decrease 
of β-catenin transcripts was observed at a concentration as low as 0.1µM, with a marked 
decrease (40%) at 25 µM. The positive control compound SB216763, did not influence β-
catenin mRNA levels (figure 39). 
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Figure 39: Effect of EGCG and SB216763 on β-catenin transcripts in HT29 cells. mRNA content was 
observed after a 24h serum free incubation. β-Catenin expression is normalized to β-actin 
expression and presented in percentage relative to the solvent control. The data are plotted as 
relative quantity ± delta Ct SD of triplicate experiments performed independently. The 
significances are calculated in relation to the solvent control using student’s t-test (* P< 0.05: 
**< 0.01). 
Incubation (serum free) of HT29 cells with quercetin for 24h caused a concentration 
dependent decrease in the level of β-catenin transcripts, which was maximal at 80µM 
quercetin with a reduction of about 23% (figure 40).  
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Figure 40: Effect of quercetin and SB216763 on β-catenin transcripts in HT29 cells. mRNA content was 
observed after a 24h serum free incubation. β-Catenin expression is normalized to β-actin 
expression and presented in percentage relative to the solvent control. The data are plotted as 
relative quantity ± delta Ct SD of triplicate experiments performed independently. The 
significances are calculated in relation to the solvent control using student’s t-test (* P< 0.05: 
**< 0.01). 
 
In summary, EGCG has been shown to effectively modulate cellular β-catenin levels in HT29 
cells. Consistent with the inhibition of GSKα/β, sequential treatment of HT29 cells with 
EGCG for 24h led to a concentration-dependent decrease in phosphorylated β-catenin (figure 
37). Phosphorylation of β-catenin within the APC complex of the Wnt signalling cascade by 
casein kinase-I and GSK-3 triggers its ubiquitination and eventual proteasomal degradation. A 
decrease in the phosphorylation of β-catenin should entail its stabilization as shown for the 
GSK-3 inhibitor SB216763 (figure 37). However, a concomitant drop significant os β-catenin 
from 25µM was registered when HT29 cells were treated with EGCG for 24h (figure 37A/B). 
The reduction of total β-catenin in the cells was also accompanied by a distinct reduction in 
nuclear β-catenin levels at 50µM EGCG (figure 38A/B). Analysis of the β-catenin transcript 
levels in HT29 cells after 24h incubation revealed a concentration dependent decrease of 
about 40% of β-catenin mRNA levels at 25µM EGCG, indicating that the drop in total β-
catenin levels might result from downregulation of β-catenin expression. In accordance with 
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the results on β-catenin homeostasis, EGCG had no stimulating effect on the Tcf/Lef driven 
transcriptional activity in HEK293 cells and HCT116 cells as measured using a reporter gene 
assay fine-tuned to capture only stimulating effects. Collectively, these results suggest that 
EGCG influences the expression of Wnt-dependent target genes by suppressing β-catenin 
expression. In support of this notion are results of two groups, who reported an EGCG-
dependent reduction of β-catenin expression and a reduction in the expression of cyclin D1 
and COX-2, genes targeted by Wnt signals (Dashwood et al. 2002; Huh et al. 2004). The 
results hence lend more support to the already existing data on the cancer preventive potential 
of EGCG, suggesting that suppression of Wnt-dependent proliferation stimulus is one 
mechanism through which EGCG may exert at least part of its anticancer effect (Orner et al. 
2002; Dashwood et al. 2002; Huh et al. 2004; Li et al. 2002). In tune with this, EGCG has 
been shown to inhibit growth of HT29 cells with IC50 values of 147 ± 18µM after 24h under 
serum deprived conditions and 40 ± 6µM after 72h in the presence of serum in the incubation 
medium (Pahlke et al. 2006). 
In contrast, treatment of HT29 cells with up 75µM of the flavonol quercetin for 24h did not 
change the levels of phosphorylated β-catenin (figure 36A/B). Consistent with this result, total 
β-catenin and nuclear β-catenin levels in HT29 cells were not affected by quercetin (figures 
36A/B & 38A/B). Accordingly, mRNA levels of β-catenin were not significantly influenced 
after 24h (figure 40). These results are in line with the results on GSK-3 activity, which was 
not influenced by quercetin as indicated by western blot analysis (figure 34A/B/C). Moreover, 
the results suggest that β-catenin/TCF/LEF-dependent gene transcription will not be 
stimulated by quercetin. In contrast though, quercetin marginally but significantly induced 
Tcf/Lef transcriptional activity in HEK293 cells and HCT116 cells suggestive of an inactive 
GSK-3 causing increased β-catenin levels. Theoritically, the stimulation of cell proliferation is 
a corollary of an increased β-catenin/Tcf transcriptionl activity. Hence, the question was 
raised whether the induced Tcf/Lef transcriptional activity by quercetin might be of any 
relevance to the proliferation of HT29 cells. At conditions similar to those used in this work, 
quercetin has been shown to rather concentration-dependently inhibit than stimulate growth of 
HT29 cells with IC50values of 124 ± 8µM in serum free medium for 24h and 52 ± 11µM in 
serum containing medium for 72h (Pahlke et al. 2006). Noteworthy are also the findings of 
van der Woude et al. (2003) who reported a quercetin-dependent growth hormesis for HT29 
cells. Up to 80µM quercetin, growth of HT29 cells was subtly stimulated, while beyond 
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80µM, growth was significantly inhibited. However, in contrast to this work, van der Woude 
and co workers modified their asssays by including 1µM ascorbic acids to stabilize quercetin, 
which may account for the initial proliferation stimulus.  
Of note, in the human adenocarcinoma cell line SW480, a reduction in nuclear β-catenin at 
unchanged cytosolic β-catenin levels by quercetin has been reported (Park et al. 2005). Such 
differential effects on β-catenin levels might indeed be a reflection of different cellular 
context and experimental conditions, leading to differential responses. Incubation with 
quercetin starting 3h after transfection was reported to result in an effective decrease of 
Tcf/Lef-mediated reporter gene expression (Park et al. 2005). In the presented work, cells 
were allowed a 48h recovery and acclimatization phase after transfection prior to the 
incubation with the test compound. Under these experimental conditions, quercetin was found 
to be a weak inducer of Tcf/Lef-mediated gene transcription, an effect, which however, did 
not translate in cell growth stimulus of HT29 cells. 
SB216763, applied at the concentration of 10µM, notably triggered a reduction of phospho-β-
catenin concentrations in HT29 cells after treatment for 24h (figure 37A/B). Concomitantly 
total and nuclear β-catenin levels were appreciably increased (figures 37A/B & 38A/B). Beta-
catenin transcript levels were indifferent to treatment with SB216763 suggesting that the 
obtained increase in total β-catenin levels is directly and solely related to the inhibition of 
GSK-3 within the APC complex. Consistent with increased cellular β-catenin levels, 
SB216763 significantly increased the Tcf/Lef- dependent transcriptional activity in HEK293 
cells by approximately 21 fold compared to the sovent control (figure 30A). In conclusion, the 
GSK-3 inhibitor, SB216763 was shown to mimic Wnt proteins stimulation of Wnt-signalling 
as seen in the increased cellular β-catenin levels. This conclusion is consistent with literature, 
where SB216763 has been shown to induce mRNA expression of the Wnt target genes COX-
2 and clycin D1 (Ma et al. 2005; Thiel et al. 2006). 
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4.3 Modulation of the Glucose-Glycogen Homeostasis 
4.3.1 Impact on Glycogen Synthase  
In addition to its role in the Wnt signalling pathway, GSK-3 is also an intergral part of the 
glycogen metabolism. GSK-3 regulates the activity of glycogen synthase (GS) by 
phosporylating the serin residues Ser653, Ser649, Ser645, and Ser641 thus being able to 
indirectly manipulate glycogen stores in the cell.  
In chapter 4.2.2.1, it was shown that the activity of GSK-3 was suppressed by EGCG after a 
24h serum free incubation of HT29 cells. To elucidate the physiological consequence of 
EGCG’s inhibition of GSK-3 on GS, GS activity was determined in a cell homogenate after 
analogous treatment of the cells. Additionally the phosphorylation status (Ser641) of GS and, 
the expression (protein level and mRNA) were also determined by western blot and 
quantitative PCR after 24h treatment with EGCG (25µM).  
4.3.1.1 Effects on the Activity of Glycogen Synthase 
To determine the effect of EGCG on GS activity, HT29 cells were incubated in serum free 
medium for 0.5h, 1h, 3h, 6h, 12h, and 24h. GS activity was determined in the cell homogenate 
as the rate of incorporation of a tritium labelled glucose moiety from [3H]-uridin diphosphate 
glucose [3H- UDPG] into glycogen in the presence and absence of glucose-6-phosphate, an 
allosteric activator of GS. EGCG was employed at the concentration of 25µM because at this 
concentration, EGCG had the highest inhibitory effect on GSK-3. SB216763, a specific 
inhibitor for GSK-3 was employed as a positive control for the induction of GS activity.  
At all time points between 0.5h and 24h, GS activity was substantially and significantly 
increased in response to treatment of HT29 cells with SB216763. The effect was not time 
dependent reaching a maximum after 6h with a roughly 2 fold increase in GS activity 
compared with control cells (DMSO (1%)) (figure 41). After 12h of incubation, although still 
significant, GS activity experienced a decline of about 75% to 150 ± 22 % which remained at 
the same level till 24h after incubation. 
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In comparison, GS activity in EGCG-treated cells remained largely unchanged up to 24h post 
incubation with 25µM EGCG. At 1h and 12h post incubation, GS activity was minutely 
decreased by EGCG, which lacked any significance. The lack of activation of GS by EGCG is 
surprising, considering that EGCG potently inhibited both isoforms of GSK-3 in HT29 cells 
under similar experimental conditions.  
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Figure 41: Effecr of EGCG and SB216763 on glycogen synthase activity in HT29 cells measured in a GS 
assay. GS activity is given as the expression of the rate of integration of a tritium labelled 
glucose molecule in glycogen by GS measured in the presence and absence glucose-6-
phosphate (G-P-6). The data are plotted as test over control (%) with the control being cells 
treated with 1% DMSO. The data representation is of the mean ± SD of at least three 
independent experiments. The significances were calculated relative to the solvent control 
using student’s t-test (*** = p < 0.001). 
4.3.1.2 Effects on the Protein Level and Phosphorylation of Glycogen 
Synthase 
To underpin the results obtained for GS-activity in the GS assay, Western blot analysis of 
phosphorylated GS was employed as an indirect measure for GS activity.The modulation of 
GS phosphorylation on Ser641 and of total GS protein level in HT29 cells was determined 
using polyclonal anti-phospho GS (Ser 641) and anti GS respectively fromCell Signaling after 
a serum free incubation for 15min, 30min and 24h with EGCG (25µM) and SB216763. The 
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serin residue 641 of GS is phosphorylated by GSK-3 and its phosphorylation is most crucial 
for the inhibition of GS activity. 
Incubation of HT29 cells with SB216763 induced a strong and significant decrease in the 
phosphorylation of GS at Ser641 (figure 42/B). As early as 15 minutes post incubation, 
dephosphorylation of GS in HT29 cells was already well over 60%. The effect remained 
sustained for as long as 24h post incubation (figure 42A/B). Contrary to SB216763, Ser641 
phosphorylation of GS in HT29 cells remained unchanged after treatment with EGCG for 
15min, 30min and 24h (figure 42A/B). 
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Figure 42 Effect of EGCG and SB216763 on the Ser 641 phosphorylation of glycogen synthase with (A) 
showing a chart representation and (B) showing an exemplary picture representation after a 
24h challenge. The GSK-3 selective inhibitor SB216763 served as positive control. The data 
are plotted as test over control (%) with control being cells treated with 1% DMSO. The data 
are the mean ± SD of at least three independent experiments. Statistical significance was 
accepted at p < 0.001 (***) using student’s t-test. Alpha- tubulin was determined as a loading 
control. 
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Alongside the phosphorylation status at Ser641, the cellular GS protein level was also 
analyzed by Western blot. Incubation of HT29 cells for 24h with SB216763 (10µM) caused a 
strong and significant increase of total GS protein levels by about 3 fold compared to the 
solvent control (figure 43A/B). EGCG caused a significant increase of total GS levels at 
25µM, however the increase was minor compared to that caused by SB216763 (figure 
43A/B).  
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Figure 43 Effect of EGCG and SB216763 on total glycogen synthase in HT29 cells with (A) showing a 
chart representation and (B) showing an exemplary picture representation after a 24h 
challenge. The GSK-3 selective inhibitor SB216763 served as positive control. The data are the 
mean ± SD of at least three independent experiments. Statistical significance was accepted at p 
< 0.001 (***) using Student’s t-test. Alpha-tubulin was determined as the loading control. 
4.3.1.3 Effect on the mRNA Levels of Glycogen Synthase 
The question whether the almost 4 fold increase in GS protein level in HT29 cells after the 
incubation with SB216763 is caused by increased GS transcripts was addressed using 
qualitative real time PCR. The effect of flavonoids on GS transcription was also studied in 
HepG2 cells. Cells were incubated for 6h with EGCG (1µM, 10µM), quercetin (20µM, 
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80µM) and for 24 h with EGCG (1µM, 10µM, 25µM), quercetin (20µM, 80µM) and 
SB216763 (10µM) under serum-free conditions prior to extraction of total RNA. Total 
mRNA was reverse transcribed with the cDNA Archive High Capacity Kit from Applied 
Biosystems after which the cDNA was amplified in a RT-PCR step using TaqMan MGB 
probes and gene specific primers and random hexamers. Beta-actin was co-amplified as 
endogenous control for normalization. Effects on both isoforms of glycogen synthase (GS), 
muscle glycogen synthase (MGS) and liver glycogen synthase (LGS) were investigated. 
 
4.3.1.3.1 HT-29 cells 
After 6h of incubation, EGCG fostered a concentration dependent decrease of the transcript 
levels of MGS and LGS (figure 44A). This effect was however abolished for LGS when 
incubations periods were prolongated to 24h (figure 44B). While mRNA levels of LGS 
responded indifferently to the 24h treatment with EGCG (figure), EGCG caused a slight 
reduction of mRNA levels of MGS. The effect, which was not concentration-dependent, 
remained at the same level between 1µM till 25µM EGCG, reaching a minimum of 77 ± 6 % 
at 1µM EGCG compared to DMSO (1%) treated control cells. 
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Figure 44: Effect of EGCG and SB216763 on the transcript level of (A) LGS and (B) MGS in HT29 cells 
after treatment for 6h and 24h. Glycogen synthase expression is normalized to β-actin 
expression and presented in percentage relative to the solvent control. The data is plotted as 
relative quantity ± delta Ct SD of triplicate experiments performed independently. 
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The GSK-3 inhibitor SB216763, applied at a concentration of 10µM did not influence cellular 
levels of MGS in HT29 cells after 24h incuabtion (figure 44B). On the other hand, LSG 
transcripts experienced a near 2 fold increase compared to the solvent control (figure 44A). 
Quercetin increased LGS levels in HT29 cells after 6h incubation by about 1.5 fold at 80µM 
(figure 45). After 24h, the LGS transcript status was not affected by quercetin (figure 45). In 
contrast, quercetin prompted a concentration dependent decrease of MGS transcript levels in 
HT29 cells after 6h (figure 45) attaining a minimum of about 40%. While MGS transcript 
levels at 20µM recuperated to the levels of DMSO treated cells after 24h, 80µM quercetin 
still caused an approximately 15% reduction in MGS RNA levels (figure 45). 
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Figure 45: Effect of quercetin on the transcript level of LGS and MGS in HT29 cells after incubation for 
6h and 24h. Glycogen synthase expression is normalized to β-actin expression and presented 
in percentage relative to the solvent control. The data is plotted as relative quantity ± delta Ct 
SD of triplicate experiments of similar outcome performed independently. 
 
4.3.1.3.2 HepG2 cells 
Short-term (6h) incubations of HepG2 cells with EGCG (1µM, 10µM) hardly influenced 
mRNA levels of MGS (figure 46A). Merely at 1µM EGCG after 24h was there an increase in 
MGS levels of about 20% compared to the solvent control (figure 46A). No substantial effect 
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on LGS mRNA levels was determined for EGCG after 6h. However, after 24h, EGCG 
decreased LGS levels by about 50% of the DMSO control (figure 46A). 
Quercetin did not substantially affect MGS transcript levels in HT29 cells after 6h and 24h of 
incubation (figure 46B). LGS RNA levels remained largely unchanged after 6h. After 24h, 
20µM quercetin appreciably reduced LGS mRNA transcription reaching 26.5 ± 15% of the 
DMSO control. At the higher concentration of 80µM quercetin LGS transcript levels 
increased by about 3 fold compared to the DMSO solvent control (figure 46B). 
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Figure 46: Effect of (A) EGCG and (B) quercetin on the transcript levels of LGS and MGS in HepG2 
cells after treatment for 6h and 24h. Glycogen synthase expression is normalized to β-actin 
expression and presented in percentage relative to the solvent control. The data is plotted as 
relative quantity ± delta Ct SD of triplicate experiments of similar outcome performed 
independently. 
 
In summary, the inhibition of GSK-3 kinase activity observed in HT29 cells after the 24h 
incubation with EGCG was on a whole without consequence for GS activity. Little to no 
change on the activity of GS was observed as determined by western blot and GS-assay, 
following the time-dependent incubation of HT29 cells with 25µM EGCG, a concentration 
that was most potent in inactivating both isoforms of GSK-3. Although the total GS protein 
level was significantly increased, it however had no influence on GS activity after 24h 
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incubation. The lack of activation of GS by EGCG is insofar surprising as EGCG (25µM) 
potently inhibited both isoforms of GSK-3 in HT29 cells. The stimulation of GS activity by 
SB216763 (10µM) dismisses the possibility of this result arising due as an assay artefact. The 
phosphorylation-dependent inactivation of GS is known to depend, not exclusively on the 
GSK-3-mediated phosphorylation of sites 4 (Ser653), 3c (Ser649), 3b (Ser645) and 3a (Ser 
641) (Poulter et al. 1988), but also, on the phosphorylation of sites 2 (Ser7) and 2a (Ser10) on 
the N terminus of GS. Phosphorylation of the N- terminal sites, which also is kinase-mediated 
(AMPK, PKA), additionally potentiates the inactivation of GS (Carling and Hardie 1989). It 
has indeed been shown that EGCG can induce AMPK (Hwang et al. 2005; Hwang et al. 2007; 
Moon et al. 2007), which targets site 2 (Carling and Hardie 1989). It is thus conceivable that, 
the AMPK-dependent inactivating effect on site 2 might be acting in opposition, thus 
compensating for the activating effect on site 3a by GSK-3 so that the overall GS activity 
experiences little change. Furthermore, PKA which also is known to target site 2 of GS is 
activated by EGCG (Lorenz et al. 2004). Lastly, site 3a of GS can also be phosphorylated in 
addition to GSK-3 by a yet unidentified kinase (Roach 1990, 2002; DePaoli-Roach et al. 
1983; Skurat et al. 2000), which may be activated by EGCG thus compensating for GSK-3 
dependent reduction of phosphorylation of Ser641 on GS.  
Alongside the phosphorylation status, the total protein level of GS was also determined in 
HT29 cells. EGCG caused a concentration dependent increase in the GS protein level (figure 
43A/B); which, even though significant at 25µM, evidently influenced neither GS activity 
(figure 41) nor GS phosphorylation after 24h incubation (figure 42A/B). Short-term 
incubation (6h) of HT29 cells with 10µM EGCG appreciably diminished the mRNA levels of 
both GS isoforms (figure 44A/B). 24h treatment of HT29 cells had no effect on LGS mRNA 
levels while mRNA for MGS was slightly reduced by an average 20% of the control (figure 
44B). The effect however remained at the same level from 1µM to 25µM. Generally, the GS 
transcript levels were on the average higher after 24h than after 6h, suggestive of cellular 
compensation through enhanced biosynthesis, which might explain the increased GS-protein 
levels detected by western blot (figure 43A/B). Quercetin had opposite effects on LGS and 
MGS transcription after 6h of incubation. While MGS transcript levels were reduced in HT29 
cells, LGS mRNA levels were concomitantly increased. After 24h both MGS and LGS 
transcription was stabilized in HT29 cells, restoring transcript levels to near control levels 
(figure 45). 
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In HepG2 cells, MGS transcript levels were slightly increased after 24h by 1µM EGCG. LGS 
mRNA levels responded indifferently to EGCG after 6h of incubation, however after 24h, 
LGS were strongly reduced (figure 46A). 20µM and 80µM quercetin provoked opposite 
responses with respect to LGS transcription. While at the lower concentration of 20µM LGS 
mRNA expression was appreciably reduced, reaching 26.5 ± 15% of control, at the higher 
concentration 80µM quercetin (figure 46B) increased LGS transcript levels by about 3 folds 
compared to the DMSO control.  
In accordance with the effects on GSK-3 activity, the GSK-3 inhibitor SB216762 (10µM) 
caused a sustained and significant activation of GS activity between 30min and 24h (figure 
41). In reflection of the increased GS activity, SB216763 appreciably diminished the 
phosphorylation of GS on Ser641 (figure 42A/B). As early as 15 minutes post incubation, 
dephosphorylation of GS in HT29 cells was already well over 60%. The effect was sustained 
for as long as 24h post incubation (figure 42A/B). Quantitive PCR results indicate a near 2 
fold increase of LGS transcripts after 24h incubation with SB216763 while MGS transcript 
levels proved unresponsive to SB216763 (figure 44A/B). The increase of LGS mRNA levels 
was accompanied by a concomitant increase in total GS protein levels of about 3 fold as 
determined by western blot (figure 43A/B). It thus would seem probable that the SB216763-
mediated increase of the LGS transcript levels translates into increased expression of GS 
protein. Taken together, the results on GSK-3 and GS argue for rather an indirect interference 
of SB216763 on GS activity via inhibition of GSK-3 than via allosteric action on GS. In 
addition the results suggest that the apparent increase in GS activity caused by SB216763 in 
HT29 cells, most likely, is a product of an initial increased dephosphorylation of GS observed 
as early as 15min post incubation that later (with increasing incubation duration upto 24h) is 
buttressed by increasing GS protein expression.  
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4.3.2 Impact on Glycogen Phosphorylase 
4.3.2.1 Expression Profile of Glycogen Phosphorylase in HT29 Cells and 
HepG2 cells   
To identify the glycogen phosphorylase isoforms expressed in HT29 cells and HepG2 cells, 
total RNA isolated from the cells was reverse transcribed using gene specific primers for 
muscle, liver and brain isoforms of glycogen phosphorylase and the titan one tube PCR kit 
from Qiagen. cDNA was resolved in a 1.3% agarose gel at 80V. DNA fragments were 
visualized by staining with ethidium bromide. β-Actin was co-detected as endogenous control. 
These results were obtained by Bülent Soyalan, in course of his “Forschungspraktikum”. 
The results of the agarose gel electrophoresis show that both cell lines; HT29 cells and HepG2 
cells express glycogen phosphorylase transcripts for the liver- and brain isotypes (figure 47). 
In accordance with literature data, BGP, a potential marker for colon carcinogenesis 
represented the most highly expressed isoform in both cell lines, evidenced in the comparably 
high band intensity with respect to β-actin (Tashima et al. 2000). In both cell lines weak 
signals for muscle-type GP transcripts were detected by RT-PCR (figure 47). The allocation 
of the DNA bands to the respective isozyme (BGP: 677 bp, MGP: 534 bp und LGP: 445 bp) 
was performed by comparison with literature values.  
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Figure 47: Agarose gel images showing the glycogen phosphorylase isoforms expressed in HT29 cell and 
HepG2 cells. The DNA samples were resolved in 1.3% agarose and visualized by staining with 
eithidium bromide. 
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4.3.2.2 Effects on the Activity of Glycogen Phosphorylase 
To determine the effect of EGCG and SB216763 on the activity of GP in HT29 cells, the cells 
were incubated time-dependently (0.5h, 1h, 3h, 6h, 12h, and 24h) in serum free medium with 
EGCG (25µM) and SB216763 (10µM). GP activity was subsequently measured in cell 
homogenate using a method that combines the GP-catalyzed breakdown of glycogen with the 
reduction of NADP+ (oxidized nicotinamide adenine di-nucleotide phosphate) to NADPH2 so 
that the process can be monitored photometrically at 340nm.  
Neither EGCG (25µM) nor and SB216763 (10µM) caused a substantial change in the activity 
of GP in HT29 (figure 48) 
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Figure 48: Time-dependent effect of EGCG and SB216763 on the activity of glycogen phosphorylase in 
HT29 cells. The data are plotted as test over control (%) with the control being cells treated 
with 1% DMSO. The data representation is of the mean ± SD of at least three independent 
experiments. 
4.3.2.3 Effects on the cellular protein level of Glycogen Phosphorylase 
The impact of EGCG on the GP protein level in HT29 cells was determined by western blot 
using anti-GP (Santa Cruz) that co-determines brain type- and muscle type-GP. The cells 
were incubated serum free with EGCG (1µM, 25µM) for 24h.  
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EGCG had no significant effect on GP protein level in HT29 cells after 24h at the 
concentrations of 1µM and 25µM EGCG (figure 49A/B). Incubation with SB216763 resulted 
too in no of change cellular GP levels (figure 49/B).  
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Figure 49 Effect of EGCG and SB216763 on the expression of glycogen phosphorylase in HT29 cells 
with (A) showing a chart representation and (B) showing an exemplary Western blot picture 
after a 24h long incubation. The data are plotted as test over control (%) with control being 
cells treated with 1% DMSO. The data are the mean ± SD of at least three independent 
experiments.  
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4.3.2.4 Effects on the Transcript Level of the GP-Isoenzymes 
The effect of EGCG on the mRNA level of BGP, LGP and MGP was investigated in HT29 
cells and HepG2 cells using TaqMan RT-PCR. The cells were incubated in serum free 
medium for 6h and 24h. Total RNA was isolated, reverse transcribed in the presence of 
random hexamers and amplified with gene specific primers. The mRNA level of the house 
keeping gene, β-actin was determined and used for normalization.  
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Figure 50: Effect of EGCG and SB216763 on the transcript level of GP in HT29 cells after (A) 6h and (B) 
24h. Glycogen synthase expression is normalized to β-actin expression and presented in 
percentage relative to the solvent control. The data is plotted as relative quantity ± delta Ct 
SD of triplicate experiments performed independently. Statistical significance was accepted 
when p < 0.05 (*) using student’s t-test.  
EGCG (1µM, 10µM) effectively downregulated LGP and BGP transcripts in HT29 cells after 
6h reaching maximal reductions of roughly 40% and 60% respectively compare to the solvent 
control (figure 50A). Although the reduction of LGP transcript levels remained till 24h after 
incubation at 1µM and 10µM, the effect however became less prominent compared to 6h, 
probably due to counter-regulatory processes in the cell (figure 50B). At 25µM, EGCG 
increased the mRNA levels of both MGP and LGP while the level of BGP, which 
quantitatively is the most predominant isoform in HT29 cells was appreciably reduced by 
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about 70% compared to DMSO (1%)-treated cells (figure 50B). Although BGP transcripts 
were strongly diminished at 25µM EGCG, this seemingly did not translate into reduction of 
the GP protein levels as determined by western blot (figure 49A/B). One could then argue that 
the increased expression of MGP compensated for the reduced level of BGP expression hence 
little change in (BGP and MGP) protein level was observed. 
The GSK-3 inhibitor, SB216763 increased MGP transcripts in HT29 cells by about 2 fold 
after 24h. BGP transcript levels were appreciably reduced by SB216763 after 24h reaching 
about 65% (figure 50B). LGP mRNA levels were not influenced by 10 µM SB216763 after 
24h (figure 50B). 
The incubation of HT29 cells with 20µM and 80µM quercetin triggered a concentration-
dependent reduction of BGP mRNA after 6h and 24h respectively reaching a minimum of 66 
± 3.1% after 6h and 40 ± 2.6% after 24h compared to the solvent control (figure 51). LGP 
transcript levels decreased by about 40% after 6h incubation with 20µM and 80µM quercetin 
(figure 51). The reductions were maintained up till 24h after incubation (figure 51). 
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Figure 51: Effect of quercetin on the transcript level of BGP and LGP in HT29 cells after incubation for 
6h and 24h. Glycogen synthase expression is normalized to β-actin expression and presented 
in percentage relative to the solvent control. The data is plotted as relative quantity ± delta Ct 
SD of triplicate experiments performed independently. 
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4.3.2.4.2 HepG2 Cells 
EGCG (1µM, 10µM) caused a concentration-dependent reduction of BGP transcript levels in 
HepG2 cells, attaining a minimum of about 73% compared to DMSO (1%) treated cells 
(figure 52A). After 24h, EGCG did not interfere with the BGP RNA levels in HepG2 cells 
(figure 52A). LGP transcript levels were also diminished in a concentration dependent fashion 
by EGCG after 6h reaching a minimum order of magnitude of about 70% of the control at 
10µM, which persisted for up to 24h post incubation (figure 52A). 
Quercetin (20µM, 80µM) also reduced BGP transcript levels dose-dependently in HepG2 
cells after 6h of incubation (figure 52B). The decrease was highest at 80µM quercetin with 
about 25% reduction. After 24h, BGP transcript levels in HepG2 cells were slightly increased 
by about 1.5 fold. LGP transcript levels dropped in a concentration dependent manner at both 
time points (6h and 24h) reaching a maximal reduction of about 33% of the control after 24h. 
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Figure 52: Effect of EGCG and quercetin on the BGP and LGP transcript levels in HepG2 cells after 
incubation for 6h and 24h. Glycogen synthase expression is normalized to β-actin expression 
and presented in percentage relative to the solvent control of three independent experiments. 
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In summary, the qualitative PCR analysis of total RNA from HT29 cells and HepG2 cells, 
indicated that both cell lines express all three forms of glycogen phosporylase LGP, MGP and 
BGP (figure 47). As can be inferred from their names, the brain-type GP is predominantly 
expressed in brain tissue while the liver and muscle types are principally expressed in liver 
and muscle tissue respectively. However, in both cancer cells lines, HT29 and HepG2 of 
colonic and liver origin respectively, BGP, was the predominantly expressed isoform (figure 
47) although it normally should be absent in these tissues. In line with this result are data 
indicating that BGP expression is highly increased in many cancer types (Shimada et al. 2002; 
Barbosa and Castro 2002; Shimada et al. 2001; Tashima et al. 2000; Shimada et al. 1999), 
giving room for conjecture that BGP might be turned on in cancerous tissues to meet 
increased energy needs of the cells. Qualitative PCR results indicated that LGP was the 
second most abundant GP isoform in HT29 cells and HepG2 cells, followed by MGP. Signals 
for MGP were very weak in both cell lines. In support of the results of qualitative PCR, data 
gathered during quantitative analysis indicated a predominant transcription of BGP, followed 
by LGP and MGP in HT29 cells. While BGP on the average had strong fluorescence signals 
already after 18 PCR cycles, signals for LGP and MGP were detected after a Ct of 23 and 32 
respectively.  
Treatment of the colon carcinoma cell line HT29 with 1µM and 10µM EGCG for 6h 
substantially reduced LGP mRNA levels, which apparently were not fully recovered after 24h 
(figure 50A). 25µM EGCG caused a distinct reduction of BGP levels after 24h, while MGP 
and LGP transcript levels were increased (figure 50B). It is hence conceivable that MGP and 
LGP expression might have been upregulated in compensation of the reduction in BGP levels 
to maintain the energy homeostasis of the cells. In support of this assumption, no change of 
protein level (BGP and MGP) was detected in HT29 cells after a 24h treatment with 25µM 
EGCG (figure 49A/B). Concomitantly, 25µM EGCG also did not influence GP activity 
(figure 48). Contribution of LGP protein modulation to the total protein could not be 
ascertained since the GP-antibody used during Western blot can only cross-detect BGP and 
MGP but not LGP.  
SB216763 (10µM) did not influence LGP transcription after 24h. However, while BGP 
transcription was distinctly downregulated by about 25%, MGP levels became upregulated by 
about 2 fold (figure 50B) suggesting a compensation process of the cells. Consistently, no 
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change in GP protein levels (BGP and MGP) was observed in Western blot analysis (figure 
49A/B). GP activity too was not influenced to EGCG at a concentration of 25µM (figure 48). 
In HepG2 cells, EGCG (1µM, 10µM) concentration-dependently reduced BGP levels after 6h 
(figure 52A). However, BGP transcript levels recuperated after 24h (figure 52A). LGP 
transcript levels were also decreased in a concentration-dependent manner after 6h (figure 
52A). In summary, transcript levels of both BGP and LGP isoforms after treatment with 
EGCG were generally higher after 24h than after 6h, suggesting a correction by biosynthetic 
control mechanisms. 
Quercetin distinctly diminished LGP transcript levels in both cell lines 6h and 24h after 
incubation suggesting a reduction in the expression of LGP in both cells lines (figure 51 & 
figure 52B). While BGP levels in HT29 cells were reduced after 6h and 24h (figure 51), in 
HepG2 cells only 80µM quercetin affected BGP transcription. After 6h BGP, transcript levels 
dropped by about 25%, whereas after 24h, they experienced a slight increase (figure 52B) 
suggesting over-correction by biosynthetic control mechanisms in HepG2 cells. 
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4.3.3 Effects on the Glycogen Levels 
To investigate whether a modulatory effect on GS and/or GP in HT29 cells has an impact on 
the glycogen deposition, cellular glycogen content was determined. HT29 cells were 
incubated with 25µM EGCG and 10µM SB216763 for 0.5h, 1h, 3h, 6h, 12h and 24h after 
which they were subjected to alkali hydrolysis. Glygogen was then precipitated with ethyl 
alcohol and sodium sulfate, and quantified spectrophotometrically at 620nm in the Anthron 
assay by means of linear interpolation and a standard curve.  
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Figure 53: Time-dependent effecr of EGCG and SB216763 on the glycogen content in HT29 cells Data 
are presented as mean ± SD of at least three independent experiments. Statistical significance 
was accepted when p < 0.05 = *; p < 0.01= **; p < 0.001= ***. 
The incubation of HT29 cells with the GSK-3 inhibitor SB216763 caused a time-dependent 
increase of glycogen, which peaked after 24h with a plus of 432 ± 32% compared to DMSO-
treated cells (figure 53). The rise in glycogen was significant as from 3h post incubation. In 
contrast, incubation of HT29 cell with 25µM EGCG for up to 6h caused no change in cellular 
glycogen levels (figure 53). However, after 12h incubation with EGCG, glycogen levels in 
HT29 cells significantly declined by 20%. The decrease in glycogen after 24h was even more 
prominent, reaching about 30% compared to the DMSO control (figure 53).  
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The cellular glycogen content was determined as a parameter that sums up the effects on the 
upstream (to glycogen) located GS and GP proteins. Incubated in time sequential fashion 
between 30min and 24h, 25µM EGCG had no effect up to 6h post incubation on the 
deposition of glycogen in HT29 cells (figure 53). After 12h and 24h cellular glycogen content 
was subtly but significantly reduced (figure 53). This is rather surprising, considering that 
neither GS nor GP activities were influenced by EGCG. Hence an indirect interference of 
EGCG on the glycogen catabolic machinery in HT29 cells might be involved causing the drop 
in glycogen. The debranching enzyme, which functions in concert with GP to breakdown 
glycogen, may be a possible candidate through whom EGCG might accelerate glycogen 
breakdown in HT29 cells. 
Antidiabetic potential of EGCG has been shown in vivo in diabetic rat models (Anton et al. 
2007; Koyama et al. 2004; Waltner-Law et al. 2002; Wolfram et al. 2006). Regulation of the 
expression of key enzymes involved in gluconeogenesis have been shown to be possible 
targets for the repression of hepatic glucose formation in these models (Anton et al. 2007; 
Koyama et al. 2004; Waltner-Law et al. 2002; Wolfram et al. 2006). The results of this work 
suggest that in HT29 cells, regulation of GS and GP of the glycogen anabolic and glycogen 
catabolic pathways respectively, may not contribute to the anti-diabetic potential reported for 
EGCG in vivo.  
In contrast, SB216763 progressively increased glycogen content over a period of 24h in HT29 
cells, reaching a maximum of fold of control (figure 4.3-13). The increased cellular glycogen 
levels correlate with the increased and sustained activity of GS activity over the entire 
incubation period of 24h (figure 41). In accordance, GP activity was not affected by 
SB216763, indicating that the deposition of the glycogen stores in HT29 cells was an additive 
process, resulting mainly from the stimulation of GS activity via GSK-3 inhibition. In 
summary, the results on glycogen deposition show that SB216763 is a potent inducer of GS 
synthase activity in HT-29 cells. This conclusion is supported by the data of Coghlan and co 
workers who reported a potent inhibition of GSK-3 also accompanied by accumulation of 
glycogen in liver cells (Coghlan et al. 2000). 
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4.4 Final Discussion  
The phosphorylation of GSK-3 on Ser21 and Ser9, consistent with inhibition of GSK-3α and 
GSK-3β (Grimes and Jope 2001) was determined by western blot as an indicator for GSK-3 
activity. The level of phosphorylated GSK-3α and -β in HT29 cells was not substantially 
influenced by quercetin (figure 34A/B/C), indicating that the inhibition of GSK-3α and GSK-
3β activity remained largely unaffected. GSK-3 protein levels were subtly but appreciably 
diminished for both proteins, however, the effect was not concentration-dependent which 
speaks for some non-specific mechanisms, rather than a specific interference of quercetin with 
the respective target enzyme. Taken together, quercetin is not expected to cause substantial 
inhibition of GSK-3α and -β in HT29 cells. In accordance with the lack of activation of both 
GSK-3isoforms, quercetin also did not appreciably alter cellular levels of β-catenin and 
phosphorylated β-catenin in HT29 cells after 24h treatment (figure 36A/B), indicating that 
quercetin possesses no β-catenin stabilizing potential in HT29 cells. Consistently, β-catenin 
mRNA (figure 39) remained unaffected up to a concentration of 50µM quercetin. Also, 
nuclear β-catenin levels were unaltered by quercetin (figure 38A/B) permitting the assumption 
that β-catenin/Tcf/Lef-dependent gene transcription will not be influenced by quercetin. 
However, in the relevant reporter gene assay models in HEK293 cells and HCT116 cells, 
incubation with quercetin (10-50µM) enhanced Tcf/Lef-driven reporter gene expression 
(figures 30A, 32A, 33A), suggesting rather a proliferative stimulus for these cells. This does 
give room for speculation if the differential effects observed may be reconciled with inherent 
differences of the various cell-types and/or variations in experimental conditions used. In this 
light quercetin has been shown in SW480 cells to cause a reduction in nuclear β-catenin at 
unchanged cytosolic β-catenin levels, resulting in an effective decrease of Tcf/Lef-mediated 
reporter gene expression (Park et al. 2005). In principle, up-or downregulation of the Tcf/Lef-
mediated gene expression is expected to either up-or downregulate proliferation respectively. 
The above mentioned discrepancy in the effects of quercetin on Tcf/Lef transcriptional 
activity in the various cells types thus raises the question whether the signals commensurately 
translate in stimulation of growth for the respective cells. Indeed, in line with the increased β-
catenin/Tcf/Lef transcriptional activity in HCT116 cells (figure 33A), these cells have been 
shown to experience a slight but significant proliferation phase within the same concentration 
range tested in this work (1-25µM) (van der Woude et al. 2005). On the other hand, at 
experimental conditions similar to those employed in this work for HT29 cells, Pahlke et al. 
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(2006) reported no stimulatory effect of quercetin on the growth of HT29 cells. In contrast, 
quercetin was found to rather inhibit the growth of HT29 cells in a concentration dependent 
manner (Pahlke et al. 2006). In view of quercetin’s negligibly small effect on total β-catenin, 
and nuclear β-catenin in particular, it can be inferred that Wnt-dependent modulation of 
growth is not a mechanism through which quercetin exacts growth inhibition of HT29 cells.  
In contrast to quercetin, the green tea catechin EGCG was identified as a potent inhibitor of 
GSK-3α- and GSK-3β activity in HT29 human colon carcinoma cells, measured (Western 
blot) as increased phosphorylation of Ser21 and Ser9 respectively. Even at low micromolar 
concentrations EGCG inhibited the activity of GSK-3α and GSK-3β in HT29 cells after 24h 
(figure 35A/B/C) independent of altered protein expression (figure 35A/B/C). However, 
EGCG has been shown to have no effect on isolated GSK-3β up to 100 µM (Schreiner 2004). 
Therefore it is thus plausible, that although EGCG has been shown to be readily taken up by 
HT29 cells and to be predominantly localized in the cytosol (Hong et al. 2002), the EGCG-
induced cellular inhibition of GSK-3 activity is mediated indirectly, probably via influencing 
intervening cellular signalling cascades upstream of GSK-3 rather than via a direct targeting 
of the enzyme. PKA of the cAMP pathway and PKB of the insulin/PI3 kinase cascade, both 
of which have been shown in vitro to target the Ser21 and Ser9 phosporylation sites of the 
GSK-3 isoforms are activated by EGCG within the same concentration range employed in this 
work (1-50µM) (Lorenz et al. 2004). EGCG has been shown to generate substantial amounts 
of H2O2 under cell culturing condition which raises the question as to whether H2O2 may be in 
part or totally responsible for the effects observed for EGCG (Hong et al. 2002; Dashwood et 
al. 2002). However, hydrogen peroxide itself (100µM and 500µM) has been reported to 
activate rather than inhibit GSK-3β in HEK293 and in other cell lines (Shin et al. 2006). 
Furthermore, GSK-3 activity was already diminished at 0.5µM EGCG (figure 35A/B), a 
concentration far below the reported concentrations of EGCG known to generate substantial 
amounts of H2O2 (Dashwood et al. 2002; Shin et al. 2006). Lastly, 25µM H2O2 has been 
shown to have no effect on Tcf/Lef transcriptional activity in HEK293 cells (Dashwood et al. 
2002). Thus, it is not likely that H2O2 production by EGCG is of substantial relevance for the 
inhibition of GSK-3 in HT29 cells. In accordance with the inhibition of the activity of GSK-
3α and -3β, incubation of HT29 cells with EGCG resulted in a concentration-dependent 
decrease of phosphorylated β-catenin (figure 37A/B). Surprisingly, the decrease of β-catenin 
phosphorylation was not associated with a stabilization of intracellular β-catenin as evidenced 
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by the reduced total and nuclear β-catenin protein levels detected by Western blot (figures 37-
A/B & 38A/B). The decrease of the cellular β-catenin level, inspite reduced phosphorylation 
might result from the suppression of β-catenin expression, indicated by the decrease of β-
catenin mRNA (figure 39). Thus, the interfering effect of EGCG with β-catenin homeostasis 
might primarily be governed by its effect on β-catenin expression. In accordance with the 
reduced β-catenin levels, EGCG did not induce Tcf/Lef-mediated gene expression in the 
reporter gene assay (figures 30B, 32B, 33B). The employed reporter gene system was 
designed and optimized to detect stimulating effects on Tcf/Lef-dependent gene expression 
which explains why no reduction of Tcf/Lef transcriptional activity could be detected. 
However in line with the reduced β-catenin levels noticed in HT29 cells, Dashwood et al 
reported a significant reduction of Tcf/Lef transcriptional activity in HEK293 cells 
(Dashwood et al. 2002). In support of the results observed with the reporter gene assay, 
EGCG has also been shown to inhibit the growth of HT29 cells in a SRB assay (Pahlke et al. 
2006). Collectively, the results obtained with EGCG permit the conclusion that EGCG may 
induce growth inhibition of HT29 cells via the Wnt pathway by downregulating β-catenin 
neogenesis, which is one mechanism probably responsible for the cancer preventive 
properties of EGCG. 
Besides its involvement in the Wnt-signalling pathway, the serine/threonine kinase GSK-3 is 
also involved in the regulation of the glucose/glycogen homeostasis by regulating glycogen 
synthase activity. To elucidate the consequence of the inhibition of GSK-3 on the glycogen 
homeostasis in HT29 cells, the cells were incubated for 24h with EGCG at the concentration 
which had the highest impact on GSK-3 inhibition (25µM). However, EGCG surprisingly had 
no effect on GS activity as measured in a GS-assay (figure 41). In accordance with this 
finding, EGCG also did not influence the phosphorylation at Ser641 of GS as determined by 
Western blot analysis (figure 42A/B). Total protein levels were slightly but significantly 
increased (figure 43A/B) apparently with no effect on GS activity. Quantitative PCR results, 
indicated that the increased GS protein levels might be a corollary of an increased expression 
of the liver isoform of GS, as evidenced by high LGS transcript levels (figure 44). Evidently 
the inhibition of GSK-3 activity by EGCG after 24h incubation was on a whole without 
relevance for GS activity in HT29 cells. A reason for the discrepancy may be interfering 
effects from/ or with other signalling pathways which converge on GS. EGCG has been 
shown to activate PKA and AMPK, both of which are known to target GS. It is thus 
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conceivable that these kinases might be acting in opposition thus compensating the 
stimulating effects mediated by the inhibition of GSK-3. In accordance with the lack of 
stimulation of GS by EGCG, cellular glycogen was not increased in HT29 cells in a 24h 
incubation time frame. On the contrary, from 12h post incubation, glycogen deposits were 
diminished (figure52) suggesting an activation of glycogen phosphorylase, the rate limiting 
enzyme, catalyzing the breakdown of glycogen. However, EGCG (25µM) did not influence 
GP activity (24h) (figure 48) thus leading to the assumption that EGCG affects the glycogen 
breakdown machinery by another mechanism. The debranching enzyme, which functions in 
concert with GP to breakdown glycogen, may be a possible candidate through whom EGCG 
might accelerate glycogen breakdown in HT29 cells. In line with the lack of change of GP 
activity, total GP proteins levels (MGP and BGP) were unaltered as determined by Western 
blot analysis. Analysis of the effects of EGCG on the expression the mRNA of the GP 
isoforms (BGP, MGP) indicated that at 25µM EGCG, BGP levels were diminished while 
MGP levels were increased. It is conceivable that due to corrections by biosynthetic control 
mechanisms, the decrease in BGP expression was compensated for by increasing the 
expression of MGP, thus leading to no net change in GP protein levels. The antidiabetic 
potential of EGCG has been shown in vivo in diabetic rat models. Regulation of the 
expression of key enzymes involved in gluconeogenesis have been shown to be possible 
mechanisms for the repression of hepatic glucose formation in these models (Anton et al. 
2007; Koyama et al. 2004; Waltner-Law et al. 2002; Wolfram et al. 2006). The results of this 
work suggest that regulation of GS and GP of the glycogen anabolic and glycogen catabolic 
pathways respectively, does not contribute to the anti-diabetic potential for EGCG in HT29 
cells. 
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5 Summary of Results  
Many beneficial health effects have been ascribed to flavonoids and the group of polyphenols 
as a whole. However, rather few studies have addressed the possible adverse health effects of 
flavonoids. The Wnt pathway represents one of the major signalling cascades which have 
been implicated in the development of colon cancer. Glycogen synthase kinase (GSK-3) is a 
key element of the Wnt-signalling pathway where it regulates cellular β-catenin levels. 
Inhibition of GSK-3 leads to the stabilization of cellular β-catenin which can then translocate 
into the nucleus and initiate processes that eventually lead to the stimulation of cell growth. 
The aim of this work was to identify flavonoids with a potential to induce a Wnt-dependent 
proliferation stimulus in human colon carcinoma cells. A flavonoid dependent growth 
stimulus may pose a potential health risk, considering that such stimulus might lead to 
increased tumourigenesis of cancer precursor cells. 
To screen for substances with a potential to induce Wnt-dependent cell growth, a relevant 
reporter gene assay was established, optimized and fine-tuned to determine only stimulating 
effects on the β-catenin/Tcf/Lef transcriptional activity in HEK293 cells and HCT116 cells. 
Quercetin emerged as a potential inducer of cell growth because it increased the Tcf/Lef 
transcriptional activity in HEK293 cells and HCT1116 cells. Moreover, quercetin has been 
shown to potently inhibit isolated GSK-3 activity (kinase assay) (Kern et al 2006). (-) 
Epigallocatechin-gallate (EGCG) on the other hand had no influence on Tcf/Lef 
transcriptional activity (reporter gene assay) and did not inhibit isolated GSK-3 activity 
(kinase assay) (Schreiner 2004). EGCG was hence included in the experiments as a negative 
control substance. The GSK-3 inhibitor, ”SB216763” significantly increased Tcf/TLef 
transcriptional activity (about 21 folds). It was employed as a positive control for activation of 
Wnt signalling. 
The effect of quercetin on the expression and activity of GSK-3α/β and β-catenin, both key 
elements of the Wnt signalling pathway was investigated by Western blot in the human colon 
carcinoma cell line HT29. Quercetin had no effect on the activity of GSK-3α and -3β in HT29 
cells, measured as phosphorylation at Ser21 and Ser9, respectively. Consistently, quercetin 
did not substantially affect β-catenin homeostasis suggesting that it might not induce a 
mitogenic stimulus in HT29 cells. Conversely quercetin stimulated the Tcf/Lef mediated 
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transcriptional activity in HEK293 cells and HCT116 cells. Incubation of HT29 cells with 
EGCG caused a potent inhibition of GSK-3α and -3β activity at unaltered total protein levels. 
Concomitantly, the amount of phosphorylated β-catenin was diminished in a concentration-
dependent manner. However, the overall amount of β-catenin was also decreased to a similar 
extent. Quantification of β-catenin transcripts in HT29 cells by RT-PCR indicated a reduction 
in β-catenin transcripts by EGCG, suggesting that the decrease in overall β-catenin levels 
might originate from a downregulation of β-catenin neogenesis. As expected, the GSK-3 
inhibitor, SB216763 reduced GSK-3 activity in HT29 cells leading to increased in total β-
catenin levels and the induced Tcf/Lef driven transcriptional activity in HEK293 cells as well 
as in HCT116 cells. In conclusion the results suggest that neither quercetin nor EGCG at the 
concentrations tested in the work mediate a proliferative stimuli in HT29 cells by interfering 
with key elements of the Wnt pathway. On the contrary, EGCG is rather expected to mediate 
anti-proliferative effects due its reduction of celular β-catenin.  
 
Besides being actively involved in the Wnt- signalling pathway, GSK-3 also influences the 
cellular glucose/glycogen homeostasis by phosphorylating and inactivating glycogen synthase 
(GS). In view of the inhibition of GSK-3 activity by EGCG in HT29 cells it raised the 
question whether this effect was of any significance for the glucose/glycogen homeostasis. 
Apparently, EGCG’s inhibition of both GSK-3 isoforms did not translate into the stimulation 
of glycogen synthase in HT29 cells since GS activity was not influence by EGCG when 
applied at 25µM, the concentration which had the most impact on GSK-3 activity. In 
accordance, the phosphorylation of Ser641 on GS was not affected as determined by Western 
blot analysis. GS protein levels were significantly increased by about 50% (T/C), however 
with no consequence on GS activity. Quantitative Real-time PCR data, indicated that 
increased LGS transcription may contribute to the increased GS protein level in HT-29 cells 
after the incubation with EGCG. In accordance with the lack of stimulation of GS by EGCG, 
glycogen was not deposited in HT29 cells. On the contrary, after prolonged incubation (12h - 
24h) with EGCG, glycogen deposits were instead diminished. A rather surprising result 
considering that the activity of glycogen phosphorylase (GP), which is the rate limiting 
enzyme catalyzing the breakdown of glycogen was also not influenced in HT29 cells by 
EGCG (25µM), upto 24h post incubation. Total GP protein levels also remained unchanged 
after the 24h exposure of HT29 cells to EGCG. Quantitative Real-time PCR analysis 
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indicated a reduction of BGP transcript levels in HT29 cells accompanied by increased 
mRNA levels of MGP and LGP. It is conceivable that due to correction by biosynthetic 
control mechanisms, the decrease in BGP (brain-type-GP) expression is compensated by 
increasing the expressions of MGP (Muscle-type-GP) and LGP (Liver-type-GP). In line with 
GSK-3 inhibition, the GSK-3 inhibitor, SB216763 (10µM) mediated an early (15min) 
conspicuous activation of GS in HT29 cells, which was mantained upto 24h. Consistently GS 
phosphorylation on Ser641 was significantly diminished as determined by Western blot 
analysis. Total GS protein level were significantly increased, presumably by the upregulation 
of LGS as evidenced by increased LGS transcripts. In accordance with the activation of GS, 
glycogen deposits were progressively increased in HT29 cells. GP activity was not influenced 
by SB216763. Collectively the results indicate that EGCG’s influence on GSK-3 has no 
consequence for the glucose/glycogen homeostasis and hence does not contribute to the anti-
diabetic property of EGCG in HT29 cells. 
5.1 Zusammenfassung 
Im Allgemeinen werden Flavonoiden gesundheitsfördernde Eigenschaften zugeschrieben. 
Wenig ist jedoch über gesundheitlich nachteilige Effekte von Flavonoiden bekannt. Der Wnt-
Signalweg zählt u. a. zu den Signalwegen, die eine wesentliche Rolle in der 
Kolonkanzerogenese spielen. Ein Schlüsselelement dieses Signalweges stellt die 
Glykogensynthasekinase 3 (GSK-3) dar, die den zellulären ß-Cateninspiegel reguliert. Kommt 
es zu einer Hemmung von GSK-3, reichert sich β-Catenin im Zytosol an und wird in den 
Zellkern transloziert. Im Zellkern fördert β-Catenin die Stimulierung proliferationsassoziierter 
Gene und somit das Zellwachstum. Das Ziel dieser Arbeit lag in der Identifizierung von 
Flavonoiden, die einen Wnt-abhängigen Proliferationsstimulus in humanen 
Kolonkarzinomzellen induzieren können. 
Im Rahmen dieser Dissertation wurden die Effekte des Flavonols Quercetin, das in 
zahlreichen Früchten und Gemüsen vorkommt und des Grünteecatechins (-)-Epigallocatechin-
3-gallat (EGCG) auf die Aktivität der GSK-3 in der humanen Kolonkarzinomzelllinie HT29 
mittels Western Blot Analyse untersucht. Quercetin ist bereits als potenter Inhibitor der 
isolierten GSK-3ß bekannt (Kern et al., 2006), während EGCG keinen Einfluss auf die 
isolierte GSK-3ß Aktivität hat (Schreiner 2004). Der GSK-3 spezifische Hemmstoff 
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SB216763 wurde als Positivkontrolle der Aktivitätshemmung eingesetzt. Als Maß für die 
Hemmung der Enzymaktivität wurde der Phosphorylierungsstatus von GSK-3α/β bestimmt, 
da durch Phosphorylierung an Ser21 und Ser9 die GSK-3α bzw.-3β Aktivität unterdrückt 
wird.  
Nach 24-stündiger, serumfreier Zellinkubation zeigte sich, dass Quercetin keinen 
signifikanten Einfluss auf den Phoshorylierungsstatus und damit auf die Aktivität der GSK-3α 
und 3β hat. In Übereinstimmung mit dem Ergebnis auf die GSK-3α/β beeinflusst Quercetin 
die β-Cateninhomeostase nicht. Dies lässt den Schluss zu, dass Quercetin keinen mitogenen 
Wachstumsstimulus in HT29 Zellen induziert. Im Gegensatz dazu erhöht Quercetin die 
Tcf/Lef vermittelte Transkriptionsaktivität in HEK293 Zellen und HCT116 Zellen.  
Die Behandlung von HT29 Zellen mit dem Grünteecatechin EGCG führt im Vergleich zum 
Quercetin zu einer Zunahme der GSK-3α/β Phosphorylierung und somit zu einer 
signifikanten Hemmung der GSK-3α/β im mikromolaren Konzentrationsbereich. Die 
Expression von GSK-3α/β wurde durch EGCG nicht beeinflusst Einher mit der Hemmung der 
GSK-3 geht eine konzentrationsabhängige und signifikante Abnahme von phosphoryliertem 
β-Catenin bei gleichzeitiger Abnahme von Gesamt-β-Catenin in HT29 Zellen. Mittels 
quantitativer real-time PCR konnte zusätzlich gezeigt werden, dass die EGCG bedingte 
Abnahme an Gesamt-β-Catenin vermutlich auf eine Reduktion der Transkription von β-
Catenin und folglich auf dessen Neogenese zurückzuführen ist. In Übereinstimmung mit der 
Abnahme von Gesamt-β-Catenin wird die Tcf/Lef vermittelte Transkriptionsaktivität im 
Reportergenassay nicht induziert. Erwartungsgemäß erwies sich SB216763 als potenter 
Hemmstoff der GSK-3 in intakten HT29 Zellen. Damit einher geht die signifikante Abnahme 
von phosphoryliertem β-Catenin. Gleichzeitig nimmt der Gehalt an Gesamt-β-Catenin zu. Die 
Ergebnisse dieser Arbeiten legen nahe, dass Quercetin und EGCG in humanen 
Kolonkarzinomzellen keinen Wachstumsstimulus über den Wnt-Signalweg induzieren und 
aufgrund der Abnahme des β-Cateninspiegels eher antiproliferative Effekte von EGCG zu 
erwarten sind. Neben der Schlüsselrolle im Wnt-Signalweg ist die GSK-3 in der Lage, die 
Glykogensynthase (GS) zu phosphorylieren und nimmt dadurch Einfluss auf die Glukose-
/Glykogehomeostase. Im Hinblick auf die potente Hemmung der GSK-3 durch EGCG stellte 
sich die Frage, ob diese Hemmung auch mit einer Modulation der Glukose- 
/Glykogenhomeostase einhergeht. Die Effekte von EGCG auf die Aktivität, Expression und 
Transkription der Schlüsselenzyme der Glukose- /Glykogenhomeostase, GS und 
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Glykogenphosphorylase (GP), wurden deshalb in HT29 Zellen untersucht. Zusätzlich wurde 
der Einfluss auf den Glykogenspiegel in HT29 Zellen bestimmt. EGCG wurde in einer 
Konzentration von 25µM eingesetzt, da bei dieser Konzentration die Aktivität der GSK-3 am 
stärksten gehemmt werden konnte. SB216763 diente als Positivkontrolle der Stimulierung der 
GS Aktivität. Eine Hemmung der GSK-3 durch EGCG führte zu keiner Stimulierung der GS 
Aktivität. In Einklang mit diesem Befund zeigen die Ergebnisse der Western Blot Analyse, 
dass die Phosphorylierungsstelle Ser641 der GS durch EGCG nicht beeinflusst wird. Der 
Gesamt-GS-Spiegel wird leicht aber signifikant erhöht, jedoch mit keiner Auswirkung auf die 
GS Aktivität. Mittels quantitativer real-time PCR konnte gezeigt werden, dass der Anstieg des 
Gesamt-GS-Spiegels womöglich auf eine gesteigerte Transkription und Expression von Leber 
GS zurückzuführen ist. Übereinstimmend mit der fehlenden Hemmung von GS durch EGCG 
kommt es zu keiner Glykogenakkumulation in HT29 Zellen. Allerdings konnte eine Abnahme 
des Glykogenspiegels beobachtet werden. Dies ist insoweit überraschend, da EGCG (25 µM) 
keinen Einfluss auf die GP Aktivität, das geschwindigkeitsbestimmende Enzym des 
Glykogenabbaus, gezeigt hat. Die Western Blot Analyse bestätigt, dass der Gesamt-GP-
Spiegel nach 24 h unverändert bleibt. Mittels quantitativer real-time PCR Analyse konnte 
gezeigt werden, dass die Transkripte für BGP (Gehirn GP) reduziert werden, während die 
Transkripte für LGP (Leber GP) nach 24 h ansteigen. Es ist also denkbar, dass die Expression 
von LGP gesteigert wird, um die Abnahme von BGP zu kompensieren. In Einklang mit der 
potenten GSK-3 Hemmung durch SB216763 (10µM) wird auch die GS Aktivität in HT29 
Zellen stimuliert. Dem entsprechend zeigen die Western Blot Daten, dass die 
Phosphorylierung von GS an Ser641 durch SB216763 signifikant reduziert wird. Damit 
einher geht die Zunahme des Glykogenspiegels in HT29 Zellen. Zusätzlich bewirkt 
SB216763 nach 24h eine signifikante Erhöhung des Gesamt-GS-Spiegels. Die quantitative 
real-time PCR zeigt, dass der Anstieg des Gesamt-GS-Spiegels vermutlich auf die erhöhte 
Transkription und Expression von LGS zurückzuführen ist. Sowohl die  Aktivität der GP als 
auch die Expression werden nicht durch den Hemmstoff SB216763 beeinflusst. Die 
Ergebnisse deuten somit darauf hin, dass die EGCG bedingte Modulation der GSK-3 keinen 
Einfluss auf die Glukose-/Glykogenhomeostase in HT29 Zellen nimmt und somit nicht zum 
antidiabetischen Potential von EGCG in HT29 Zellen beiträgt. 
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6 Materials and Methods 
6.1 Cell Culture 
Cell culture embodies the practices implemented in order to achieve and maintain an 
atmosphere most conducive for the vital growth of cells. The factors that negatively influence 
mammalian cell vitality include: maintaining a confluent population in the culture flask, 
maintaining high concentrations of cellular metabolic wastes in the growth medium, no 
contamination of cell cultures with bacteria and/or fungus and lastly, a deviation from optimal 
growth conditions (37°C, 5% CO2 and 95% air moisture). When growing, cells go through the 
3 growth phases depending on their type, plating density, media ingredient and antecedent 
handling: 
− An opening quiescent lag phase 
− A log phase when growth is exponential and the metabolic activity is at its 
highest  
− Finally, a stationary phase where the cell number is constant. 
6.1.1 Cell Lines 
6.1.1.1 HEK-293 Cell Line 
HEK-293 cells also known plainly as 293, are fibroblastoid semi-adherent cells that grow as a 
monolayer with a doubling time of 20-24h. They were established in 1977 from a human 
primary embryonal kidney using the adenovirus type 5. They are rated “risk category 1” by 
the German Central Commission for Biological Safety (DSMZ). 
HEK-293 cells were grown in Dubelscco‘s Modified Eagle Medium (with 4500 mg/l Glucose, 
and pyridoxin HCl, without Natrium-Pyruvat) containing 1% (v/v) penicillin/streptomycin 
(10,000 units/10,000µg per ml), 10% (v/v) heat-inactivated fetal calf serum (FCS) in a 
humidified incubator.  
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6.1.1.2
6.1.1.3
6.1.1.4
 HT29 Cell Line 
HT29 cells are epithelial-like adherent cells that grow as monolayer in large colonies with a 
doubling time of 40-60h. They were first established in 1964, originally from a primary 
colonic tumour of a 44-year old Caucasian female. They form a well-differentiated 
adenocarcinoma consistent with colony primary grade I and possess a hyper-triploid 
karyotype with a 17.5% polyploidy (DSMZ). HT29 cells have been described to have a 
mutation in the APC gene and an intact β-catenin gene (CTNNB1) (Ilyas et al. 1997).  
HT29 cells were cultured in Dubelscco‘s Modified Eagle Medium (with 4500 mg/l Glucose, 
and pyridoxin HCl, without Natrium-Pyruvat) containing 1% (v/v) penicillin/streptomycin 
(10,000 units/10,000µg per ml), 10% (v/v) heat-inactivated FCS in a humidified incubator. 
 HCT-116 Cells 
HCT116 cells are colon carcinoma cells with a diploid karyotype (DSMZ, Braunschweig). In 
contrast to HT29 cells, HCT-116 cells have an intact APC gene. The β-catenin gene, CTNNB1 
has a three base deletion mutation of heterozygous nature corresponding to codon 45 in Exon 
3, which causes an in frame deletion of the β-catenin protein (Ilyas et al. 1997). The cells 
were a gift from Prof Dr. Bibby of the Tom Connors Cancer Reseach centre, University of 
Bradford. 
HCT116 cells were cultured in RPMI 1640 medium containing L-glutamin, 1% (v/v) 
penicillin/streptomycin (10,000 units/10,000µg per ml), 10% (v/v) heat-inactivated FCS and 
1% (v/v) sodium pyruvate in a humidified incubator. 
 HepG2 cells 
HepG2 cells are human hepatoma cancer cells which were established from the tumour of a 
15 year old Argentinian harboring a hyperploid kayrotype (DMSZ). They are adherent cells 
which grow in a monolayer. 
HepG2cells were cultured in RPMI 1640 medium containing L-glutamin, 1% (v/v) 
penicillin/streptomycin (10,000 units/10,000µg per ml), 10% (v/v) heat-inactivated FCS and 
1% (v/v) sodium pyruvate in a humidified incubator. 
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6.1.2 Changing Cell Medium 
The medium in which cells are cultured has a dual function. Primarily, it acts as a conduit 
through which cells are provided with nutrients vital for cell growth, and secondly, it 
functions as the collector for excreted cellular wastes. Increasing accumulation of cellular 
metabolic excrements leads to an increasing acidity of the growth medium, which can be 
monitored by the gradual change in the colour (from red to yellow) of the phenol red indicator 
contained in the growth medium. This rising acidity of the medium plus the increasing dearth 
of nutrients, if sustained, will negatively influence cell growth and vitality.  
To change the growth medium, old medium is removed and the cells are rinsed once with 
10ml PBS (37°C) to wash out dead cells. Subsequently, 40ml of pre-warmed (37°C) adequate 
growth medium is added and the flask (175cm2) is placed in the humidified incubator (37°C, 
5% CO2, 95% moisture). 
6.1.3 Subculture of Cells 
Many adherent cell lines, tumour or otherwise artificially transformed cell lines, grow 
optimally as monolayer in cell culture flasks. On attaining a confluent population, some cell 
lines transcend to multilayer growth by adding multiple layers over first, in which case the 
cells growth is suppressed (contact inhibition) and the cells experience a change in 
metabolism. To maintain monolayer cell growth, the cells were passaged when they had 
reached a semi-confluent population.  
The growth medium is aspirated and the cells are rinsed with 10ml PBS to remove dead cells 
and residual growth medium (would inactivate Trypsin/EDTA and hinder cell detachment). 
2.5ml pre-warmed (37°C) Trypsin/EDTA is added and the culture is placed in a humidified 
incubator (HT29: 3min, HEK-293: 10s, HCT-116: 1min). The culture flask is gently clapped 
to detach the cells. 8ml pre-warmed (37°C) serum-supplemented medium is added (inhibits 
the lysing activity of Trypsin/EDTA) and the cells are re-suspended by pipetting up and 
down. 0.5-1ml of the cell suspension is transferred to an unused culture flask (175cm2). 40ml 
adequate pre-warmed serum and antibiotic supplemented medium is added, and the cells are 
incubated under normal growth conditions (37°C, 5% CO2). 
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Phosphate Buffered Saline (PBS), 10x NaCl 1.71M 
  Na2HPO4 0.10M 
  KCl 34mM 
  KH2PO4 8mM 
   
   
Dissolved with 1l re-distilled water. Set 
to pH 7.4. Diluted to 1x and sterilized 
by autoclaving before use.  
Trypsin/EDTA Trypsin (3.6U/mg) 500mg 
  EDTA 250mg 
  10x PBS 100ml 
   
   
   
Stirred overnight at 4°C. Set to pH 7-
7.4 and filled to 1l mark with re-
distilled water. Filtered (0.22µm) 
sterilely and aliquoted (5ml) before use. 
Stored at -20°C. 
6.1.4 Counting Cells 
To enumerate cells, a standard Neubauer double grid ruling counting chamber was employed 
(figure 54). Shortly before the cells are passaged, the counting chamber is prepared as 
follows: the cover glass and the external supports of the counting chamber are breath-
moistened. The cover glass is then gently slid onto the counting chamber. The formation of 
Newton rings between the external support and the cover glass indicates correct positioning of 
the cover glass. Equal volumes of cell suspension (preparation see chapter 6.1.3) and the cell 
dye Trypanblue are mixed homogeneously in a 1.5ml test tube. To load the counting chamber, 
the pipette is held at an oblique angle and its tip placed at the juncture between cover glass 
and counting chamber. As a result of the capillary effect, the liquid is drawn in between the 
cover glass and the chamber. Counting is performed in the squares denoted 1, 2, 3 and 4 
(figure 54) under a light microscope. Living cells appear illuminated because of their ability 
to actively eliminate the dye (trypan blue) while dead cells lacking this ability appear blue. 
Only the living cells are counted. The mean value for all four counting nets is multiplied by 
the dilution factor 2 and 10000 to obtain the amount of cells/ml of the cell suspension (Lindl 
2000). 
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Figure 54: Neubauer improved cell counting chamber [modified] (Lindl 1987). 
6.1.5 Storage of Cells 
For the storage of cells 3ml (30%, v/v) DMSO-solution is added to 7ml (70%, v/v) FCS-
solution, mixed thoroughly and dispensed into 20 sterile cryotubes at 500µl for each tube. 1ml 
of the cell suspension is then added to each tube thereby diluting DMSO, which functions as 
an anti-freeze to 10% (v/v). The tubes are capped and stored at –80°C in a freezer (Lindl 
1987)  
6.1.6 Re-culturing Cells 
During cell culture, it is of utmost importance to be mindful because some cell lines, while in 
culture, change their physiological properties with increasing passage number. It is therefore 
necessary to replace old cells from stocks to maintain reproducible results. Cells were 
replaced after attaining a passage number of 30 (Lindl 1987). 
The frozen cell suspension is thawed quickly in a water bath at 37°C. The cell suspension is 
taken up straightaway in 10ml medium (10% FCS, v/v) and centrifuged at R.T and 200g for 4 
min. The supernatant is discarded and the cell pellet re-suspended in 5ml FCS (20%, v/v) 
supplemented medium. Finally, the entire cell suspension is transferred to a small tissue 
culture flask (25cm2) and incubated at 37°C, 5% CO2 and 95% humidity (Lindl 1987). Upon 
achieving high confluency, the cells are passaged into a medium culture flask (80cm2) and 
1 2 
4 3 
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thereafter into a large culture flask (175 cm2). Cells were maintained for at least 2 week in 
culture before attaining experimental competence. 
6.1.7 Testing for Mycoplasma Contamination 
Mycoplasma, also called pleuropneumonia-like organisms is defined as any of a genus 
(family Mycoplasmataceae) of pleomorphic gram-negative and chiefly non-motile bacteria of 
mostly parasitic nature. They vary in form and size, ranging from 0.22µm to 2µm. 
Contamination of cultures with mycoplasma is durable and brings about metabolic alterations 
in the infected cells. This calls for frequent testing and in positive cases urgent removal of the 
mycoplasma (Lindl 1987). 
To test for mycoplasma infection, the cells are plated on a glass slide and allowed 24h for 
regeneration and growth. Thereafter, the growth medium is washed off the slide with cold 
methanol (-20°C) and the slide placed in methanol (-20°C) for at least 15min to affix the cells. 
Subsequently, the cells are stained with DAPI/SR101 solution (4’-6-diamidino-2-phenylindol-
di-hydrochloride/sulforhodamine 101) and scrutinized under a fluorescence microscope. 
Nucleic acid appears blue (DAPI) and plasma-proteins appear red (SR101). Scattered small 
bluish dots seen over the red regions of the plasma are a positive sign for mycoplasma 
infection (Lindl 1987). 
DAPI/SR 101-Solution (Partec) Tris-Cl, pH 7.6 0.2M 
 4´, 6-Diamidino-2 phenylindoldihydrochloride 8µM 
  Sulforhodamine 50µM 
  NaCl 0.2mM 
Materials and Methods  Seeding Cells 
 
 ▓ PAGE 105 ▓ 
6.1.8 Seeding Cells 
6.1.8.1
6.1.8.2
6.1.8.3
 Seeding HT29 Cells for Western Blot, Glycogen Synthase Assay, 
Glycogen Phosphorylase Assay and Glycogen Assay 
2.5 x 106 cells are seeded per Petri dish (175cm2) in a volume of 20ml Dulbecco’s Modified 
Eagle Medium DMEM (4500 mg/ml glucose, L-glutamine, without sodium pyruvate, 
Invitrogen GmbH)) supplemented with FCS (10%, v/v) and penicillin/Streptomycin (1%, 
v/v). They are grown for 72h in a humidified incubator at 5% CO2 and 37°C. Thereafter, the 
old medium is replaced with medium whose FCS content is 1% (v/v). After a further 24h of 
growth, the cells are incubated in a serum free environment with the compound(s) of interest. 
 Seeding HT29 Cells for Gene Expression Analysis with TaqMan® 
RT-PCR 
1.2 x 106 cells are seeded per Petri dish (55cm2) in a volume of 10ml Dulbecco’s Modified 
Eagle Medium DMEM (4500mg/ml glucose, L-glutamine, without sodium pyruvate, 
Invitrogen GmbH)) supplemented with FCS (10%, v/v) and penicillin/Streptomycin (1%, 
v/v). They are grown for 48 hours in a humidified incubator at 5% CO2 and 37°C after which 
the old medium is replaced with medium whose FCS content is 1% (v/v). After a further 24h 
of growth, the cells are incubated in a serum free environment with the compound(s) of 
interest. 
 Seeding HEK-293 Cells and HCT-116 cells for Tcf/Lef Reporter 
Gene Assay 
0.5 x 106 cells per Petri dish (55cm2) are seeded in a volume of 10ml Dulbecco’s Modified 
Eagle Medium DMEM (4500mg/ml glucose, L-glutamine, without sodium pyruvate) that is 
supplemented with FCS (10%, v/v) and penicillin/Streptomycin (1%, v/v). They are grown for 
72h in a humidified incubator at 5% CO2 and 37°C before being transfected with the 
plasmid(s) of interest (chapter 6.3.7). 
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6.1.9 Incubating Cells  
6.1.9.1
6.1.10.1
 Incubation of HT29 Cells 
By virtue of their labile nature in aqueous solution, the candidate compound(s) (flavonoids), 
once weighed, are dissolved appropriately in DMSO and diluted in serum free DMEM 
medium (so that DMSO has and end concentration of 1% (v/v)), moments prior to 
application. Before the application of the diluted compound, the cells are rinsed two 
consecutive times with sterile 10ml and 5ml 1x PBS to removes all traces of FCS containing 
DMEM medium. For all experiments, a solvent control plate (DMSO 1%, v/v) is always 
included. 
6.1.10 Harvesting cells and Preparation of Protein Extracts 
 Lysis of Cells for Luciferase Assay 
At the end of the incubation period the medium is removed and the cells are rinsed with 1ml 
1x ice cold PBS. Since HEK-293 cells easily detach from the surface of the Petri dish due to 
their semi-adherent nature, the washing step is performed, with extreme care taken to avoid 
high loss of cells. After the washing step, 500µl of 1x cell culture lysis reagent (Promega) is 
added per well and the cells incubated for 15min at room temperature under mild shaking. 
After lysis, cell debris is separated from the lysate by centrifugation for 2min at 4°C and 
1000rpm (Eppendorf 5804R). The debris free lysate is employed in a luciferase assay. The 
protein concentration of the lysate is determined for normalization purposes (chapter 6.2.1).  
Cell Culture Lysis Reagent, 1x Tris-phosphate (pH 7.8) 25mM 
(Promega) DTT 2mM 
 1,2-diaminocyclohexane-N,N,N´,N´-tetraacetic acid 2mM 
  Glycerol 10% 
  Triton® X-100 1% 
   CCLB is delivered as a 5x 
concentrate. Before use, it is diluted 
to 1x with distilled water 
Materials and Methods  Harvesting/Preparation of Protein Extracts 
 
 ▓ PAGE 107 ▓ 
6.1.10.2 Lysis of HT29 Cells and Extraction of Total Protein 
Harvesting cells and the preparation of the cell lysate is performed entirely on ice (4°C). 
− The lysis buffer is prepared freshly prior to use. The medium is decanted and 
the cells rinsed twice with 10ml of ice-cold 1x PBS respectively. The cells 
are scraped in 500µl lysis buffer, and then transferred to an ice-cooled 2ml 
glass homogenizer. With 40 strokes of the tight pistill, the cells are disrupted 
and homogenized. Cell debris is separated by centrifugation at 20,000g and 
4°C for 15min. The supernatant is transferred to a pre-cooled 1.5ml reaction 
tube. The protein concentration of the supernatant is determined using the 
Bradford assay as described in chapter 6.2.1. 
Lysis Buffer Tris-Cl 25mM 
  EDTA 3mM 
  EGTA 3mM 
  Sucrose 0.27M 
  NaF 50mM 
  β-Glycerophosphate 10mM 
  Sodium Pyrophosphate 5mM 
  Igepal-CA-630 or Triton X 100 1% (v/v) 
  Na3VO4 2mM 
  Complete Enzyme Coctail   
(Protase inhibitor mix ) 
2% (v/v) 
  2-Mercaptoethanol 0.1% (v/v) 
Complete Enzyme Coctail (Roche) 1 Tablet Dissolved in 2ml re-distilled water 
 
6.1.10.3 Lysis of HT29 Cells and Extraction of Nuclear Proteins 
The entire process is carried out on ice (4°C) 
− The medium is decanted and the cells washed twice with 10ml ice-cold of 1x 
PBS respectively. The cells are diligently scraped in 1ml ice-cold PBS. The 
cell suspension is transferred to a pre-cooled 1.5 reaction tube and pelleted 
by centrifugation at 15,000g and 4°C for 5min. The supernatant is discarded. 
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The pellet is treated with 200µl buffer A and incubated on ice for 20min, 
after which the test tube are centrifugated for 5min at 15,000g and 4°C. The 
supernatant is discarded and the pelleted nuclei are re-suspended in 200µl 
buffer B. The pellet is incubated in buffer B for 20min on ice. The nuclear 
extract (supernatant) is obtained by centrifugation at 20,000g and 4°C for 
5min. The protein content of the nuclear extract is determined with the 
bradford assay (chapter 6.2.1). 
Buffer A HEPES-KOH, pH 7.9 10mM 
  MgCl2 1.5mM 
  KCl 10mM 
  Following components are added freshly 
  DTT 0.5mM 
  PMSF 0.2mM 
  Igepal CA-630 0.5% (v/v) 
  Complete Enzyme Coctail 
(Protease inhibitor mix) 
2% (v/v) 
Buffer B HEPES-KOH,pH 7.9 20mM 
  MgCl2 1.5mM 
  NaCl 0.42mM 
  EDTA 0.2mM 
  Glycerol 25% (v/v) 
  Following components are added freshly 
  DTT 0.5mM 
  PMSF 0.2mM 
  Complete Enzyme Coctail 
(Protease inhibitor mix) 
2% (v/v) 
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6.2 Biochemical Methods 
6.2.1 Determining Protein Concentration with the Bradford Assay 
The protein concentration of samples was determined using a photometric method developed 
by Bradford (Bradford, 1976). This method is based on the strong binding affinity of the dye, 
coomassie brilliant blue G-250 (figure 55) to proteins. The dye interacts electro-statically in 
acidic medium with the amino and carboxyl groups of proteins to form strong non-covalent 
bonds. The protein/coomassie bond causes a shift of the absorption maximum in the 
absorption spectrum of the dye from λ = 465nm (red) to λ = 595nm (blue). The colour 
response is non-linear over a wide range of protein concentrations. A standard curve is 
therefore required. 
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Figure 55: Structure of the coomassie brilliant blue G250 
Procedure 
− A sequential standard row from 0.1-1.0mg/ml protein (Table 6.2-1) is 
prepared with bovine serum albumin (BSA, 2mg/ml, Pierce). If required, the 
samples are diluted with re-distilled water. 10µl of (diluted) probe is pipetted 
into a 1.5ml reaction tube. 10µl of each standard is pipetted into separate 
1.5ml eppendorf tubes. 1ml of Bradford solution is added to each tube. 200µl 
of each probe and standard is pipetted in triplicates into a 96 well dish. The 
96 well plate is measured at λ = 595nm in a microplate reader. 
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Table 5: Diluting bovine serum albumin to create a standard row for the determination of protein 
concentration 
Final [mg/ml] BSA [2mg/ml] Distilled water  
0.1 10µl 190µl 
0.2 20µl 180µl 
0.4 40µl 160µl 
0.5 50µl 150µl 
0.6 60µl 140µl 
0.8 80µl 120µl 
1.0 100µl 100µl 
 
Bradford Reagent: Coomassie-Blue G250 0.10g 
  Ethanol 50ml 
  Ortho-phosphorous acid 100ml 
   
   
Filled with re-distilled water to 1l. 
Stored in the dark (RT) for a minimum 
of one month before use. Filtered 
before use. 
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6.2.2 Analysis of Glycogen Phosphorylase Activity in HT29 Cells 
HT29 Cells were seeded and treated with the compound(s) of interest as described in chapters 
6.1.8.1 and 6.1.9.1 respectively. After incubation of the cells, a whole cell lysate of the cells 
was prepared as described in chapter 6.1.10.2 and the glycogen phosphorylase activity was 
determined in a glycogen phosphorylase assay. 
6.2.2.1 Glycogen Phosphorylase Assay 
The method employed for the characterization of the glycogen phosphorylase (GP) activity is 
a modification of the method described by (Layzer et al. 1967) and (Kaiser et al. 2001). It 
couples a GP catalysed enzymatic reaction with other enzymatic reactions that have NADP+ 
(oxidized nicotinamide adenine di-nucleotide phosphate) as a co-substrate, whereby NADP+ 
is reduced to NADPH2. The reduction of NADP+ to NADPH2 causes a shift in its absorption 
maximum from λ = 260nm to λ = 340nm in the UV spectrum. This shift in the absorption 
maxima makes it possible to optically follow the course of the reaction. The activity of GP is 
determined by measuring the absorbance at λ = 340nm over 9min. The slope of the curve is 
an expression of GP activity.  
The enzyme processes involved in glycogen phosphorylase assay is tiered in 3 stages.  
− Glycogen phosphorylase (GP) cleaves an α-D-glucose molecule from 
glycogen to form α-D-glucose-1-phosphate  
(n) Glycogen + Pi → (n-1) Glycogen + α-D-glucose-1-phosphate 
− Phosphoglucomutase (PGM) transforms α-D-Glucose-1-phosphate to α-D-
glucose-6-phosphate. 
α-D-glucose-1-phosphate → α-D-glucose-6-phosphate 
− Glucose-6-dehydrogenase (DH) dehydrogenates α-D-glucose-6-phosphate is 
to 6-phosphogluconate while NADP+ is reduced to NADPH2. 
α-D-glucose-6-phosphate + β-NADP+ → 6-phosphogluconate + β-NADPH2 
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Procedure 
− A master mix is prepared on ice in a 50ml Polypropylene (PP)-tube by 
mixing the assay components chronologically as shown in table 4. The 
samples are vortexed briefly but thoroughly and 50µl lysate of each sample 
prepared as described in chapter 6.1.10.2 is pipetted into a 1.5ml semi-micro 
cuvette (12.5x12.5x45mm). For the blank, 50µl of the cell lysis buffer is 
employed. 900µl of the master mix is dispensed in each semi-micro cuvette. 
The cuvettes are loaded on the sample chamber in the photometer and 
temperated for 2min to 25°C. 50µl (20mg/ml) of glycogen solution is added 
into each cuvette as a reaction starter. The enzyme reaction is measured 
photometrically over a period of 9min (Cary 1 Bio UV-Visible 
Spectrophotometer, Varian) 
Table 6: Preparation of the GP master mix. To allow for incidental fluid losses that occur during 
pipetting, an n = 4+1 is prepared for 4 samples. DH: Glucose-6-dehydrogenase, NADP+: 
oxidized nicotinamide adenine di-nucleotide phosphate, PGM: phosphoglucomutase 
Reagent [Stock]  Blank  n = 1 n = 4+1 
Assay Buffer - 780 780 3900 
NADP+ 20mM 50 50 250 
DH 0.5U/10µl 30 30 150 
PGM 0.8U/10µl 40 40 200 
 
To capture the effects on the constitutionally lesser active form of glycogen phosphorylase, 
GPb, it is activated post isolation, with the allosteric GPb activator, AMP at a concentration of 
200nM (table 5). GP activity is normalized against protein concentration and expressed as 
percentage change relative to the DMSO control sample which is set at 100%. 
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Table 7: Pipetting chronology for the preparation of the master mix used for the glycogen 
phosphorylase assay with the addition of AMP as a GPb allosteric activator.  
Reagent [Stock]  Blank  n = 1 n = 4+1 
Assay Buffer - 780 780 3900 
NADP+ 20mM 50 50 250 
AMP 200mM 50 50 250 
DH 0.5U/10µl 30 30 150 
PGM 0.8U/10µl 40 40 200 
 
Assay Buffer (AB) 20mM Na2HPO4 2.84g 
  2.0mM MgSO4 0.24g 
   
   
Dissolved in 1l re-distilled water. pH 
adjusted to 7.2 with H2SO4. Stored at 
4°C. 
Nicotinamide Adenine di-Nucleotide   
Phosphate (NADP+) (Sigma) 20mM 76.56mg 
   Dissolved in 5ml AB. Stored at -20°C. 
Glucose-6-Dehydrogenase (Sigma) 0.5U/10µl re-distilled water. Stored at 
4°C.
Phophoglucomutase (Sigma) 0.8U/10µl AB. Stored at 4°C 
Glycogen (Sigma) 20mg/ml 100mg 
  Dissolved in 5ml AB. Stored at 4°C 
AMP (Sigma) 200 mM 14 mg 
  Dissolved in 10ml AB. Stored at 4°C 
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6.2.3 Analysis of the Glycogen Synthase Activity in HT29 Cells 
After incubation of the HT-29 cells, a whole cell lysate of the cells was prepared as described 
in chapter 6.1.10.2 and the glycogen synthase activity was determined in a glycogen synthase 
assay. 
6.2.3.1 Glycogen Synthase Assay 
The sequential phosphorylation of glycogen synthase by glycogen synthase kinase 3 (GSK-3) 
on the serin residues 652, 648, 644, 640 renders the enzyme inactive. However, the allosteric 
effector of glycogen synthase, glucose-6-phosphate (G-6-P) is capable of restoring full 
activity to the phosphorylated enzyme. The glycogen synthase (GS) activity can hence be 
determined by measuring the rate of incorporation of a tritium labelled glucose moiety of 
[3H]-uridin diphosphate glucose [3H- UDPG] (figure 56) into glycogen in the absence and 
presence G-6-P. The ratio of the two activities i.e. activity without G-6-P to activity with G-6-
P is employed as an index of the state of activation of glycogen synthase (Thomas et al. 
1968). 
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Figure 56: Scheme showing the basic reaction of the glycogen synthase assay where tritium labelled 
glucose is incorporated into an existing glycogen chain by active glycogen synthase. 
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Procedure 
− The assay reaction buffers A and B are prepared on ice. Two master mixes 
(A and B) are prepared by adding the appropriate volume of UDP-[6-3H]-
Glucose solution (10µl of a 100µCi UDP-[6-3H]-Glucose solution) to assay 
buffers A and B and vortexing briefly. 45µl lysate of sample (prepared as 
described in chapter 6.1.10.2) is introduced into each of 2 pre-cooled 1.5ml 
reaction tubes previously labelled as 1A and 1B. In order to detect the 
background activity, a blank using 45µl of cell lysis buffer is employed. 55µl 
of master mix A are pippeted in the caps of the reaction tubes 1A and 55µl 
master mix B in 1B. The reaction tubes are capped and the assay buffers 
spun down in a centrifuge. The reaction is started by incubating the reaction 
tubes at 37°C for 30min. Every 10min, the contents of the reaction tubes are 
homogenized by tipping the tubes. After 30min, the reaction tubes are placed 
on ice and incubated for 3 min to stop the reaction. The reaction tubes are 
vortexed and the content of each tube is pipetted in triplicates onto 
previously cut and numerated whatmann® cellulose sheets (1.2x1.2cm) at a 
volume of 28µl per cellulose sheet. The cellulose sheets are air dried for 
5min then washed 3x consecutively, the first two times for 5min and lastly 
for 10min in 66% (v/v) ethanol. The cellulose sheets are again washed, this 
time in aceton for 5min and subsequently air-dried. The cellulose sheets are 
introduced into scincillation tubes, which were previously filled with 4.5ml 
scincillation coctail. The tubes are capped, shaken vigorously and measured 
in a β-counter for 2min (LS 1701, Beckman) 
 
Calculation of the Index of the Glycogen Synthase Activity 
Counts per minute (cpm) of reaction without glucose-6- phosphate 
Index = 
Counts per minute (cpm) of reaction with glucose-6- phosphate 
 
The index for the solvent control sample is arbitrarily set as 100%. The rest of the samples are 
expressed as percentage change with respect to the solvent control sample. 
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Tris-Cl/EDTA 200mM Tris-Cl, pH 7.5 [Roth] 33.3ml 
  100mM EDTA, pH 7.5 [Roth] 6.7ml 
  Water 35ml 
   Stored at 4°C 
1, 4-Dithiothreitol [Roth] 20mM DTT 
   
Diluted 1M stock solution 1:50 in re-
distilled water i.e. 1ml stock + 49ml 
re-distilled water.  
UDP-[6-3H-Glucose] 
(Amersham) 
100µCi UDP-[6-3H]-Glucose Diluted 1mCi stock solution 1:10 in re-
distilled water i.e. 10µl activity +90µl 
re-distilled water 
Assay Buffer A (1ml) Tris-Cl/EDTA 750.0µl (67mM Tris-Cl/6.7mM EDTA) 
  DTT 250.0µl (5mM) 
  89 mM UDP-Glucose 54.3mg 
  Glycogen 13.0mg 
   Mixed by vortexing until no clumps 
are visible 
Assay Buffer B (1ml) Tris-Cl/EDTA 750.0µl (67mM/6.7mM) 
  DTT 250.0µl (5mM) 
  UDP-Glucose 54.3mg (89mM) 
  Glucose-6-phosphate 6.8mg (20mM) 
  Glycogen 13.0mg 
   Mixed by vortexing until no clumps are visible 
Master Mix A Assay Buffer A 45.0µl 
  UDP-[6-3H]-Glucose solution 
(100µCi) 
10.0µl (10µCi end concentration) 
Master Mix B Assay Buffer B 45.0µl 
  UDP-[6-3H]-Glucose solution 
(100µCi) 
10.0µl (10µCi end concentration) 
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6.2.4 Analysis of Glycogen Content in HT29 Cells 
HT29 cells were seeded and treated with the compound(s) of interest as described in chapters 
6.1.8.1 and 6.1.9.1 respectively. Incubation of the cells is terminated as described below. 
6.2.4.1
6.2.4.2
 Harvesting cells and Isolation of Glycogen  
− The medium is discarded and cells are rinsed with ice cold 1x PBS. The cells 
are scraped in 400µl 30% (g/v) potassium hydroxide and transferred to a 2ml 
reaction tube. To ensure complete lysis of the cells, the tube is capped and 
heated at 95°C for 15min, after which the tubes are cooled on ice. 200µl 
sodium sulfate and 1.2ml 66% (v/v) ethyl alcohol are added to precipitate 
glycogen. The sample is stored over night at 4°C. On the following morning, 
the precipitated glycogen is pelleted by centrifuging at 20,000g and 4°C for 
30min. The pelleted glycogen is rinsed with 2ml 66% (v/v) ethyl alcohol and 
subjected to another centrifugal step for 30min at similar conditions. The 
supernatant is discarded. Residual traces of ethanol are removed with a filter 
paper and the pellet air-dried. The dry pellet is employed in the anthron 
assay.  
 Anthron Assay 
Glycogen was determined using a simplified modification of the method described by 
(Pfluger 1905). Glycogen is released from the cells by means of alkali lysis and precipitated 
with sodium sulfate and ethyl alcohol. The alkali stable but acidic-labile α-glycosylic bonds of 
glycogen are subsequently hydrolized to open chain glucose molecules by heat treatment in 
concentrated sulfuric acid. The high temperature together with the acidic medium provokes 
the formation of the furane compound (hydroxymethyl-furfural, HMF) through a mechanism 
marked by tautomerism, ring formation and triple dehydration of glucose (figure 57 and 58).  
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Figure 57: Mechanism of the formation of hydroxymethylfurfural (HMF) from glucose under acidic 
conditions and high temperatures. 
In the ensuing step, HMF reacts with anthron in a colorimetric assay to a green complex, 
which has an absorption maximum of 620nm. With the aid of a standard curve, the glycogen 
content in each sample is quantifiable by means of linear interpolation. 
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Figure 58: Reaction of HMF and anthron to a green complex with a maximum absorption at 620nm. 
Procedure 
− The dry glycogen pellet (chapter 6.2.4.1) is taken up in 1ml anthron II 
solution, vortexed until the pellet comes off the wall of the tube and heated at 
95°C under vigorous agitation for 15min (Eppendorf Thermomixer 5436, 
Heinz). Simultaneous to the sample set up, a sequential 10 points glycogen 
standard row is prepared in bi-distilled water as indicated in table 6 and 
diluted with 720µl anthron I solution. The standard row is heated likewise 
the samples at 95°C under vigorous agitation for 15min (Eppendorf 
Thermomixer 5436, Heinz). The tubes are cooled to 4°C on ice, the samples 
appropriately diluted and their absorptions measured photometrically in a 
cuvette at 620nm. Each sample is measured twice. The glycogen 
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concentration in the sample is established by means of linear interpolation 
from the generated standard curve. Anthron II solution is employed as blank. 
Table 8: Preparation of the glycogen standard row (1ml) 
Desired Glycogen 
Concentration [µg/ml] 
Required Volume of a 
0.1mg/ml Stock Glycogen 
Solution [µl] 
Re-distilled Water 
[µl] 
Anthron I Solution 
[µl] 
2 20 260 720 
4 40 240 720 
6 60 220 720 
8 80 200 720 
10 100 180 720 
12 120 160 720 
14 140 140 720 
16 160 120 720 
18 180 100 720 
20 200 80 720 
 
Anthron Solution I, 10ml Anthron [Sigma] 210µg (0.21%) [Sigma] 
  Concentrated H2SO4 10ml 
   Always prepared freshly 
Anthron Solution II, 10ml Anthron [Sigma] 150µg (0.15%)  
  Aqueous H2SO4 10ml (H2O : H2SO4, 1 : 2.5) 
   Always prepared freshly 
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6.2.5 SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis) 
6.2.5.1 Denature of Proteins 
The sample is prepared in a sample buffer, which contains amongst others, sodium dodecyl 
sulfate (SDS) and 2-mercaptoethanol. SDS is an anionic detergent that binds to proteins and 
in the course of doing so disrupts their quaternary, tertiary and to a certain extent their 
secondary structures. Together with 2-mercaptoethanol it accounts for the cleavage of inter- 
and intra-chain disulphide bonds. As a result, the proteins are enveloped uniformly in a 
coating of SDS. This bestows a net negative charge upon the proteins. The motility of the 
proteins is now determined solely by their relative molecular weight, which now possesses a 
relationship of simple linearity with their electrophoretic mobility.  
Procedure 
− The protein concentration in each sample is ascertained by means of the 
bradford assay (chapter 6.2.1) and diluted to 2mg/ml with re-distilled water. 
A volume of 10µl of the diluted sample containing 20µg protein is mixed 
with 2µl sample buffer and heated at 95°C for 15min (Eppendorf 
Thermomixer 5436, Heinz). The sample is loaded on the gel immediately 
after protein denature. 
SDS Sample Buffer, 6x 0.5M Tris-Cl, pH 6.8 [Roth] 50ml 
  Glycerol [Merck] 40ml
  SDS [Roth] 1.24g
  Bromophenol blue [Sigma] 0.16g
  2-Mercaptoethanol [Roth] 5% (v/v)
  2-Mercaptoethanol is added 
freshly before use 
6.2.5.2 Discontinuous Zone Electrophoresis 
Discontinuous zone electrophoresis, also known as disc-electrophoresis for short, is the 
standard technique mostly employed nowadays for the analysis of proteins. This technique 
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derives its name from the fact that the polyacrylamide gel used in the methodology is made up 
of 2 dissimilar parts: 
− The first moiety to concentrate the sample called, the stacking gel, which is 
buffered by Tris-Cl at pH 6.8, and whose characteristical low acrylamide/bis-
acrylamide concentration ensures a high porosity of the gel. 
− The second moiety to separate the sample, called the resolving gel, which is 
also Tris-Cl-buffered (pH 8.8), but is characterized by smaller pores due to a 
higher acrylamide composition. 
Additionally, discontinuous zone electrophoresis is distinguishably marked by its use of 
different types of charge carriers: firstly, there are the chloride ions that are prevalent in both 
sample and gel and, secondly, the glycine ions, which are profuse in the electrophoresis 
buffer. During electrophoresis, the chloride ions in the gel migrate with high mobility toward 
the anode thus quickly creating an anion gradient between the cathode end and the anode end 
of the gel. The glycine ions on the other hand, moving from the running buffer into the 
stacking gel take up a zwitterionic configuration due to the almost neutral pH of 6.8 in the 
stacking gel, migrate slowly as a consequence and play a subordinate role in current transfer. 
The SDS coated protein molecules, which have a lower charge to mass ratio than chloride 
ions but a greater mass to charge ratio than glycine zwitterions, align themselves as current 
carriers between the fast chloride ions and the lagging slower glycine zwitterions, so that 
another anionic gradient builds up toward the cathode. This leads to the formation of tight 
successive stacks of proteins between the leading chloride ions and lagging glycine ions at the 
boundary of the stacking and separating gels. When the sample front enters the separating gel, 
which has a higher pH (pH 8.8) than the stacking gel, the glycine ions become fully 
dissociated and migrate faster. They overtake the proteins so that the proteins are forced to act 
as charge carriers behind the glycinate and chloride ions. The SDS-coated protein molecules, 
whose migration is now restricted by the sieving effect of the separating gel slow down and 
become separated according to size, whereby smaller proteins are less restrained and thus 
migrate faster than larger proteins (Pingoud 2002). 
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Casting Discontinuous Polyacrylamide Gels 
The SDS-PAGE was carried out using a vertical flatbed apparatus (figure 59), Mini-
PROTEAN II Electrophoresis cell from BIO-RAD using slab gels 
− The glass plates and spacers needed for casting of the gels are thoroughly 
cleaned with 70% (v/v) ethanol to rid them of grease that will disturb gel 
polymerization.  
− After assembling of the glass plates and spacers (0.1cm thickness) on the 
casting stand to form a cassette (figure 59), the components for the 
separating monomer gel are mixed chronologically as depicted in table 13 
and introduced into the cassette to a height of 5cm (~ 3.5ml).  
 
         side view                                                   frontal view 
Figure 59: Sketch of the vertical flatbed apparatus Mini-PROTEAN® II from BIO-RAD displaying A: 
the frontal and sideways view of the clamp assembly mounted with the glass plates and spacer 
forming a cassette. 
− The gel is overlayed with water-saturated n-butanol, which serves to exclude 
oxygen that impedes polymerization and to flatten the top surface of the gel. 
Upon completion of the polymerization (45-60min), the overlay solution is 
rinsed with distilled water and the area above the separating gel dried with 
filter paper.  
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− A comb is placed between the sandwiched plates (figure 59). 
− The reagents for the stacking gel are combined as shown on table 14 and the 
monomer solution loaded. When polymerization is completed, the comb is 
removed and the residual water is aspirated from the gel pockets. 
− Alongside with the sample (12µl, ≅ 20µg protein per pocket), is also loaded 
in both outermost wells, 15µl of the tracking dye (table 15, SeeBlue® Plus2, 
Invitrogen) to enable the monitoring of the electrophoresis. Both upper and 
lower electrophoresis chambers are filled with running buffer (1x) and the 
gel ran for 120min, initially at a constant voltage of 100V then eventually at 
120V when the sample front reaches the separating gel. 
Table 9: Preparation of separating gels for SDS-PAGE. The rotiphorese solution [Roth] contains 
acrylamide (AA) and N, N’ methylene bis-acrylamide in a ratio of 37.5:1. The acrylamide 
concentration determines the length of the polyacrylamide chain. Bis-acrylamide determines 
the degree of cross-linking. N, N, N’, N’ tetra-methylendiamine (TEMED) [Roth] acts as a 
catalyst for the reaction. Ammonium persulphate (APS) [Roth] is a radical starter and 
initiates the polymerisation reaction. 
Seperating gel 
Component 
10% AA 12% AA 
Re-distilled water 2.05ml 1.72ml 
Tris-Cl (1.5M), pH 8.8, [Roth] 1.23ml 1.23ml 
Rotiphorese (37.5:1)-solution [Roth] 1.65ml 1.97ml 
10% SDS solution [Roth] 49.2µl 49.2µl 
10% APS solution [Roth] 24.6µl 24.6µl 
TEMED [Roth] 2.46µl 2.46µl 
∑ 5.0ml 5.0ml 
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Table 10: Preparation of the stacking gel with an acryl amide content of 4% for SDS-PAGE. 
Stacking gel 
Component 
4% AA 
Re-distilled water 1.20ml 
Tris-Cl (0.5M), pH 6.8 [Roth] 500ml 
Rotiphorese (37.5:1)-solution [Roth] 250µl 
10% SDS solution [Roth] 20µl 
10% APS solution [Roth] 20µl 
TEMED [Roth] 2µl 
Table 11: Apparent molecular weights of the protein bands in SeeBlue® Plus2 Pre-Stained Standard 
(Invitrogen) in a Tris-Glycine buffer system 
Myosin 250kDa 
Phosphorylase 148kDa 
BSA 98kDa 
Glutamic Dehydrogenase 64kDa 
Alcohol Dehydrogenase 50kDa 
Carbonic Anhydrase 36kDa 
Myoglobin Red 22kDa 
Lysosome 16kDa 
Aprotinin 6kDa 
Insulin, B Chain 4kDa 
 
Running Buffer, 10x 250mM Tris-Cl [Roth] 60.6g 
  2M Glycin [Roth]  300g 
  1% (w/v) SDS [Roth] 20g 
   Dissolved in 2l re-distilled water. Set to 
pH 8.3 with HCl. 
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6.2.5.3 Western Blot 
To further characterize proteins which have been separated by SDS-PAGE (chapter 6.3.4) 
often requires their extraction from the electrophoresis gel onto a nitrocellulose membrane. 
“Semi-dry blotting” was employed for protein transfer (figure 60). The gel is placed on a 
sheet of nitrocellulose membrane. Both gel and membrane are sandwiched between two pairs 
of whatmann filter paper (figure 10). Prior to use, the whatmann filter paper and nitrocellulose 
membrane are soaked in 1x blotting buffer for 30min. The sandwiched gel is clamped 
between the horizontal electrodes of the blotter so that the membrane lies contiguous to the 
anode and the gel bordering the cathode. Before blotting is commensed, air bubbles caught in 
the filter papers, which will impede current transfer, are released using a roller pin. The blot is 
run for 90min at a current of 50mA per gel. (Blotter (SEMI-PHOR™ Blotter, Hoefer 
Scientific Instruments, San- Francisco). 
 
Figure 60: Schematic representation of a “semi-dry western blot” 
Blotting Buffer, 2x 96mM Tris-Cl [Roth] 23.3g 
  78mM Glycin [Roth] 11.7g 
  0.074% (w/v) SDS [Roth] 1.48g 
  40% (v/v) Methanol [Merck] 800ml 
   Dissolved in 2l with re-distilled water 
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6.2.5.4 Blocking the non-specific Protein Binding Sites on the Membrane 
Nitrocellulose membranes can bind protein indiscriminately with a binding capacity between 
100-200µg/cm2. To prevent the non-specific binding of antibodies on the nitrocellulose 
membrane, unoccupied hydrophobic binding sites on the membrane are blocked by incubating 
the membrane in blocking buffer containing non-fat dried milk for 1h at room temperature 
with gentle agitation.  
Tris Buffered Saline (TBS) (20x) 2.6M NaCl 303.9g 
  0.4M Tris-Cl 96.9g 
   Dissolved in 2l re-distilled water. Set to 
pH 7.6 with HCl 
TBS/0.1%Tween-20 (1x) TBS (1x) 100ml (20xTBS) 
  Tween-20 (0.1%) [Sigma] 2ml 
   Diluted in 2l re-distilled water. Store at 
RT
Blocking Buffer (1x) TBS / (0.1%) Tween 20 100 ml 
  5% (w/v) Non-Fat Dried Milk 5g 
6.2.5.5 Immunological Detection 
− After blocking the nitrocellulose membrane, it is washed 3 times 
consecutively for 5min respectively in wash buffer. 
− The membrane is incubated with the primary antibody (diluted in (1x) TBS- 
(0.1%) Tween 20) overnight at 4°C with gentle agitation. (The primary 
antibody binds specifically to the protein of interest). 
− The membrane is again washed 3 times consecutively for 5 min respectively 
in washing buffer. 
− The membrane is incubated with the secondary antibody (1:2000) for 1h at 
room temperature with gentle agitation. The secondary antibody is coupled 
with HRP (horse raddish peroxidase), an enzyme that catalyzes the 
chemiluminescent reaction between luminol and peroxide (figure 61) thus 
making it possible to visualize of the proteins. 
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− The membrane is washed 3 times consecutively for 5min each in washing 
buffer. 
− The membrane is incubated with 10ml LumiGLO® reagent (Cell Signaling 
Technology) with gentle agitation for 1min at room temperature. 
− The detection of chemiluminescence is carried out on the Lumi-Imager™ 
(Boehringer Mannheim) 
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Figure 61: Chemiluminescent reaction between luminol and H2O2 catalysed by horse raddish peroxidase 
Washing Buffer TBS (1x) 250ml (20x TBS) 
  Tween-20 (0.3%) 15ml 
   Diluted in 5l-distilled water. Stored at 
RT
LumiGLO™ Detection Solution 20x Luminol  0.5ml 
(Cell Signaling Technology) 20x Peroxide 0.5ml 
  Water 9ml 
Primary Antibody Dilution (1x) TBS-(0.1%)-Tween 20 10ml 
 Bovine Serum Albumin (Pierce) 0.5g 
Secondary Antibodies: HRP-coupled „Anti-mouse“-IgG (Santa Cruz) and HRP-coupled „Anti-rabbit“-
IgG (Cell Signaling Technology) were diluted in blocking buffer. 
Materials and Methods  SDS-PAGE/Western Blot 
 
 ▓ PAGE 128 ▓ 
6.2.6 Semi-quantitative Analysis of Protein Phosphorylation and 
Protein Expression in HT29 Cells using Western Blot 
Analysis 
To determine the flavonoid-dependent modulation of phosphorylated and total protein levels 
for the proteins listed in table 12, 2.0 x 106 HT29 cells seeded per Petri dish (175cm2) were 
cultivated under the conditions described in chapter 6.1.8.1 and incubated in serum free 
medium with the compound(s) of interest (chapter 6.1.9.1).  
Table 12: Table of the characterized proteins, showing their molecular weights and the acrylamide 
concentration in the separating gel used for SDS-PAGE. 
Protein Apparent Molecular Weight [kDa] Acrylamide Gel 
GSK-3β 47 12%  
GSK-3α 51 12%  
Glycogen synthase 85 10%  
β-Catenin 92 10% 
Glycogen phosphorylase 97 10%  
 
6.2.6.1 Detection of Total GSK-3α/β, Glycogen Synthase, Glycogen 
Phosphorylase and β-Catenin 
To capture the modulations in the protein level of GSK-3-α/β, glycogen synthase, glycogen 
phosphorylase and β-catenin, after the treatment of HT29 cells with the compound(s) of 
interest (SB216763, EGCG, quercetin) a protein fraction of incubated HT29 cells (chapter 
6.1.9.1) is isolated as described in chapter 6.1.10.2. 10µl (20µg) of the whole protein extract 
is heat-treated (95°C) for 15min with 2µl 6x SDS sample buffer (chapter 6.3.4.1). The 
proteins are separated by SDS-PAGE (chapter 6.3.4.2), which precedes their transfer onto a 
nitrocellulose membrane (chapter 6.3.4.3, (50mA per membrane for 90min)) and blocking of 
the nitrocellulose membrane (1h, RT, chapter 6.3.4.4). The nitrocellulose membrane is 
subsequently incubated, first, with the specific primary antibody (overnight at 4°C), and then 
with the appropriate secondary antibody (1h, RT (table 13)). To visualize the protein bands on 
the membrane, it is incubated in LumiGLO™ (Cell Signaling Technology) for 1min and 
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luminescence measured in the LumiImager (Boehringer Mannheim). The protein bands are 
analysed with the Lumianalyst 3.0 software (Boehringer Mannheim). The results are 
expressed as percentage change with respect to the DMSO-solvent control (T/C (%)) 
Table 13: Table showing the used antibodies, their concentrations, and the duration of the exposure of 
the nitrocellulose membranes during detection. The secondary antibodies were employed at 
the dilution of 1:2000 in blocking buffer. 
Primary Antibody Dilution Source Secondary Antibody Exposure Time
Anti-GSK-3α/β-IgG2a    
(0011-A) (Santa Cruz) 
1:2000 Mouse monoclonal 
HRP-anti-Mouse IgG   
(Santa Cruz) 30s 
Anti-β-Catenin              
(Cell Signaling) 1:1000 
Rabbit 
Polyclonal 
HRP-anti-Rabbit IgG    
(Cell Signaling) 5min 
Anti-β-Catenin-IgG1 (E-5) 
(Santa Cruz) 1:2000 
Mouse 
Monoclonal 
HRP-anti-Mouse IgG  
(Santa Cruz) 30s 
Anti-GS                    
(Cell Signaling) 1:2000 
Rabbit 
Polyclonal 
HRP-anti-Rabbit IgG    
(Cell Signaling) 5min 
Anti-GP-IgG1 (9F5)       
(Santa Cruz) 
1:2000 Mouse Monoclonal 
HRP-anti-Mouse IgG  
(Santa Cruz) 30s 
 
6.2.6.2 Detection of Nuclear GSK-3 and β-Catenin 
Nuclear proteins are extracted as described in chapter 6.1.10.3. 10µl (20µg total protein) of 
nuclear lysate is subjected to heat treatment (95°C) for 15min in the presence of SDS-buffer 
(2µl 6x SDS sample buffer (chapter 6.3.4.1). The proteins are subsequently separated by 
SDS-PAGE (chapter 6.3.4.2) and transferred onto a nitrocellulose membrane (50mA per 
membrane for 90min) chapter 6.3.4.3). After an initial blocking incubation in non-fat dry milk 
(1h, RT chapter 6.3.4.4)), the nitrocellulose membrane is consecutively incubated, first, with 
the specific primary antibody (overnight at 4°C), then with the appropriate secondary 
antibody (1h, RT, table 13). The nitrocellulose membrane is then incubated in LumiGLO™ 
(1min, Cell Signaling Technology) and luminescence is measured in the LumiImager 
(Boehringer Mannheim). The protein bands are analysed with the Lumianalyst 3.0 software 
Materials and Methods  SDS-PAGE/Western Blot 
 
 ▓ PAGE 130 ▓ 
(Boehringer Mannheim). The results are expressed as percentage change with respect to the 
DMSO-solvent control (T/C (%)) 
6.2.6.3 Detection of the Phosphorylated GSK-3β, Glycogen Synthase and β-
Catenin 
To determine the phosphorylation state of GSK-3-α/β (Ser21/Ser9), glycogen synthase (Ser 
641), and β-catenin (Thr41/Ser37/Ser33) in HT29 cells in response to the intervention with 
the compound(s) of interest, a cellular extract of the incubated HT29 cells (chapter 6.1.8.1) is 
prepared as described in chapter 6.1.10.2. 10µl (20µg total protein) of the whole protein 
extract is heat-treated (95°C) for 15min with 2µl 6x SDS sample buffer (chapter 6.3.4.1). The 
proteins are separated by SDS-PAGE (chapter 6.3.4.2), transferred onto a nitrocellulose 
membrane (chapter 6.3.4.3, (50mA per membrane for 90min)) and the nitrocellulose 
membrane blocked for 1h at RT (chapter 6.3.4.4). The nitrocellulose membrane is 
subsequently incubated, firstly, with the specific primary antibody (overnight at 4°C, table 1), 
then with the appropriate secondary antibody (1h, RT, table 14). To visualize the protein 
bands on the membrane, it is incubated in LumiGLO™ (Cell Signaling Technology) for 1min 
and luminescence measured in the LumiImager (Boehringer Mannheim). The protein bands 
are analysed with the Lumianalyst 3.0 software (Boehringer Mannheim). The results are 
expressed as percentage change with respect to the DMSO-solvent control (T/C (%)). 
Table 14: Table showing the primary antibodies used to detect phosphorylated proteins, the 
concentrations at application dilution factors and the duration of exposure of the 
nitrocellulose membranes in the LumiImager. 
Primary Antibody Dilution Source Secondary Antibody Exposure time 
Anti phospho-GSK-3α/β (ser21/9)   
(Cell Signaling) 1:1000 
Rabbit 
Polyclonal 
HRP-anti-Rabbit IgG 
(Cell Signaling) 10min 
Anti.phospho-β-catenin 
(ser33/37/Thr41)                 
(Cell Signaling) 
1:1000 Rabbit Polyclonal 
HRP-anti-Rabbit IgG 
(Cell Signaling) 10min 
Phospho-glycogen synthase 
(ser641)                       
(Cell Signaling) 
1:1000 Rabbit Polyclonal 
HRP-anti-Rabbit IgG 
(Cell Signaling) 10min 
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6.3 Molecular Biological Methods 
6.3.1 Isolation of Total RNA 
Total RNA was isolated with the RNeasy Mini Kit from Qiagen. This method takes advantage 
of the highly selective binding property of silica-gel membranes to RNA. The silica-gel 
membrane can bind up to 100µg RNA, of a size of 200 nucleotides and longer. It provides 
thus an enrichment of mRNA since most RNA < 200 bases such as tRNA and 5S RNA, that 
make up 15-20% of total RNA are selectively excluded.  
To avoid contamination with RNases and unwanted nucleic acids, the following precursions 
are taken, gloves were worn, the working utensils (pipettes, working bench) were cleaned 
with RNase away, and moreover sterile filter tips were used for pipetting. 
Harvesting Cells 
− The medium is aspirated and the cells are washed with 10ml ice-cold PBS. 
PBS is removed and 600µl Buffer RLT containing 1% (v/v) β-
Mercaptoethanol (10µl in 1ml buffer RLT) is added to the cell-culture dish. 
Buffer RLT contains highly denaturing guanidine isothiocyanate, which 
immediately inactivates RNases to ensure isolation of intact RNA.  
− The cells are scraped and the cell lysate collected with a sterile disposable 
cell scrapers. The cell lysate is transferred to a sterile 1.5ml microcentrifuge 
tube.  
RNA-Isolation 
− In order to shear genomic DNA and reduce the viscosity of the cell lysate, it 
is passed 5x through a sterile 20-gauge needle (0.9mm diameter) fitted onto 
an RNase-free syringe.  
− 600µl 70% (v/v) ethanol is added to the lysate and mixed by pipetting up and 
down. Ethanol provides appropriate binding conditions for RNA to bind to 
the silica-gel membrane and causes the precipation of proteins. 
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− The RNeasy® mini column is fitted in a 2ml collection tube. 600µl of the 
sample, along with any precipitate that may have been formed is loaded on 
the Rneasy® mini column where the total RNA binds to the silica gel 
membrane. The column is centrifuged (13.000rpm for 15s, centrifuge 5415, 
Eppendorf) and the flow-through is decanted. The centrifugal process 
repeated with the remaining 600µl of the sample. 
− To wash away contaminants, the RNeasy column is washed once with Buffer 
RW1 and twice with Buffer RPE. 
o 700µl Buffer RW1 (13.000rpm for 15s, centrifuge 5415, Eppendorf). 
o  The RNeasy column is transferred into a new 2ml collection tube.  
o 500µl RPE Buffer (13.000rpm for 15s, centrifuge 5415, Eppendorf). 
o The flow through is discarded. 
o 500µl RPE Buffer (13.000rpm for 2min, centrifuge 5415, 
Eppendorf). 
− The column is transferred to a sterile 1.5ml reaction tube and centrifuged at 
14,000rpm for 1min (centrifuge 5415, Eppendorf) in order to remove 
residual RPE Buffer and dry the column. Buffer RPE contains ethanol, which 
would interfere with elution of RNA if not entire removed. Also residual 
ethanols might reduce the efficiency of reverse transcription. The dried 
column is transferred to a sterile 1.5ml reaction tube.  
− Total RNA is eluted with 60µl (2x 30µl) RNase-free water (14,000rpm for 
60s). The eluted total RNA solution is apportioned in 30µl aliquots (sterile 
micro-centrifuge tubes) and stored at -80°C. 
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6.3.2 Qualitative Gene Expression Analysis of the Iso-forms of 
Glycogen Phosphorylase (GP) in HT29 Cells  
To identify the isoforms of glycogen phosphorylase that are expressed in HT29 cells, 1.2 x 
106 cells are plated (55cm2) and incubated at normal growth conditions (37°C, 5% CO2) for 
48h. Total RNA was extracted (chapter 6.3.1) and subjected to RT-PCR with the Titan One 
Step RT-PCR kit from ROCHE. The sequences for the human GP-isoform specific primers 
were synthsized by MWG Biotechnology. Beta-actin was co-amplified and detected as the 
endogenous control. 
6.3.2.1 One Step RT-PCR with the Titan One-Tube Kit  
The Titan One Step PCR assay is designed to perform the processes of reverse transcription 
and cDNA amplification in a single reaction set-up. The AMV-RT (avian myeloblastosis 
virus reverse transcriptase) is responsible for the synthesis of the first strand DNA from 
mRNA, while two DNA-polymerases, Taq DNA polymerase and Tgo DNA polymerase 
perform the amplification of DNA in concert with one another. 
Brain GP forward primer:                            5´-GCT CAA CGG GGC CCT CAC CAT CGG C-3´ 
Concentration in 1ml 43pmol/µl 
Volume needed for 100pmol/µl 430µl (DEPC-H2O) 
MW 7589g/mol 
Tm 72.8°C 
GC-percentage 72% 
Brain GP, reverse primer:                              5´-ACT AGG AGC ACT TCT AGC ACA TTC C-3´ 
Concentration in 1ml 50pmol/µl 
Volume needed for 100pmol/µl 500µl (DEPC-H2O) 
MW 7586g/mol 
Tm 63°C 
GC-percentage 48% 
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Muscle GP, forward primer:                         5´-GCT CAA CGG GGC TCT GAC CAT TGG C -3 
Concentration in 1ml 38pmol/µl 
Volume needed for 100pmol/µl 380µl (DEPC-H2O) 
MW 7659g/mol 
Tm 69.5°C 
GC-percentage 64% 
Muscle GP, reverse primer:                         5´-TGG CCC AAG AGA GTG TGA CAG ACT C -3´ 
Concentration in 1ml 34pmol/µl 
Volume needed for 100pmol/µl 340µl (DEPC-H2O) 
MW 7716g/mol 
Tm 66.3°C 
GC-percentage 56% 
Liver GP, forward primer                            5´-GAG GCA CTT CCA GAG CTG AAG CTG G -3´ 
Concentration in 1ml 20pmol/µl 
Volume needed for 100pmol/µl 200µl (DEPC-H2O) 
MW 7732g/mol 
Tm 67.9°C 
GC-percentage 60% 
Liver GP, reverse primer                               5´-TCC CTC CCC ATT CCC AGA GAT ACT C -3´ 
Concentration in 1ml 51pmol/µl 
Volume needed for 100pmol/µl 509µl (DEPC-H2O) 
MW 7458g/mol 
Tm 66.3°C 
GC-percentage 56% 
β-actin, forward primer                                                 5´-CCC CAT TGA ACA CGG CAT TG -3´ 
MW 6062 
Tm 59,4 °C 
GC-percentage 55% 
β-actin, reverse primer                                                  5´-GGA GTC CAT CAC AAT GCC AG -3´ 
MW 6111 
Tm 59.4 °C 
GC-percentage 55% 
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Procedure 
− Before beginning, all utensils are cleansed with RNase Away (Invitrogen). 
The components of the titan one tube kit are thawed, vortexed briefly and 
placed on ice.  
− The components for master mix I (table 15) and master mix II (table 16) are 
pipetted together on ice into two separate RNase-free microfuge tubes. The 
components of master mix II are pippetted together the enzyme mix (table 
16), which is added only moments prior to use. On ice, the forward and 
reverse primers are pipetted into a RNase-free microfuge reaction tube. The 
master mixes I and II are added to the microfuge reaction tube containing the 
primers. The tube is vortexed briefly and centrifuged to collect the contents 
at the bottom of the tube (table 17). The PCR run is performed using the 
program shown on table 20 
To exclude artefacts from DNA targets, for example, genomic DNA residual of RNA 
preparations or contaminating DNA from previous PCR experiments, a no-template control 
reaction (table 18) and a no-reverse transcriptase control reaction (table 19) is always set up. 
After the RT-PCR assay, the PCR products are detected on agarose gel (1.2%) with ethidium 
bromide staining (chapter 6.3.6).  
The RT-PCR experiments were carried out by Bülent Soyalan in the course of his 
“Forschungsarbeit” (Soyalan 2005) 
Table 15: Master mix I (n=1)     Table 16: Master mix II (n=1) 
DEPC-H2O 11µl 
DTT (100 mM) 2.5µl 
dNTP (10 mM each) 1µl 
RNase inhibitor 0.5µl 
Template RNA (50ng/µl) 2µl 
Σ 17µl  
DEPC-H2O 14µl 
RT-PCR Buffer (5x) 10µl 
Enzyme mix 1µl 
Σ 25µl  
Table 17: Set up for a RT-PCR reaction of n=1  Table 18: Master mix I for no-template control  
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Upstream primer (5µM) 4µl 
Downstream primer (5µM) 4µl 
Master mix I 17µl 
Master mix II 25µl 
Σ 50µl  
DEPC-H2O 13µl 
DTT (100mM) 2.5µl 
dNTP (10mM each) 1µl 
RNase Inhibitor 0.5µl 
Σ 17µl  
Table 19: Master Mix II for minus RT reaction (n=1) 
DEPC-H2O 15µl 
RT-PCR Buffer (5x) 10µl 
Σ 25µl 
Table 20: Thermal cycling conditions for RT-PCR with the Titan one step PCR kit from Roche. 
Reverse transcription 
Step Temperature Duration 
1 50°C 31min 
2 ENDE  
PCR 
Step Temperature Duration 
1 94°C 2min 
2 94°C 30s Denature 
3 67°C 1min Annealing 
4 68°C 3min Elongation 
5 Repeat steps 2-4 (9 ) 
6 94°C 30s 
7 67°C 1min 
8 68°C 3min 
9 68°C 5s + 5s/ Cycle 
10 Repeat steps 6-9 (25 times) 
11 68°C 7min 
12 4°C  
13 ENDE 
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6.3.3 DNA Agarose Gel Electrophoresis 
Agarose gel electrophoresis is the most prevalent method employed in molecular biology for 
the analysis and characterization of nucleic acids. It owes its popularity to a couple of factors 
namely, it’s applicability as a high resolution method for a wide range of nucleic acid sizes 
(100bp - 10kbp), the reproducibility of results, and finally because it presents the possibility 
to obtain the products for preparative purposes. Separation of DNA takes place according to 
DNA size in the agarose gel connected to an electric field, whereby smaller DNA molecules 
by virtue of their size migrate through the pores of gel faster than larger molecules migrate 
(Brown 2002). The pore size and structure is determined by the concentration of agarose. 
High agarose concentrations yield small pores while low agarose concentrations give rise to 
large pores. Most commonly used are gels with agarose concentrations between 0.7-1% (w/v), 
however, gels with as low a concentration as 0.3% (w/v) agarose or as high as 2% (w/v) 
agarose can be employed depending on the size of the DNA fragments expected. 
6.3.3.1 Casting Agarose Gel and Electrophoresis 
The casting of agarose gels for the purpose of DNA characterisation was performed in a 
horizontal flat-bed apparatus. 
− The casting tray is sealed off on both ends with tape and placed in the 
chamber on a flat surface. In a 250ml Schott bottle, 1.2g agarose powder and 
100ml 1x TAE buffer (1.2% w/v) are heated while stirring until the solution 
boils and the agarose is melted completely. The contents of the bottle are 
cooled under a running tap to about 60°C. 5µl of a 10mg/ml concentrated 
solution of ethidium bromide (has final concentration of 0.5µg/ml) is added 
and the solution mixed thoroughly. 
− The gel is poured carefully into the casting tray with a comb inserted on the 
cathode bordering side of the gel. Air bubbles trapped in the gel are quickly 
shifted to a corner. The gel is allowed to cool at room temperature. Upon 
cooling, the galactose and 3,6 anhydrogalactose chains of agarose is 
rearranged into helical structures, which bundle up into a three dimensional 
network (Pingoud 2002). When the gel has solidified, the comb is removed 
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and the chamber filled with 1x TAE buffer (Tris-acetate, EDTA) until the gel 
is slightly but entirely submerged. 
− 20µl sample is mixed with 4µl (6x) loading dye solution (MBI Fermentas) 
and subsequently loaded on the agarose gel using a pipette. To facilitate the 
allocation of the DNA fragments after electrophoresis, 5µl of an appropriate 
DNA-marker (DNA-Marker-Mix und 1kb DNA-Marker, MBI Fermentas) is 
also loaded in a separate well. 
− The apparatus is closed and the gel ran at 60-70V. Due to the net negative 
charge of DNA, owing to the negatively charged phosphate groups in the 
DNA backbone, DNA molecules migrate toward the anode upon application 
of current, whereby, small DNA molecules migrate faster than large 
molecules  
− After electrophoresis, the DNA fragments are visualized as distinct bands 
within the gel on a UV-transillumator (Eagle Eye™ II, Stratagene®). This is 
made possible by ethidium bromide (added to the gel), which can bind 
double stranded DNA indiscriminately by intercalating between the base 
pairs. The bond with DNA provokes a sharp increase in the fluorescence of 
ethidium bromide upon excitation with UV light (excitation: λ=302nm), 
which otherwise fluoresces weakly when unbound. After excitation, ethidium 
bromide emits light of wavelength λ=510nm (Pingoud 2002). 
Tris-Acetate-EDTA-Buffer (TAE) 50 x Tris-Cl 242.0g  
  Acetic acid 51.1ml
 0.5M EDTA-solution 100.0ml
  
  
   
Filled to 1l with re-distilled water. Set 
to pH 8.0-8.3. Diluted to 1x before use. 
The 1x working solution is 40mM Tris-
acetate/ 1mM EDTA. Stored at RT. 
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6.3.4 Plasmid Preparation 
Prior to this thesis, the plasmids described in the following section were transformed, 
amplified and subsequently stored (–80 °C) as E. Coli glycerol stocks by Claudia Handrich 
during her diploma thesis (Diplom Arbeit, 2004). Before being employed for transfection 
reactions, the plasmids were isolated and their integrity ascertained as described in the 
following chapter. 
6.3.4.1 TOPflash (Tcf Reporter Plasmid) 
Location: 
TCF-Binding site  404 - 492 bp 
HSV-TK-promoter 528 - 688 bp 
Luciferase-ORF  691 - 2343 bp 
Figure 62: Vector map of the Tcf Reporter 
Plasmid TOPflash (Upstate Biotechnology, 2003) 
 
TOPflash is a 5.5 kb construct made up of 6 copies of the wild type Tcf binding site arrayed 
in 2 two groups of 3 each, that lie back to back. The two groups lie in opposite orientation to 
one another (figure 62). The cluster of Tcf binding sites is flanked upstream by a sequence 
that encodes for the selective marker ampicillin and downstream by a Thymidin Kinase (TK) 
minimal promoter that drives the transcription of the open reading frame for the monomeric 
61kDa luciferase enzyme (figure 62). A replication origin of the natural occurring E. coli 
plasmid, colicin E1 guarantees the expression and amplification of TOPflash in the E. coli 
(figure 62) 
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6.3.4.2
6.3.4.3
 FOPflash (TCF Reporter Plasmid) 
Location: 
TCF-Binding site  396 - 480 bp 
HSV-TK-promoter 518 - 678 bp 
Luciferase-ORF 681 - 2333 bp 
Figure 63: Vector map of the Tcf Reporter 
Plasmid FOPflash (Upstate Biotechnology, 2003) 
 
FOPflash is used as a negative control to TOPflash. It has an identical molecular weight and is 
similarly constructed as TOPflash but possesses mutated copies of the Tcf binding sites 
(figure 63). Hence binding of β-catenin/Tcf/Lef is less efficient and luciferase expression is 
less. 
 pFLAG-CMV5a-Δ45-β-Catenin 
ß-C
ateninΔ45  2343bp
 
Figure 64: Circle map of pFLAG-CMV5a-Δ45-β-catenin plasmid (7011 bp) (Handrich 2004). 
Beta catenin was isolated from HCT-116 cells and cloned into a pFLAG-CMV-5a vector 
(figure 64) by (Sigma, 03/1999). The pFLAG-CMV-5a vector in to which β-catenin cDNA 
was cloned is a component of the Mammalian Carboxy-terminal FLAG® Transient 
Expression Kit from Sigma and contains following elements; a CMV-promoter that drives the 
transcription of the FLAG fusion construct (419-909 bp), a multiple cloning site with 9 
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different restriction sites (912-974 bp), a FLAG Tag made up of 8 amino acids (N-
AspTyrLysAspAspAspAspLys-C), which can be used to monitor protein expression using 
anti-FLAG antibodies (975-998 bp), origin of replications (ori) of SV40 (1652-2002 bp) and 
E.coli for replication in COS cells and E.coli respectively, and finally a β-lactamase coding 
gene segment (Ampr) that confers ampicillin resistance to E.coli. The pFLAG-CMV5a-β-
catenin plasmid is used to validate the reporter gene assay. As a result of the mutation on Ser 
45, β-catenin escapes degradation and is expected to bind to initiate expression of luciferase 
when the plasmid is cotranfected with TOPflash. 
6.3.4.4 pRL-TK Vector 
Lokation: 
HSV-TK-Promoter  7 - 759 bp 
T7 RNA polymerase-promotor (-17 bis +2) 1006 - 1024 
bp 
Rluc Reporter gene 1034 - 1969 bp 
SV40 Late Polyadenylation signal 2011 - 2212 bp 
ß-Lactamase (Ampr) coding region 2359 - 3219 bp 
 
Figure 65: The pRL-TK vector map and sequence reference points. -^-, position of intron; Rluc, cDNA 
encoding the Renilla luciferaseenzyme; Ampr, gene conferring ampicillin resistance in E. coli; 
ori, origin of plasmid replication in E. coli. Arrows within the Rluc and Ampr gene indicate 
the direction of transcription (Promega-(7/01)) 
The pRL-TK vector (figure 65) is a 4 kb construct intended for use as an internal control 
reporter in a dual luciferase reporter gene assay. It contains the cDNA (Rluc) encoding a 
Renilla luciferase originally cloned from the marine Renilla reniformis. Rluc is located 
downstream a thymidin kinase promoter derived from the Herpes simplex virus that provides 
low to moderate levels of the monomeric Renilla luciferase (36kDa) expression. Situated 
between Rluc and the open reading frame of a gene Ampr encoding ampicillin resistance is an 
SV40 late poyladenylation signal. The origin of replication ori guarantees the replication of 
pRL-TK-vector in E.coli (Promega-(7/01)).  
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6.3.4.5 Plasmid Purification 
Plasmids were isolated using anion exchange chromatography with the Qiagen Plasmid Maxi 
Kit that yields a maximum of 500µg plasmid. The procedure is based on the interaction 
between the negatively charged phosphate groups of the DNA backbone and the positively 
charged diethyl-aminoethanol (DEAE) groups of the resin (figure 66). At neutral pH and 
medium salt concentrations, DNA binds to the resin while impurities like RNA, proteins and 
carbonhydrates are washed out. At high salt concentrations, DNA is eluted because chloride 
anions compete with DNA-phosphate groups for the DEAE groups.  
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Figure 66: Interaction between negatively charged phosphates of the DNA backbone and positively 
charged DEAE groups on the surface of the resin (Qiagen 09/2000) 
6.3.4.6 Incubation of the Starter Culture 
A sterile pipette tip is used to inoculate frozen Escherichia coli cells habouring the 
appropriate vector (glycerin stock) into 5ml LB-medium that contains ampicillin (5µl of a 
50mg/ml stock). The cells are incubated for 8h at 37°C with vigorous shaking (275rpm). The 
entire starter culture is pipetted into a 1l sterile Erlenmeyer flask and diluted with 250ml of 
ampicillin supplemented (250µl of a 50mg/ml stock).LB medium. The cells are then 
incubated for 16h at 37°C under vigorous shaking (275rpm)  
 
 
 
Materials and Methods  Plasmid preparation 
 
 ▓ PAGE 143 ▓ 
LB Medium Tryptone 10g 
  Yeast Extract 5g 
  NaCl 10g 
   Dissolved in 1l re-distilled water. Set to 
pH 7.0. Sterilized by autoclaving. 
6.3.4.7 Extraction of Plasmid DNA 
Before the plasmid isolation is commensed, the centrifuge is pre-cooled to 4°C 
− The E. coli cells are harvested by centrifugation at 6000g for 15min at 4°C. 
The supernatant is decanted and the centrifugation tube cleared of all traces 
of supernatant with a filter paper. The pellet is completely re-suspended in 
10ml Buffer P1 by pippeting up and down until no cell clumps are visible. 
Buffer P1 contains RNase A, which digests RNA liberated in the following 
step (alkali lysis). The bacteria are lysed in 10ml NaOH-SDS lysis buffer 
(Buffer P2) for a maximum of 5min. SDS solubilizes the phospholipid and 
protein components of the cell membrane while NaOH denatures proteins. 
Prolonged lysis, i.e. above 5min, can irreversibly denature the plasmid and 
make it resistant to restriction enzyme digestion. The lysate is neutralized 
with 10ml of ice cold Buffer P3 (acidic potassium acetate) and incubated on 
ice for 20min. SDS inhibits the binding of DNA to the resin. So, to allow 
complete precipitation of SDS, the tube is capped and the contents gently and 
thoroughly mixed. A white fluffy precipitate containing cellular debris, 
denatured proteins, chromosomal DNA and potassium dodecyl sulphate is 
formed. The plasmid DNA is separated from the precipitate by centrifugation 
at 20,000g for 30min at 4°C. The plasmid containing supernatant is 
transferred to a new sterile centrifugation tube. The supernatant is 
centrifuged at 20,000g for 15min at 4°C. At this stage, the plasmid DNA re-
natures, since the solution is now free of denaturing compounds. The 
Qiagen-tip 500 is equilibrated with 10ml Buffer QBT. The column is allowed 
to empty by gravity flow. (The equilibaration of the Qiagen-tip 500 is begun 
simultaneously to the previous step so that the column is ready by the end of 
the centrifugation). The equilibrated column is loaded with the plasmid 
containing supernatant and allowed to empty by gravity flow. At this step 
Materials and Methods  Plasmid preparation 
 
 ▓ PAGE 144 ▓ 
plasmid DNA binds to the resin. The column is washed with 60ml Buffer QC 
(contains 1M NaCl, pH 7). While plasmid DNA remains bound to resin, 
contaminants like RNA and carbonhydrates are washed off. Plasmid DNA is 
eluted with 15ml Buffer QF (Elution Buffer, contains 1.25M NaCl, pH 8.5). 
The eluate is collected in a 30 ml centrifugation tube. To precipitate plasmid 
DNA, 10.5ml isopropanol (RT) is added. The contents of the centrifugation 
tube are mixed properly and centrifuged at 15,000g for 10min at 4°C. The 
supernatant is discarded and with a bold marker the position of the pellet 
marked on outside of the tube. The pellet is washed with 15ml 70% (v/v) 
ethanol (temperated to RT) and centrifuged at 15,000g for 10min at 4°C. The 
supernatant is decanted with care in order not to disrupt the pellet. The pellet 
is air-dried for approximately 10min. The plasmid DNA is dissolved in a 
suitable volume of water or 10mM Tris-Cl, pH 8.5 (200µl-300 µl) by rinsing 
the walls of the tube. Pipetting up and down for re-suspension is avoided 
because this would cause shearing of the DNA. Plasmid DNA yield and 
purity is determined using 260nm absorption and 260/280nm ratio on a UV-
spectrophotometer (Nano Drop) respectively. Restriction mapping is used to 
ascertain the “quality” of DNA isolated (chapter 6.3.6.8). The plasmid 
solution is diluted to 500ng/µl and stored at -20°C. 
6.3.4.8 Restriction Mapping of Plasmid DNA 
Restriction mapping was used to determine the integrity of the isolated plasmid DNA. It 
entails specifying the location of a set of restriction sites on the plasmid DNA using restriction 
endonucleases. The resulting DNA fragments are separated by electrophoresis in an agarose 
gel and viualised under UV light. A comparative analysis of the results of single and double 
digestions forms the basis for the identification and verification of the “quality” of the DNA 
(Pingoud 2002). 
6.3.4.8.1 Restriction Digestion 
Restriction digestion is the cutting of DNA into fragments with restriction enzymes. 
Restriction enzymes recognize and cut duplex DNA at enzyme specific recognition sites, 
which have sequences of mostly palindromic nature. The resulting fragments can have one of 
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three different kinds of ends: 5’ overhang, 3’ overhang (sticky ends) and blunt end. The 
cleavage leaves a phosphate group at the 5’ end and a hydroxyl group at the 3’ end. The 
restriction enzymes employed for the characterization of plasmid DNA are shown on (table 
21) 
Table 21: Table of the restriction enzymes employed to characterize plasmid DNA. 
Plasmide DNA Linear Digestion Double Digestion 
TOPflash BamHI  BamHI/NotI 
FOPflash BamHI  SacI/NotI 
pFLAG-CMV5a-Δ45-β-Catenin BamHI BamHI/KpnI 
pRL-TK-Renilla Luciferase BamHI BamHI/EcoRI 
 
Procedure 
− Water, DNA-solution, restriction enzyme and respective buffers are mixed in 
a sterile DNase-free 1.5ml reaction tube at the volumes indicated in tables 
(22 to 25). The reaction tube is incubated for 90min in a water bath 
temperated at 37°C. After the incubation period, the reaction tube is placed 
on ice to stop the reaction. 20µl of the probe is then mixed with 4µl DNA 
loading dye (6x Mass Loading Dye Solution, MBI Fermentas), vortexed 
briefly and applied to agarose gel electrophoresis (chapter 6.3.3). 
Table 22: Restriction digestion of TOPflash. 
 Water (DEPC) Buffer 
Plasmid  
(0.5µg/µl) 
Restriction 
Enzyme Site 
Size of 
Fragment 
No Digestion 19.5µl - 0.5µl - -  
Linearistion 16.5µl 2µl BamHI Buffer 0.5µl 1µl BamHI 519bp 5500bp 
1µl BamHI 519bp 1893 Double 
Digestion 16.5µl 
4µl Y+/Tango 
Buffer 0.5µl 1µl NotI 2412bp 3607 
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Table 23: Restriction digestion of FOPflash 
 Water (DEPC) Buffer 
Plasmid  
(0.5µg/µl) 
Restriction 
Enzyme 
Cleaving 
Site 
Size of 
Fragment 
No Digestion 19.5µl - 0.5µl - -  
Linearistion 16.5µl 2µl BamHI Buffer 0.5µl 1µl BamHI 509bp 5500bp 
1µl SacI 2402bp 889bp Double 
Digestion 16.5µl 
4µl Y+/Tango 
Buffer 0.5µl 1µl NotI 3291bp 4611bp 
Table 24: Restriction digestion of pRL-TK-renilla plasmid. 
 Water (DEPC) Buffer 
Plasmid 
(0.5µg/µl) 
Restriction 
Enzyme 
Cleaving 
Site 
Size of 
Fragment 
No Digestion 19.5µl - 0.5µl - -  
Linearistion 16.5µl 2µl BamHI Buffer 0.5µl 1µl BamHI 2223bp 4045bp 
1µl EcoRI 649bp 1574bp Double 
Digestion 16.5µl 
4µl Y+/Tango 
Buffer 0.5µl 1µl BamHI 2223bp 2471bp 
Table 25: Restriction digestion of pFLAG-CMV5a-Δ45-β-Catenin. 
 Water (DEPC) Buffer 
Plasmid 
(0.5µg/µl) 
Restriction 
Enzyme 
Cleaving 
Site 
Size of 
Fragment 
No Digestion 19.5µl - 0.5µl - -  
Linearistion 16.5µl 2µl BamHI Buffer 0.5µl 1µl BamHI 963bp 7071bp 
1µl BamI 963bp 1574bp Double 
Digestion 16.5µl 
4µl 
Y+/Tango 
Buffer 
0.5µl 
1µl KpnI 973bp 2471bp 
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6.3.5 Tcf/Lef Reporter Gene Assay 
Reporter genes are molecular biological tools, which can be employed to study cellular 
processes like receptor function, protein-protein interactions, intracellular signal transduction, 
gene promoter regulation and the actions of certain transcription factors (Promega Notes, 
1998). They are usually cloned into a plasmid, downstream of an “indicator sequence” 
specific to the experimental question. Introduced into an organism, their expression is 
independently driven by a separate promoter and is either constitutive or triggered by external 
intervention. Once expressed, they confer measurable and identifiable characteristics such as 
fluorescence and luminescence to the organism. Today’s popular reporter genes include green 
fluorescent protein (GFP), luciferase (LUC), β-galactosidase (LacZ), β-glucuronidase (GUS) 
and chloramphenicol acetyl transferase (CAT) (Ziemienowicz 2001) 
To investigate the influence of flavonoids/ polyphenols on the β-catenin-Tcf/Lef driven 
transcriptional activity in HEK-293 cells and HCT-116 cells, a mammalian cell-based reporter 
gene assay system from Upstate Biotechnology was employed in combination with the 
pFLAG-CMV5a-Δ45-β-catenin plasmid (chapter 6.3.6.3). The assay kit from Upstate 
Biotechnology consists of the two plasmids, TOPflash (chapter 6.3.6.1) and FOPflash 
(chapter 6.3.6.2), where TOPflash is the experimental plasmid and FOPflash the negative 
control.  
6.3.5.1 Optimization of the dual luciferase assay reporter gene assay 
Transfection of cells is most efficient when the cells are in the log-phase of growth. 
Therefore, to determine the starting cell number that will yield a 60-70% confluency at the 
time point of trasfection, HEK293 cells were seeded in 24 well dishes at varying starting 
populations between 10,000 cells per well and 40,000 cells per well. The optimization of the 
starting cell population was performed by Claudia Handrich in the course of her Diploma 
thesis (Handrich 2004). 
6.3.5.1.1 Transfection with FuGENE 6 Transfection Reagent 
Serum-and antibiotic free medium is pipetted in to a DNase free 1.5ml reaction tube and the 
appropriate amount of FuGENE 6 is added to the tube by pipetting directly into the medium 
without making contact with the plastic surfaces of the tube. Prior contact of FuGENE 6 with 
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plastic surfaces of the reaction tube negatively influences transfection efficiency. The tube is 
flicked to mix its contents and then incubated for 5min at room temperature. Plasmid DNA 
added accordingly, the tube is capped, vortexed briefly and incubated for 15min at room 
temperature. The FuGENE 6: plasmid DNA complex is added drop-wise to the cells and the 
Petri dish swirled to ensure an even distribution.  
6.3.5.1.2 Transfection Optimization in 24 well plates 
Table 26 shows the parameter used for the optimization experiments carried out in 24 well 
dishes. 40,000 HEK293 cells seeded per well and grown for 48h yielded the required cell 
confluency optimal for transfection experiments i.e. between 60-70%. Hence, this cell number 
was employed for transfection optimization experiments in 24 well plates. 
Table 26: Optimization of the transfection efficiencies in HEK293 cells in 24 well dishes. 
 
TOP-/FOPflash 
[ng] 
pRL-TK-vector 
[ng] 
pFLAG-CMV5a-
Δ45-β-catenin [ng] 
FuGENE 6: DNA 
ratio 
Optimization of the 
FuGENE 6: plasmid ratio 
300 30 - 3:1, 3:2, 6:1 
Optimization of the 
TOPflash/FOPflash 
concentration 
100, 200, 300, 
400, 500 
10, 20, 30, 40, 50 - 3:1 
Optimization pRL-TK-
vector concentration 
400 40, 45, 50, 55, 60 - 3:1 
Optimization pFLAG-
CMV5a-Δ45-β-catenin 
concentration 
400 40 5, 10, 15, 20, 30 3:1 
 
Lysis of the cells is performed in passive lysis buffer (Promega) at room temperature. The 
cells are lysed by adding 100µl of the passive lysis buffer per well and incubating the cells at 
room temparture on a shaker for 15min. Measurement of luciferase activity is performed 
immediately using the Stop and Glo buffers of the dual-luciferase™ reporter assay system 
(Promega), which enables the determination of both firefly and renilla luciferase activities in 
the same reaction. 10µl of the lysate is transferred in duplicates to a 96 well dish (Lumitrac 
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200 (Greiner-Bio-One) or fluoroNunc (Nunc)) and luciferase activity measured with the 
luminometers Sirius HT from MWG or Luminoskan RT from Labsystems at the parameters 
indicated on table 27 and 28 respectively. After data analysis, the firefly luciferase activity is 
normalized to the the renilla luciferase activity. 
Table 27: Reading parameters on Sirius HT (MWG) for the dual luciferase assay 
 Volume Read Interval Sensitivity Reading mode 
Dispenser 1         
Luciferase assay 
reagent II 
50µl @ 300µl/sec 12s 1s 
Dispenser II         
Stop and Glo Buffer 50µl @ 300µl/sec 12 1s 
125 Kinetic 
Table 28: Reading parameters on Luminoskan from Labsystems for the dual luciferase assay 
 Volume Shake before read Read Interval 
Luciferase assay reagent II 50µl 2s 10s Continuous 
Stop and Glo Buffer 50µl 2s 10 Continuous 
 
Luciferase assay buffer I 10ml Dual luciferase reporter Assay 
system (Promega) 
Luciferase assay substrate Lyophilized 
   
   
   
The kit components are frozen (dry ice) 
at delivery. Stored before reconstitu-
tion at -20°C and after reconstitution at 
-80°C. Before use, the assay buffer is 
thawed in the dark and temperated to 
RT. The lyophilized substrate is 
dissolved in entire 10 ml of assay 
buffer.  
Stop & Glo Buffer 10ml  
Stop & Glo substrate 200µl 
   
   
Stored before reconstitution at -20°C 
and after reconstitution at -80°C. 
Entire 200µl of substrate is added to 
buffer before use. Kept away from 
direct light.  
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6.3.5.2 Optimization of the firefly luciferase assay in 10cm Petri dishes 
To determine the optimal seeding cell number, seeding experiments were performed at 
varying starting cell populations for 48h and 72h. 500,000 HEK293 cells and 300,000 
HCT116 cells incubated for 72h yielded a confluency of about 70%. Transfection 
optimization experiments were hence performed with this starting cell number. Table 29 and 
table 30 shows the parameter used for the optimization experiments carried out with HEK293 
cells and HCT116 cells respectively. 
Table 29: Optimization of the transfection efficiencies in HEK293 cells in 10cm Petri dishes. 
 
TOPflash/FOPflash 
[µg] 
pFLAG-CMV5a-
Δ45-β-catenin 
[µg] 
FuGENE 6: DNA 
ratio 
Optimization of the FuGENE 6: 
plasmid ratio 
5 - 3:1, 6:1, 9:1 
Optimization pFLAG-CMV5a-Δ45-β-
catenin concentration 
5 0.5, 1.0, 2.0 3:1 
Table 30: Optimization of the transfection efficiencies in HCT116 cells in 10cm Petri dishes 
 TOPflash/FOPflash [µg] FuGENE 6: DNA ratio 
Optimization of the FuGENE 6: plasmid ratio 1, 2.5, 5 3:1, 6:1, 9:1 
 
24h post transfection, the cells are lysed in 500µl 1x cell culture lysis buffers and the 
luciferase activity measured (Sirius HT, MWG or Luminoskan RT, Labsystems).under the 
conditions depicted in tables 34 and 35. 
6.3.5.3 Transfection of HEK-393 Cells and HCT-116 Cells with FuGENE 6 
at the optimized experimental conditions 
72h prior to transfection, 0.5 x 106 HEK-293 cells per 10cm Petri dish and 0.3 x 106 HCT-116 
cells per 10cm Petri dish are plated in serum and antibiotics containing DMEM and RPMI 
medium respectively (37°C, 5% CO2, (chapter 6.1.8.3)). Transfection was performed with 
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FuGENE 6 (Roche Applied Sciences), at a transfection reagent/plasmid DNA ratio of 3:1 
(v/w) for HEK293 cells and 9:1 for HCT116 cells. 
Tables 31 to 33 show the volumes for transfection reactions prepared with FuGENE 6 for the 
transfection of HEK293 cells and HCT116 cells with TOPflash/FOPflash and the co-
transfection of HEK293 cells with TOPflash/FOPflash and pFLAG-CMV5a-Δ45-β-Catenin. 
Transfection was performed 72h after seeding. 
Table 31: Transfection of HEK-293 cells with TOPflash/FOPflash at a FuGENE 6 reagent: DNA ratio of 
3:1 (n = 1 Petri dish). 
DMEM-medium (serum and antibiotic free) 475µl 
FuGENE 6 15µl 
TOPflash/FOPflash (500ng/µl) 10µl (5µg) 
∑ 500µl 
Table 32: Co-transfection of TOPflash or FOPflash and pFLAG-CMV5a-Δ45-β-catenin into HEK-293 
cells at a FuGENE 6 reagent: DNA ratio of 3:1 (n = 1 Petri dish). 
DMEM-medium (serum and antibiotic free) 465µl 
FuGENE 6 18µl 
TOPflash or FOPflash (500ng/µl) 10µl (5µg) 
pFLAG-CMV5a-Δ45-β-catenin (100ng/µl) 10µl (1µg) 
∑ 500µl 
Table 33: Transfection of HCT116 cells with TOPflash/FOPflash at a FuGENE 6 reagent: DNA ratio of 
9:1 (n = 1 Petri dish). 
RPMI-medium (serum and antibiotic free) 475µl 
FuGENE 6 45µl 
TOPflash/FOPflash (500ng/µl) 10µl (5µg) 
∑ 500µl 
 
24h post transfection, the Fugene 6 containing medium is aspirated. The cells are rinsed in 
5ml 1x PBS. 1ml trypsin/EDTA is added and spread to cover cells by swirling the dish (max 
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10sec for HEK293 cells and 1min for HCT116 cells). The cells are resuspended in 10ml of 
appropriate medium and counted and reseeded in a 12 well dish, HEK-293 cells at a density 
of 0.2 x 106 cells per well and HCT-116 cells at 0.15 x 106 cells per well. The cells were 
incubated at normal culturing conditions (37°C, 5% CO2) for 24h before treatment with the 
compound(s) of interest. 
6.3.5.4
6.3.5.5
6.3.5.6
 Incubation of HEK-293 Cells  
The fact that HEK-293 cells are semi-adherent in nature makes them detach very easily from 
the surface of the culture dish. To prevent cell loss during incubation, the candidate 
compound was weighed, dissolved in DMSO and diluted with DMEM medium (FCS 10%, 
(v/v), 1%, (v/v) pen/strep) so that DMSO has a concentration of 2% and candidate compound 
2 times more concentrated as the final concentration. 1ml of the 2 fold concentrated 
compound dilution is added drop-wise into the well containing 1ml of medium from re-
seeding.  
 Incubation of HCT-116 Cells  
The candidate compound is weighed, dissolved appropriately (DMSO), and diluted with 
RPMI medium (FCS 10%, (v/v), 1%, (v/v) pen/strep) so that DMSO has a final concentration 
of 1%. Old growth medium is aspirated and the wells rinsed once with pre-warmed (37°C) 1x 
PBS. 1 ml of the diluted compound solution is added to the well by pipetting on the wall. 
 Luciferase Assay 
The luciferase assay is conducted using Promega’s firefly luciferase assay system kit. To 
terminate the incubation of the cells with the candidate compound(s), the compound dilution 
is aspirated, and the wells of the cell culture dish are rinsed in quick succession with ice cold 
1x PBS (1 ml). Diligence is required in handling HEK-293 cells because they detach easily 
from the surface of the dish. After rinsing, PBS is removed completely and the cells are 
incubated for 15min in 1x luciferase cell culture lysis buffer (500µl/well) (chapter 6.1.10.1). 
The cell lysate is transferred to 1.5 ml reaction tubes and centrifuged (2min, 1000rpm, 4°C, 
(Eppendorf 5804 R)) to separate cell debris. The supernatant is transferred in duplicates to a 
fluoroNunc 96 well dish (10µl/well) and the plate measured immediately in the luminometer. 
Two different luminometers, whose reading parameters are depicted in table 35 and table 35, 
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were employed for the measurement of luminescence (Sirius HT, MWG and Luminoskan RT, 
Labsystems). The luminometers automatically add 50µl of reconstituted luciferase assay 
reagent per well. 
 Volume  Read Interval Sensitivity Reading mode 
Dispense/well 50µl @300µl/sec 12s Every 1s 125 Kinetic 
Table 34: Reading setting on Sirius HT (MWG) for the Luciferase assay 
 Volume  Shake before read Read Interval 
Dispense/well 50µl 2s 10s Continuous 
Table 35: Reading setting on Luminoskan from Labsystems for the Luciferase assay 
 
Luciferase assay buffer 10ml Luciferase Assay Reagents 
(Promega) 
Luciferase assay substrate Lyophilized 
   
   
   
The kit components are frozen (dry ice) 
at delivery. Stored before reconstitu-
tion at -20°C and after reconstitution at 
-80°C. Before use, the assay buffer is 
thawed in the dark and temperated to 
RT. The lyophilized substrate is 
dissolved in entire 10 ml of assay 
buffer.  
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6.3.6 Reverse Transcription of Total RNA 
Total RNA was reversed transcribed using the High Capacity cDNA Archive Kit from 
Applied Biosystems and the PTC 100™ programmable Thermal Controller from MJ 
Reasearch, Inc. The High Capacity cDNA Archive Kit contains a multiscribe reverse 
transcriptase and a recombinant moloney murine leukamia virus (rMoMuLV) reverse 
transcriptase, which allows for the reverse transcription of up to 10µg RNA.  
All steps during the reverse transcription were carried out on ice. Prior to the reverse 
transcription, the RNA-concentration was determined using the Nano Drop® System from 
Agilent. The following description is exemplary for an n = 1, 10µg cDNA per 100µl volume. 
− The components of the High Capacity cDNA Archive Kit are thawed. A 
volume (Xµl) of total RNA-solution containing a maximum of 10µg RNA is 
added to a RNase free PCR-tube. DEPC- treated water is pipetted in a PCR-
tube (Volume of water = 71 µl – volume of RNA solution (µl)). A 2x RT-
master mix is prepared by chronologically pipetting the kit components 
together as shown in table 36. To prepare the 2x RT-master mix for one 
sample, allowances have to be made for the incidental loss of solution that 
occurs during pipetting. E.g. for an n = 1 reaction, a master mix is prepared 
for (1 + 1) reactions. 29µl of the 2x RT-master mix is added to the PCR-tube 
to a total volume 100µl. The PCR-tube is closed, vortexed, briefly 
centrifuged, placed in a thermal cycler and the reaction started. The cycling 
conditions for the amplification are shown below in table 37. 
Table 36: 2x RT-master mix for the reverse transcription of total RNA 
Component n = 1 +1 
Reverse Transcription Buffer, 10x 20µl 
dNTPs, 25x 8µl 
random primers, 10x 20µl 
Multiscibe™ Reverse Transcriptase, 50 U/µl 10µl 
∑ 58µl 
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Table 37: Thermal cycling conditions for the reverse transcription of total RNA (10µg) with the High 
Capacity cDNA Archive kit from Applied Biosystems 
 Step 1 Step 2 Step 3 
Temperature 25°C 37°C 4°C 
Time 10min 120min 24h 
 
To verify for genomic DNA contamination, a reaction containing no reverse transcriptase 
(Multicribe™) is also reverse transcribed. Also, a no template control, a reaction without 
RNA-template is carried out to verify the quality of the reverse transcription. After the reverse 
transcription, obtained cDNA solutions are stored at -20°C. 
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6.3.7 Quantitative Gene Expression Analysis of GSK-3β, GS, GP 
and β-Catenin using TaqMan® Real-time PCR 
6.3.7.1 TaqMan® Real-time PCR 
Real-time PCR represents a molecular biological technique of high sensitivity that enables, in 
contrast to conventional PCR, the amplification and detection of specific nucleic acids in real 
time. The PCR product are detected using either fluorescent dyes capable of binding double-
stranded DNA e.g. SYBR Green I or fluorescently labelled sequence-specific probes e.g. 
TaqMan® probes, molecular beacons, FRET probes. 
The TaqMan® real-time PCR makes use of TaqMan® MGB probes. These are sequence 
specific oligonucleotide that carry on the 5’ base, a fluorophore e.g. 5- 6-carboxyfluorescein 
[5(6)-FAM], and on the 3’ base, a quenching dye e.g. 5-(and 6)-carboxy-tetramethyl 
rhodamine [5(6)-TAMRA] or a minor groove binder (MGB) (figure 67) (P.E Applied 
Biosystems). MGBs increase the stability of the template-probe hybrid by binding snugly into 
the minor grooves of duplex DNA (P.E Applied Biosystems).  
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Figure 67: Structures of A: 5(6)-FAM and, B: 5(6)-TAMRA. FAM is excited at 494 nm and emits at 518 
nm. TAMRA is excited at 560 nm and emits at 582 nm 
At close proximity to one another, the quencher dye quenches the fluorescence of the reporter 
dye by means of fluorescence resonance energy transfer (FRET). However, during the PCR 
extension step, the probe - hybridized specifically to its target sequence that lies between the 
forward and reverse primer binding sites (figure 68) is cleaved by the 5’-3’ exonuclease 
activity of Amplitaq® DNA polymerase. This leads to the separation of the fluorescent and the 
quencher dyes. FRET becomes interrupted (figure 68) making it possible for the reporter to 
fluoresce upon excitation with laser light of wavelength between 500-660nm. Since this 
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process recurs in every PCR cycle, the fluorescent signal increases progressively and does so 
proportionally to the amount of PCR product produced (Qiagen).  
 
Figure 68: Schematic illustration of the chemistry of TaqMan real-time PCR. R: reporter dye, Q: 
quencher dye (Applied Biosystems). 
6.3.7.2 TaqMan RT-PCR using Pre-developed Assay Reagents (PDAR) and 
Assays on Demand (AOD) 
The ABI PRISM™ 7900 sequence detection system from Applied Biosystems was employed 
in combination with the TaqMan® RT-PCR method to study the effects of the compound(s) of 
interest on gene expression in HT29 cells. Listed in table 38 are the genes, whose expressions 
were investigated using assays from Applied Biosystems. Each assay contained a gene 
specific MGB-probe and a gene specific primer pair, 20 times more concentrated than the 
final concentration per reaction (of 250nM for the MGB-probe and 900nM for each primer). 
Due to the photosensitive character of the MGB-probe, exposure of the assays to daylight was 
avoided at all times.  
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Table 38: List of genes quantified using PDARs and AOD’s from Applied Biosystems. 
Gene Assay ID RefSeq Reporter dye 
Glycogen synthase (muscle type) Hs00157863_m1 NM_002103.3 FAM 
Glycogen synthase (liver type) Hs00608677_m1 NM_021957.2 FAM 
Glycogen phosphorylase (muscle type) Hs00194493_m1 NM_005609.1 FAM 
Glycogen phosphorylase (liver type) Hs00161132_m1 NM_002863.3 FAM 
Glycogen phosphorylase (brain type) Hs00267875_m1 NM_002862.3 FAM 
β-Catenin Hs99999168_m1 NM_001904 FAM 
β-Actin (endogenous control)   VIC (MGB) 
 
Before amplification, total RNA is isolated (chapter 6.3.1) from the treated HT29 cells 
(chapter 6.1.9), reverse transcribed (chapter 6.3.9) and the obtained cDNA amplified in a 
TaqMan® RT-PCR assay as described below.  
For each round of PCR, i.e. on each 96 well plate, a No Template Control, which is a reaction 
containing no cDNA, is performed and β-actin is always co-amplified as the endogenous 
control.  
− The 20x target mix is thawed at 4°C and kept in the dark (refrigerator). It 
contains the sequence specific forward and reverse primers as well as the 
TaqMan® probe in already optimized concentrations. Simultaneously, the 
cDNA probes, generated by reverse transcription with the High Capacity 
Archive Kit from Applied Biosystems (chapter 6.3.9) are also thawed and 
kept on ice. 2µl cDNA-solution containing 200ng cDNA (stock: 100ng/µl) is 
pipetted into a sterile DNase-free PCR test tube. In a DNase-free 1.5 reaction 
tube, a master mix made up of DEPC-water, 20x target mix and 2x universal 
PCR master mix is prepared on ice. The universal master mix contains 
AmpliTaq GOLD® polymerase, AmpErase UNG, dNTPs, a passive 
reference dye and optimized buffer components. 98µl of the master mix is 
dispensed into a PCR tube containing cDNA. The tube is capped and 
vortexed briefly. The contents of each tube are loaded in triplicates at 
25µl/well in a 96 well optical reaction plate. Each well contains a final 
cDNA template amount of 50ng. The 96 well plate is sealed with a ABI 
Materials and Methods   TaqMan RT-PCR 
 
 ▓ PAGE 159 ▓ 
PRISM™ optical adhesive cover. The plate is centrifuged for 5min at 
800rpm and 4°C (Minifuge T, Hereaus). The plate is loaded in the sequencer 
(ABI PRISM™ 7900 Sequence Detection System) and the gene specific 
sequence amplified using the thermal cycling conditions indicated on table 
40 
Table 39: PCR reaction mix for routine analysis with a PDAR. The dye-labeled MGB-probe has a final 
concentration of 250nM and each primer has a final concentration of 900nM. The table is 
exemplary for 2 samples. To allow for pipetting solution loss, a master mix for n = 2.5 samples 
is prepared.  
Components Final concentration n = 1 n = 2.5 
cDNA 100µg/µl 50ng/ well 2µl - 
DEPC-H2O - 43µl 107.5µl 
Target Mix, 20x - 5µl 12.5µl 
Universal Master Mix, 2x - 50µl 125µl 
Total  100µl 245 µl 
 
The results are analysed with the help of the software SDS 2.1 (Applied Biosystems) using 
the relative quantification method with β-actin as the endogenous control and DMSO solvent 
sample as the sample control. 
Table 40: Universal thermal cycling conditions for template amplification in the 7900 HT sequence 
detection system. UNG (AmpErase® uracil-N-glycosylase) contained in the Universal Master 
mix prevents cross over contamination of the samples by the hydrolysis of uracil-glycosidic dU 
containing single and double stranded DNA, thereby creating an alkali-sensitive apyrimidic 
site in the DNA (Longo et al. 1990). 
PCR 
UNG incubation AmpliTaq Gold activation Cycle (40 cycles) Step 
HOLD HOLD Denature Anneal/Extend 
Temperature 50°C 95°C 95°C 60°C 
Time 2min 10min 15s 1min 
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6.3.7.3 Gene Expression Assays designed with Primer Express™ Software 
To study the gene expression profile of GSK-3β in HT29 cells after the incubation with the 
compound(s) of interest, a set of primers, and the TaqMan® (table 41) for the gene expression 
assay was designed with the Primer Express™ software version 2.0 (Applied Biosystems) and 
sent for synthesis to Applied Biosystems.  
Table 41:  Accession number, location and sequence of the set of primers and the TaqMan® probe 
designed and employed for GSK-3β expression analysis 
GSK-3β Assession number Location 
Exon 
boundary  Sequence 
Forward Primer L33801 852 - AGGGAGCAAATCAGAGAAATGAA 
Reverse primer L33801 979 - AGACGGCTACACAGTGCAATTG 
TaqMan® probe L33801 915 E8/E9, 929 CATCCTTGGACTAAGGTC 
 
The assay components were stored upon delivery at -20°C. Each primer solution and the 
TaqMan® probe solution had a stock concentration of 10mM. The TaqMan® probe being 
photosensitive was always handled in the dark.  
Procedure 
The solutions containing the forward primer, the reverse primer and TaqMan® probe are 
thawed at 4°C in a dark environment (refrigerator). The reaction mix is pipetted successively 
into a sterile DNase-free PCR reaction tube as shown in table 42. The tube is capped and 
vortexed briefly. A volume of 25 µl of the reaction mixture is loaded in triplicates into a 96 
well optical reaction plate. The plate is sealed with the ABI PRISM™ optical adhesive cover, 
then centrifuged for 5min at 800rpm and 4°C (Minifuge T, Hereaus) and detected in 7900 HT 
sequence detection system at the thermal cycling conditions shown in table 40. The results are 
analysed with the help of the software SDS 2.1 (Applied Biosystems) using the relative 
quantification method with β-actin as the endogenous control and DMSO solvent sample as 
sample control. 
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Table 42:  PCR reaction mix for routine analysis of GSK-3β. The dye-labeled MGB-probe has a final 
concentration of 200nM and each primer has a final concentration of 900nM. The table is 
exemplary for 4 samples. To allow for pipetting solution loss, a master mix for n = 5 samples is 
prepared. 
Components  Volume / Reaction n = 4+1 Concentration/ Well 
DEPC-H2O 2µl 10µl - 
Forward primer (9mM) 2.5µl 12.5µl 900nM 
Reverse primer (9mM) 2.5µl 12.5µl 900nM 
DNA sample (100ng/µl) 0.5µl 2.5µl 50ng 
TaqMan® probe (2mM) 2.5µl 12.5µl 200nM 
Universal Master Mix, 2x 12.5µl 62.5µl 1x 
∑ 25 µl 125µl  
 
 
.
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8.2 Optimization of the dual luciferase reporter gene assay in HEK293 
cells (24 well plate format) 
Data to figure 23: Transient transfection of HEK293 cells with TOPflash and FOPflash  
TOPflash/pRL-TK 50/5 100/10 200/20 300/30 400/40 500/50 
              
3105-03.06.05 1.28 1.25 2.43 4.17 4.68 6.95 
08.06-11.06.05 1.09 2.06 6.21 8.93 11.66 11.58 
14.06-17.06.05 1.4 1.6 2.8 3.74 5.74 6.89 
              
MW 1.26 1.64 3.81 5.61 7.36 8.47 
STABW 0.12763 0.3317 1.70142 2.3518 3.0712 2.19688 
 
FOPflash/pRL-TK 50/5 100/10 200/20 300/30 400/40 500/50 
              
3105-03.06.05 1.08 1.53 2.04 3.03 3.32 4.00 
08.06-11.06.05 1.55 2.08 3.04 3.92 4.84 7.13 
14.06-17.06.05 1.15 1.56 2.6 3.44 3.83 4.67 
              
MW 1.26 1.72 2.56 3.46 4.00 5.27 
STABW 0.207 0.2525 0.4092 0.3637 0.6316 1.3457 
 
Data to figure 24: Determination of the optimal pRL-TK-vector DNA concentration 
TOPflash/pRL-TK 400/40 400/45 400/50 400/55 400/60 
Total DNA 440.00 445.00 450.00 455.00 460.00 
            
05.07-08.07.04a 5.7 5.6 4.9 2.3 2.2 
05.07-08.07.04b 3.1 3.5 3.6 3.4 3.2 
05.07-08.07.04c 3.3 3.4 3.2 5.2 4.3 
            
MW 4.03 4.17 3.90 3.63 3.23 
STABW 1.18 1.01 0.73 1.20 0.86 
 
 
 
 
 
 
 
Addendum 
 
 ▓ PAGE 4 ▓ 
FOPflash/pRL-TK 400/40 400/45 400/50 400/55 400/60 
Total DNA 440.00 445.00 450.00 455.00 460.00 
            
05.07-08.07.04a 3.1 3.9 2.73 2.7 2 
05.07-08.07.04b 3.4 3.6 3.1 2.5 2 
05.07-08.07.04c 2.1 2.9 3.1 4.28 3.1 
            
MW 2.87 3.47 2.98 3.16 2.37 
STABW 0.56 0.42 0.17 0.80 0.52 
 
Data to Figure 25: Co transfection of HEK293 cells with TOPflash/FOPflash (400ng) 
and pFLAG-CMV5a-Δ45-β-Catenin. 
TOPflash       
 β-catenin 0 ng/ml  5 ng/ml  10 ng/ml 15 ng/ml 20 ng/ml  30 ng/ml  
         
0608-090804 a 7.6 23.1 35.7 33 57.9 62.5 
0608-090804 b 8.4 28.7 35.1 36.7 74.3 102.6 
0608-090804c 8.1 24.3 49.8 67.8 89.7 116.9 
0908-120804 8.4 25.6 46 49.5 61 57.2 
         
MW 8.1 25.4 41.7 46.8 70.7 84.8 
STABWN 0.3 2.1 6.4 13.6 12.6 25.5 
 
FOPflash       
β-catenin 0 ng/ml  5 ng/ml  10 ng/ml  15 ng/ml 20 ng/ml  30 ng/ml  
         
0608-090804a 4.1 4.5 3.7 5.5 6.5 5.9 
0908-1208 6.4 6.5 7.2 7.6 6.7 8.4 
              
MW 5.3 5.5 5.5 6.6 6.6 7.2 
STABWN 1.2 1.0 1.8 1.1 0.1 1.3 
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 ▓ PAGE 5 ▓ 
8.3 Optimization of the luciferase reporter gene assay (10 cm Petri dish 
format) 
Data to figure 26A: Determination of the optimal FuGENE 6/TOPflash ratio in HEK293 
cells (10cm plate) 
TOPflash 5 µg  
DNA:Fugene 6 1:3 1:6 1:9 
        
1406-180605a 274487 344324 246595 
1406-180605b 312238 304040 418011 
1706-210605a  259526 162953 
1706-210605b 620608 369892 133802 
        
MW 402444 319446 240340 
STABWN 155033 34633 106162 
 
Data to figure 26B: Determination of the optimal pFLAG-CMV5a-Δ45-β-catenin for co-
transfection experiments with TOPflash/FOPflash. 
TOPflash 5 µg  
beta-catenin ∆45 0 µg 0,5 µg 1 µg 2 µg 
          
26/05/2005 187502 4161756 6308530 11594871 
02/06/2005 46146 265580 1871318   
          
MW 116824 2213668 4089924 11594871 
STABWN 70678 1948088 2218606 0 
 
FOPflash 5 µg  
beta-catenin ∆45 0 µg 0,5 µg 1 µg 2 µg 
          
26/05/2005 86842 160440 311025 405217 
02/06/2005 25290  60261   
          
MW 56066 160440 185643 405217 
STABWN 30776 0 125382 0 
 
 
 
Addendum 
 
 ▓ PAGE 6 ▓ 
Data to figure 27: Determination of the optimal FuGENE 6/plasmid DNA ratio in 
HCT116 cells with TOPflash (10cm plate) 
TOPflash 1 µg 2.5 µg 5 µg 
  1:3 1:6 1:9 1:3 1:6 1:9 1:3 1:6 1:9 
            
0306-070605 11764 26415 143355 10858 33625 322983 11236 44425 1001791 
0606-100605       44979 64293 296296 
            
MW 11764.0 26415.0 143355.0 10858.0 33625.0 322983.0 28107.5 54359.0 649043.5
STABWN 0 0 0 0 0 0 16871.5 9934 352748 
 
Data to figure 28: Effect of serum on the transfection efficiency in HEK293 cells 
measured 19h post transfection 
TOPflash    
FCS 0.0% 10.0% 20.0% 
        
1309-160904 3.2 6.1 6.3 
0410-081004 3.4 5 5.40 
1110-141004 5.2 10.6 12.6 
       
MW 3.9 7.2 8.1 
STABW 0.90 2.42 3.20  
 FOPflash    
FCS 0.0% 10.0% 20.0% 
    
1309-160904 2.1 5.7 4.6 
    
MW 2.1 5.7 4.6  
 
Data to figure 29: Effect of LiCl and SB216763 on the transcriptional activity of Tcf/Lef 
diven luciferase activity in HEK293 cells after 19h incubation 
Renilla normalization   
  10 mM LiCl 
5 µM 
SB216763 
10 µM 
SB216763 
        
3008-030904 128.4    
0609-100904 82.7    
2009-240904 115.6    
2709-011004 74.3    
0410-081004 159.5 341.9 1882.9 
1110-151004 92.8 244.1 1331.2 
1810-221004 102.5 220.7 1168.4 
1810-221004 105.6 270.8 1269.6 
        
MW 107.7 269.4 1413.0 
STABW 25.42 45.47 277.44  
 Protein normalization   
  10 mM LiCl 
5 µM 
SB216763 
10 µM 
SB216763 
        
3008-030904 263.5    
0609-100904 266.9    
2009-240904 436.4    
2709-011004 382.5    
0410-081004 343.0 235.5 1882.7 
1110-151004 264.5 235.3 1391.0 
1810-221004 267.6 219.0 1121.2 
1810-221004 295.2 244.2 1171.2 
        
MW 315.0 233.5 1391.5 
STABW 61.47 9.11 301.19  
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8.4 Effect on the β-Catenin/Tcf/Lef-mediated Transcriptional Activity 
Data to figure 30A: Effect of quercetin and SB216763 on Tcf-Lef driven gene 
transcription in HEK293 cells  
TOPFLASH  *    
Quercetin 
[µM] 50  25 10 1 
17.03.05 157.0  119.0  
24.03.05 164.0  111.0  
14.04.05 217.0  117.0  
09.06.05 208.0 175.0   
07.07.05 167.0 169.0  120.0 
18.08.05  137.0  104.0 
MW 182.6 160.3 115.7 112.0 
STABWNA 24.8 16.7 3.4 8.0  
 FOPFLASH     
Quercetin 
[µM] 50  25 10 1 
17.03.05   42.0  
31.03.05 76.0  47.7  
14.04.05 82.0  60.0  
09.06.05  102.0 78.0  
07.07.05 83.0 77.0  48.0 
18.08.05  134.0  125.0 
MW 80.3 104.3 56.9 48.0 
STABWNA 3.1 23.3 13.8 38.5  
 
Topflash SB216763 10 µM  Fopflash 
SB216763 
10µM 
1012-161204 3589.0  0701-120105 66.0 
1401-190105 3267.0  1401-190105 123.0 
2101-260105 a 1534.0  2101-260105 a 96.0 
2101-260105 b 1448.0  2101-260105 b 131.0 
0402-1002 2760.0  2801-0302a 89.0 
1102-1702 1100.0  2801-0302b 93.3 
1102-1702 a 1143.0  0402-1002 124.0 
1103-1703 2274.0  1102-1702 92.0 
1803-2403 1950.0  1103-1703 104.0 
140405 1341.0  1803-2403 95.0 
020605 2215.0  090605 84.0 
090605 1393.0  180805 72 
070705 2529.0  MW 97.4 
180805 3343  STABWNA 19.3 
MW 2134.7    
STABWNA 825.1    
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Data to figure 30B: Effect of EGCG on Tcf-Lef driven gene transcription in HEK293 
cells  
TOPFLASH   
EGCG [µM] 0.1  1  10  25  50 
            
140705  80.9 80.9 70.00 83 
180805 112.0  95.0 100.0 81.0
020905a 81.0 76.0 99.0 86.0 68.0
020905b 111.0 99.0 84.0 91.0 81.0
            
MW 101.3 85.3 89.7 86.8 78.3
STABWNA 14.4 9.9 7.5 10.9 6.0  
 FOPFLASH  
EGCG [µM] 0.1  1  10  25 50  
            
140705  65.0 71.0 53.0 83.0
180805 91.0 108.0 98.0 81.0 84.0
020905 67.0 58.0 70.0 59.0 65.0
020905 73.0 68.0 76.0 73.0 73.0
            
MW 77.0 74.8 78.8 66.5 76.3
STABWNA 10.2 19.5 11.3 11.1 7.8  
 
Data to figure 31A: Effect of AE02 on Tcf-Lef driven gene transcription in HEK293 cells  
TOPFLASH       FOPFLASH      
AE02 
[µg/ml] 500 400 300 200 100  
AE02 
[µg/ml] 500 400 300 200 100 
170305            170305 59         
240305    98.0 99.0  240305       
310305   122.0 93.0 100.0  310305    32 22 
070405   123.0 139.0    070405  93.0 52 51   
140405   122.0 130.0    140405  67.0 64 50.5   
210405    124.0    210405 57   63   
280405  94.0   94.0  280405     137 
020605 109.0 102.0 101.0     020605 64 56 67.7    
090605 97.0       090605 68      
180805 116.0 106.0 105.0 84.0    180805   80 73 76 74 
MW 107.3 100.7 114.6 111.3 97.7  MW 62.0 74.0 64.2 54.5 77.7
STABWNA 7.8 5.0 9.6 20.6 2.6  STABWNA 4.3 13.9 7.7 14.6 47.0
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Data to figure 31B: Effect of phloretin, phloridzin, epicatechin on Tcf-Lef driven gene 
transcription in HEK293 cells  
TOPFLASH   FOPFLASH  
Phoretin [µM] 10  Phoretin [µM] 10 
19.01.05 119.0  19.01.05 51.0 
26.01.05a 123.0  26.01.05a 35.0 
26.01.05b    26.01.05b 38.0 
03.02.05 87.0  03.02.05 65.0 
10.02.05 118.0      
MW 111.8  MW 47.3 
STABWNA 14.4  STABWNA 11.9 
 
TOPFLASH    FOPFLASH   
Phloridzin [µM] 50  10  Phloridzin [µM] 50  10 
10.02.05 122    10.02.05 150   
17.02.05 84    17.02.05 96   
17.03.05 82    17.03.05 30   
24.03.05 93    24.03.05    
31.03.05a  122  31.03.05a  43 
31.03.05b  94  31.03.05b  43 
07.04.05  101  07.04.05  38.7 
14.04.05   89.1  14.04.05   46.5 
MW 95.25 101.525  MW 92 42.8 
STABWNA 15.99 12.55  STABWNA 49.07 2.76 
 
TOPFLASH    FOPFLASH   
EC [µM] 100 50   EC [µM] 100 50 
16.12.04 74.0 95.0   16.12.04  66.0   
26.01.05a  115.0   26.01.05a  31 
26.01.05b  82.0   26.01.05b  36.5 
07.04.05 85 91   07.04.05 46.5 46.7 
21.04.05 96    21.04.05  52.3   
MW 85.0 95.8   MW 54.9 38.1 
STABWNA 9.0 12.1   STABWNA 8.2 6.5 
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 ▓ PAGE 10 ▓ 
Data to figure 32A: Effect of quercetin on Tcf-Lef driven gene transcription in HEK293 
cells tranfected co transfected with pFLAG-CMV-Δ45-β-catenin 
 TOPFLASH/ beta catenin (Δ45) 
Quercetin 
[µM] 50 25 10 1 0.1 
090605 205.0 193.0 145.0     
70705  180.0 137.0 96.0   
270705    102.0 89.0 
110805 170.0 173.0 114.0 96.9 102.0
250805 162.0 159.0 96.0  89.0 
MW 179.0 175.0 118.3 98.3 93.3 
STABWNA 18.7 14.0 20.2 2.6 6.1  
  FOPFLASH/ beta catenin (Δ45) 
Quercetin 
[µM] 50 25 10 1 0.1 
270705 4.2 2.9 1.7 1.2 1.2 
110805 2.0 2.1 2.0 1.4 1.5 
250805 2.2 2.1 2.5 3.0 2.2 
MW 2.8 2.4 2.1 1.9 1.6 
STABWNA 1.0 0.4 0.3 0.8 0.4  
 
TOPFLASH /beta catenin 
(Δ45) 
  SB216763 10µM 
090605 124.0 
070705 148.0 
140705 157.0 
MW 143.0 
STABWNA 13.9  
FOPFLASH /beta catenin 
(Δ45) 
  SB216763 10µM 
090605   
070705 1.5 
140705 1.5 
MW 1.5 
STABWNA 0.0  
 
Data to figure 32B: Effect of EGCG on Tcf-Lef driven gene transcription in HEK293 
cells tranfected co transfected with pFLAG-CMV-Δ45-β-catenin 
 TOPFLASH/ beta catenin (Δ45) 
EGCG [µM] 0 1 10 25 50 
140705  98.0 117.0  107.0 
040805 102.0 93.0 103.0 93.0 100.0 
110805 102.0 96.0 108.0 92.0 91.0 
250805 92.0 96.0  89.0   
MW 98.7 95.8 109.3 91.3 99.3 
STABWNA 4.7 1.8 5.8 1.7 6.5  
 FOPFLASH/ beta catenin (Δ45) 
EGCG [µM] 0 1 10 25 50 
140705  1.50 1.80 2.00 2.10 
040805 3.40 3.00 3.20 3.10 2.80 
110805 1.50 1.30 1.60 1.40 1.20 
250805 1.70 1.70 1.60 1.40 0.80 
MW 2.2 1.9 2.1 2.0 1.7 
STABWNA 0.9 0.7 0.7 0.7 0.8  
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Data to figure 33A: Effect of Quercetin and SB216763 on Tcf-Lef driven gene 
transcription in HCT116 
TOPFLASH Quercetin [µM] SB216763 [µM] 
 1 10 25 10 
230504       149.0 
230605 98.0 182.0 391.0 188.0 
140705 81.0 205.0 524.0 144.0 
MW 89.5 193.5 457.5 160.3 
STABWNA 8.5 11.5 66.5 19.7  
FOPFLASH Quercetin [µM] SB216763 [µM] 
 1 10 25 10 
230504       89.0 
230605 53.0 74.0 136.0 32.5 
140705 51.0 86.0 172.0 40.7 
MW 52.0 80.0 154.0 54.1 
STABWNA 1.0 6.0 18.0 24.9  
 
Data to figure 33B: Effect of EC, EGCG and phloretin on Tcf-Lef driven gene 
transcription in HCT116 
TOPFLASH    
  EC 50µM EGCG 10µM Phoretin 10 µM 
2101-270105 a 102.0 112.0 140.0 
2101-260105 b 103.0 91.0 126.0 
2101-260105 c 88.0 104.0 115.0 
MW 97.7 102.3 127.0 
STABWNA 6.85 8.65 10.23 
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 ▓ PAGE 12 ▓ 
8.5 Effect on GSK 
Data to figure 34A: Effect of quercetin and SB216763 on GSK-3α and phospho-GSK-3α 
GSK-3α      
 Q_10 µM Q_25 µM Q_ 50 µM Q 75 µM SB21 _10µM 
070405a  72.0 94.9 94.9  
070405b  82.0 61.0 56.0  
210405    161.0 129.0 
280405    162.0  
070705 82.0 90.0 70.0 75.0  
140705_1 77.4 75.5 90.0 78.5  
280705     106.0 
120807 91.5 87.5 71.5  114.0 
180805     118.0 
250805     98.6 
MW 83.63 81.40 77.48 104.57 113.12 
SD 5.87 6.85 12.83 41.81 10.38 
n 3.00 5.00 5.00 6.00 5.00 
 
Phopho-GSK-3α    
 Q_10 µM Q_25 µM Q_ 50 µM Q 75 µM SB21_10 µM 
070405a    142.0  
210405 89.0    120.0 
280405 52.0  134.0 182.0  
070705_1  66.0 107.0 132.0  
140705_1 48.8 59.4 68.0 72.0  
140705_2 52.6 72.6 60.2 71.9  
120805 89.9 80.7 92.2  155.0 
250805     180.0 
MW 66.46 69.68 92.28 119.98 151.67 
SD 18.82 7.89 26.74 42.64 24.61 
n 5.00 4.00 5.00 5.00 3.00 
 
 
 
 
 
Addendum 
 
 ▓ PAGE 13 ▓ 
Data to figure 34B: Effect of quercetin and SB216763 on GSK-3β and phospho-GSK-3β 
GSK-3β      
  Q_10 µM Q_25 µM Q_ 50 µM Q 75 µM SB21 _10µM 
070405a   103.0 101.0 98.0   
070405b  94.0 82.0 85.0   
210405     89.0 
70705 86.0 83.0 81.0 76.0   
140705 73.5 85.5 91.7 86.8   
280705     138.0 
120805 84.0  76.2  122.0 
180805     116.0 
250805         100.6 
MW 81.17 91.38 86.38 86.45 113.12 
SD 5.48 7.85 8.87 7.82 17.00 
n 3.00 4.00 5.00 4.00 5.00 
 
Phopho-GSK-3β     
  Q_10 µM Q_25 µM Q_ 50 µM Q 75 µM SB21 _10µM 
070405a   88.0 111.0 83.0   
210405     46.0 
280405    85.0 48.4 
070705_0 108.0 83.0 101.0 100.0   
140705_1  72.2 60.0 95.3   
140705_2 94.9 83.3 99.0    
280705     32.0 
120805 107.0  54.0  30.0 
250805         39.0 
MW 103.30 81.63 85.00 90.83 39.08 
SD 5.95 5.79 23.30 7.06 7.31 
n 3.00 4.00 5.00 4.00 5.00 
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 ▓ PAGE 14 ▓ 
Data to figure 35A: Effect of EGCG on GSK-3α and phospho-GSK-3α 
GSK-3α       
EGCG 0.1 0.5 1 10 25 50 
070405a     70.0 86.0 73.0   
070405b   63.0 83.0 67.0   
210405   107.0  163.0 94.0 
280405   126.0 82.0 140.0 139.0 
300606_0   80.0 79.0 105.0 88.0 
300605_1   121.0 103.0 110.0 120.0 
300605_2   126.0 108.0 112.0 91.6 
070705_0    68.0 73.0 62.0 
140705   63.8 80.9    
210705      93.0 
210705_1   66.0 83.0 98.5 80.0 
040805 98.0 125.0 107.0     
120805 87.0 96.9 88.0     
180805 104.0 128.0 111.0 112.0 112.0 53.0 
250805 82.0 98.6 98.3 87.6 93.9   
MW 92.75 112.13 94.39 88.41 104.31 91.18 
SD 8.70 14.43 23.02 12.87 27.58 24.88 
n 4.00 4.00 13.00 11.00 11.00 9.00 
 
 
Phospho-GSK-3α      
  0.1 0.5 1 10 25 50 
070405a       268.0 229.0   
210405   209.0  286.0 175.0 
280405   114.0 221.0 256.0 245.0 
300605_0   116.0   165.0 
300605_1   193.0 247.0 209.0 251.0 
040805 147.0 152.0 181.0    
120805 114.0 152.0 285.0    
180805 115.0 161.0  225.0  219.0 
250805 120.0   172.6 224.0 271.0   
MW 124.00 155.00 181.51 237.00 250.20 211.00 
SD 13.47 4.24 54.15 18.06 27.91 35.30 
n 4.00 3.00 7.00 5.00 5.00 5.00 
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 ▓ PAGE 15 ▓ 
Data to figure 35A: Effect of EGCG on GSK-3β and phospho-GSK-3β 
GSK-3α        
EGCG 0.1 0.5 1 10 25 50 SB21_ 10µM 
070405a     70.0 86.0 73.0     
070405b   63.0 83.0 67.0     
210405   107.0  163.0 94.0 129.0 
280405   126.0 82.0 140.0 139.0 106.0 
300606_0   80.0 79.0 105.0 88.0   
300605_1   121.0 103.0 110.0 120.0   
300605_2   126.0 108.0 112.0 91.6   
070705_0    68.0 73.0 62.0   
140705   63.8 80.9      
210705      93.0   
210705_1   66.0 83.0 98.5 80.0   
040805 98.0 125.0 107.0       
120805 87.0 96.9 88.0     114.0 
180805 104.0 128.0 111.0 112.0 112.0 53.0 118.0 
250805 82.0 98.6 98.3 87.6 93.9   98.6 
MW 92.75 112.13 94.39 88.41 104.31 91.18 113.12 
SD 8.70 14.43 23.02 12.87 27.58 24.88 10.38 
n 4.00 4.00 13.00 11.00 11.00 9.00 5.00 
 
Phospho-GSK-3β       
EGCG 0.1 0.5 1 10 25 50 SB21_ 10µM 
070405a     158.0 158.0 173.0     
210405   190.0    46.0 
280405       48.4 
300605_0   120.0 131.0 160.0 163.0   
300605_1    145.0 177.0 180.0   
070705_0     146.0 128.0   
140705_1   141.0      
210705     1.6E+02 1.2E+02   
210705_1    142.0     
280705       32.0 
040805 97.0        
120805 137.0 150.0 172.0    30.0 
180805 145.0 139.0  143.0     
250805 115.0 149.0 130.0 161.0 164.0   39.0 
MW 123.50 146.00 151.83 146.67 162.67 148.75 39.08 
SD 18.83 4.97 24.18 10.14 10.35 23.57 7.31 
n 4.00 3.00 6.00 6.00 6.00 4.00 5.00 
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 ▓ PAGE 16 ▓ 
8.6 Effect on β-catenin 
Data to figure 36: Effect of quercetin on total β-catenin and phosphorylated β-catenin 
Total β-catenin     
  Q_10 µM Q_25 µM Q_ 50 µM Q 75 µM SB21_10µM 
070405a   130.0 118.0 132.0   
070405b  69.0 75.0 75.0   
210405       
280405 108.0  109.0 101.0   
200505a       
200505b 90.0 119.0 76.0  153.0 
020605 49.0 55.0  80.0   
090605   68.0    
230605 132.0  69.9  144.8 
070705_0 56.0 77.0 89.0 96.0   
140705 63.9 66.5 96.5 122.0   
040805     158.0 
120805 113.0 89.6 74.0    
250805         162.0 
MW 87.41 86.59 86.16 101.00 154.45 
SD 29.49 26.04 17.06 20.59 6.42 
n 7.00 7.00 9.00 6.00 4.00 
 
Phospho β-catenin    
  Q_10µM Q_25 µM Q_ 50 µM Q 75 µM SB2167 10 µM 
020605 171.0 125.0 153.0 134.0   
090606 172.0 190.0     
230607 151.0 144.0 127.0 97.0 29.0 
070705_0 80.0 61.0 76.0 75.0   
40805     21.0 
120805 60.5 33.0   28.3 
180805     26.0 
250805         38.0 
MW 126.90 110.60 118.67 102.00 28.46 
SD 47.26 56.76 31.98 24.34 5.53 
n 5.00 5.00 3.00 3.00 5.00 
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 ▓ PAGE 17 ▓ 
Data to figure 37: Effect of EGCG on total β-catenin and phosphorylated β-catenin 
Beta Catenin       
EGCG 0.1 0.5 1 10 25 50 SB21_ 10µM 
070405a     72.0 74.0       
070405b     52.0    
210405   129.0  60.0 40.0   
280405    81.0 36.0 59.0   
200505b       153.0 
230605       144.8 
300605   79.0 86.0 61.0 57.0   
070705_0    62.0 41.0    
140705   116.0 58.6     
210705   110.0  42.0 55.0   
040805 113.0 97.0 97.0    158.0 
120805   112.0 118.0     
250805          162 
MW 113.00 104.50 108.17 71.90 48.00 52.75 154.45 
SD 0.00 7.50 19.61 10.58 9.62 7.50 6.42 
n 1.00 2.00 7.00 5.00 6.00 4.00 4.00 
 
Phospho Beta catenin       
EGCG 0.1 0.5 1 10 25 50 SB21_ 10µM 
230605             29.0 
300605   115.0 83.0 21.0 36.0   
300605_1   127.0  78.0    
070705_0    66.0 28.0    
210705   98.6 81.8 49.0 25.0   
040805 67.0 96.3 81.0    21.0 
120805   84.0    28.3 
180805 73.0 90.0 70.0 78.0 72.0 34.9 26.0 
250805 81.0 141.0 118.0  41.0 28.0 38.0 
100905a 170.0     34.9   
100905b 156.0     34.1   
100905c 134.0       
              
MW 113.50 109.10 90.32 75.27 47.50 31.38 28.46 
SD 41.39 22.70 19.97 6.72 21.04 4.13 5.53 
n 6.00 3.00 7.00 4.00 6.00 6.00 5.00 
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 ▓ PAGE 18 ▓ 
Data to figure 38: Effect of quercetin and EGCG on nuclear β-catenin 
Quercetin [µM]     
 DMSO 1 10 25 50 
95.45   104.00 73.00 76.00 
13/10/2005 
104.55     
105.10 90.00 89.60 80.00 94.50 
01.12.2005 
94.90     
103.50 88.00 78.20 66.70  
08.12.2005 
96.50     
97.30 96.40 69.40 92.90 83.00 
15.12.2005 
102.70     
87.40 94.20 107.00 94.50 98.50 12.01.2006 
112.60     
MW 100.00 92.15 89.64 81.42 88.00 
SD 8.31 3.32 14.48 10.89 8.97 
 
EGCG [µM]        
 DMSO 0.1 1 10 25 50 SB216763 
109.20     114.00 115.00     
29/09/2005 
90.80        
90.80  108.50 101.00 125.00 47.00 156.50 
07/10/2005 
109.20        
79.00   94.40 98.00    
13/10/2005 
121.00        
93.40     43.40   13/10/2005 
106.60        
99.60 88.70 90.00 88.15   150.00 
20/10/2005 
100.40        
83.70    109.60    
20/10/2005 
116.30        
89.80 99.40 102.20 127.00     10/11/2005 
110.20        
87.30   132.00 78.90    10/11/2005 
112.70        
97.30  92.00 69.30 45.00  140.50 17/11/2005 
102.70        
81.10 77.00 95.30  52.90 46.00   17/11/2005 
118.90        
86.10 90.50 86.10 61.90 44.60 48.95 166.70 24/11/2005 
113.90        
108.40  80.25  42.30 44.20   24/11/2005 
91.60             
MW 100.00 88.90 93.48 98.47 79.03 45.91 153.43 
SD 12.29 7.98 8.85 23.71 31.76 1.98 9.55 
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 ▓ PAGE 19 ▓ 
Data to figure 39: Effect of EGCG and SB216763 on β-catenin transcripts 
Sample Detector Avg delta Ct 
delta Ct 
SD 
delta delta 
Ct RQ RQ Min RQ Max 
DMSO beta-catenin 3.0963905 0.0172983 0 1 0.975373 1.025249 
EGCG 1µM beta-catenin 3.4379334 0.0182923 0.34154296 0.789197 0.768267 0.810697 
EGCG 10µM beta-catenin 3.6277173 0.0204269 0.5313268 0.691918 0.671074 0.71341 
EGCG 
0.1µM beta-catenin 3.3458343 0.012753 0.24944377 0.841221 0.824566 0.858212 
EGCG 25µM beta-catenin 3.748485 0.0228702 0.6520946 0.636356 0.613513 0.660049 
SB21 10 µM beta-catenin 3.1901023 0.0231288 0.09371185 0.937109 0.902249 0.973315 
 
Data to figure 40: Effect of quercetin on β-catenin transcripts 
Sample Detector Avg delta Ct delta Ct SD
delta delta 
Ct RQ RQ Min RQ Max 
DMSO 1 % beta-catenin 1.852802 0.116724 0 1 0.710707 1.407051 
Quercetin 20 mM beta-catenin 1.974798 0.308844 0.121996 0.918915 0.372271 2.268254 
Quercetin 80 mM beta-catenin 2.216008 0.281081 0.363206 0.777435 0.341605 1.769313 
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 ▓ PAGE 20 ▓ 
8.7 Effect on GS 
Data to figure 41: Effect of EGCG and SB216763 on GS activity  
EGCG 25 µM       
Date 0.5h 1h 3h 6h 12h 24h 
              
            26.04.06 
          103.60 
            04.05.06 
          98.30 
            11.05.06 
      121.00 86.60   
            18.05.06 
    110.00   97.90   
            31.05.06 
    89.70 120.00 62.20 73.30 
97.00 70.00 104.00       13.06.06 
            
            08.08.06 
  80.00         
            09.08.06 
87.00 83.30         
            11.08.06 
103.00 87.00         
            15.08.06 
    87.20 111.00     
            16.08.06 
          102.00 
            17.08.06 
    107.00 119.00   82.00 
            22.08.06 
      146.00 71.80 100.00 
            24.08.06 
        90.30   
            06/12/2006 
  95.00         
            03/01/2007 
121.00           
            12/01/2007 
102.20 74.30         
MW 102.04 81.60 99.58 123.40 81.76 93.20 
SD 11.06 8.19 9.32 11.84 12.95 11.40 
n 5.00 6.00 5.00 5.00 5.00 6.00 
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 ▓ PAGE 21 ▓ 
SB216763 10µM      
Date 0.5h 1h 3h 6h 12h 24h 
              
        120.00   11.05.06 
            
            18.05.06 
  168.00 149.00   153.60   
            31.05.06 
      175.00 131.00   
            13.06.06 
199.00 137.00 148.00       
            08.08.06 
  297.00         
            09.08.06 
167.00 290.00         
            11.08.06 
148.00 147.00         
            15.08.06 
    228.00 229.00     
            17.08.06 
    225.00 225.00   132.00 
            22.08.06 
        175.00 138.00 
05/12/2006             
    144.00         
13/12/2006             
            157.00 
            03/01/2007 
208.00   144.00 257.00     
            07/01/2007 
          158.00 
            10/01/2007 
          123.00 
            12/01/2007 
    142.00   173.00   
MW 180.50 197.17 172.67 221.50 150.52 141.60 
SD 24.17 68.80 38.15 29.54 22.03 13.84 
n 4.00 6.00 6.00 4.00 5.00 5.00 
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 ▓ PAGE 22 ▓ 
Data to figure 42: Effect of EGCG and SB216763 on the phosphorylation of GS 
Phospho GS 15 min 
Date DMSO EGCG 25µM 
SB216763 
10 µM 
94.00     
10.11.2006_a 
106.00 87.00 46.00 
90.00     
15/11/2006 
110.00 135.90   
95.20     22/11/2006 
104.80 80.95   
83.00     
28/11/2006 
117.00 71.00 31.60 
82.00     
06/12/2006 
118.00 97.00 39.00 
98.00     
13/12/2005 
102.00 133.30   
90.00     16/01/2007 
110.00 130.00 34.00 
MW 100.00 105.02 37.65 
SD 11.19 25.36 5.51 
n 14.00 7.00 4.00  
Phospho GS 60min  
Date DMSO EGCG 25 µM 
SB216763 
10 µM 
        
92.00     10/11/2006 108.00 117.00 41.00 
93.00     16/11/2006 107.00 92.50 33.90 
83.00     22/11/2006 117.00 88.65 53.83 
71.80     28/11/2006 128.20 111.00 19.00 
78.00     06/12/2006 122.00   24.00 
99.00     13/12/2006 
101.00 95.00 48.00 
97.00     04/01/2007 
103.00   49.00 
79.00     16/01/2007 
121.00 92.00 28.00 
MW 100.00 99.36 37.09 
SD 16.33 10.66 11.98 
n 16.00 6.00 8.00  
 
Phospho GS 24h   
Date DMSO EGCG 1 µM EGCG 25 µM SB216763 10 µM 
98.40       16/11/2006 
101.60   108.20 39.10 
83.00       22/11/2006 
117.00 105.00 128.00 38.50 
94.00       29/11/2006 
106.00   111.00 46.60 
100.00       07/12/2006 
100.00 124.00   41.00 
94.00       14/12/2006 
106.00 115.00 102.00 55.00 
89.00       10/01/2007 
111.00 116.00 100.00 40.00 
68.00       11/01/2007 
132.00 108.00 123.00 51.00 
MW 100.00 113.60 112.03 44.46 
SD 14.68 6.65 10.30 6.03 
n 14.00 5.00 6.00 7.00 
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 ▓ PAGE 23 ▓ 
Data to figure 43: Effect of EGCG and SB216763 on total GS 
Date DMSO EGCG 1 µM EGCG 25 µM SB216763 10 µM 
88.00       07/12/2006 
112.00 119.00 138.00 383.00 
94.00       14/12/2006 
106.00 140.00 156.00 345.00 
93.00       10/01/2007 
107.00 142.00 152.00 240.00 
81.00       11/01/2007 
119.00 75.00     
85.00       17/01/2007 
115.00     234.00 
94.00      20/01/2007 
106.00 84.00 139.00 337.00 
91.00       24/01/2007 
109.00 135.00 151.00 403.00 
MW 100.00 115.83 147.20 323.67 
SD 11.54 26.85 7.30 65.18 
n 14.00 6.00 5.00 6.00 
 
Data to figure 44A: Effect of EGCG and SB216763 on LGS transcripts 
LGS (6h)        
Sample Detector 
Avg delta 
Ct delta Ct SD
delta  
delta Ct RQ RQ Min RQ Max 
EGCG 1µM liverGS 14.51568 0.4716113 0.1793375 0.8831084 0.1850427 4.214598 
EGCG 10µM liverGS 15.812203 0.18751161 1.4758606 0.3595189 0.1980647 0.6525839
 
LGS (24h)        
Sample Detector 
Avg delta 
Ct delta Ct SD 
delta 
delta Ct RQ RQ Min RQ Max
DMSO control liverGS 15.31534 0.12463336 0 1 0.826842 1.209421
EGCG 10 µM liverGS 15.29578 0.11573198 -0.01955 1.013644 0.849583 1.209387
EGCG 25 µM liverGS 15.47835 0.10359465 0.16301 0.89316 0.76259 1.046085
SB216763 10 µM liverGS 14.35601 0.06322499 -0.95932 1.9444 1.765611 2.141293
EGCG 1 µM liverGS 15.11299 0.19766417   0.890139 0.484668 1.634822
NTC liverGS             
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 ▓ PAGE 24 ▓ 
Data to figure 44B: Effect of EGCG and SB216763 on MGS transcripts 
MGS (6h)        
Sample Detector 
Avg 
delta Ct delta Ct SD 
delta delta 
Ct RQ RQ Min RQ Max 
EGCG 1µM muscleGS 5.503043 0.04700203 0.313826 0.804506 0.696226 0.929625 
EGCG 10µM muscleGS 6.488787 0.037180193 1.29957 0.406247 0.362352 0.45546 
 
MGS (24h)        
Sample Detector 
Avg delta 
Ct delta Ct SD 
delta delta 
Ct RQ RQ Min RQ Max 
DMSO control muscleGS 5.2078996 0.032014396 0 1 0.9523322 1.0500537
EGCG 10 µM muscleGS 5.5052667 0.046053227 0.2973671 0.8137361 0.758526 0.8729648
EGCG 25 µM muscleGS 5.5598145 0.01791002 0.3519149 0.7835434 0.762424 0.8052478
SB216763 10 µM muscleGS 5.315325 0.01680099 0.1074252 0.9282432 0.9047531 0.9523432
EGCG 1 µM muscleGS 5.5817127 0.024860997 0.3738132 0.77174 0.7409253 0.8038364
 
Data to figure 45: Effect of quercetin on MGS transcripts 
LGS (6h)        
Sample Detector 
Avg delta 
Ct delta Ct SD 
delta delta 
Ct RQ RQ Min RQ Max 
Quercetin 20µM liverGS 14.134944 0.124662295 -0.2013989 1.1498127 0.7836465 1.6870735
Quercetin 80µM liverGS 13.736491 0.16853501 -0.5998516 1.5155606 0.9025416 2.544951 
 
MGS (6h)        
Sample Detector 
Avg delta 
Ct delta Ct SD 
delta delta 
Ct RQ RQ Min RQ Max 
Quercetin 20µM muscleGS 5.8334765 0.01467803 0.6442595 0.6398211 0.6115806 0.6693658
Quercetin 80µM muscleGS 6.4878325 0.02164198 1.2986155 0.4065161 0.3803395 0.4344944
 
LGS (24h)        
Sample Detector 
Avg delta 
Ct delta Ct SD 
delta delta 
Ct RQ RQ Min RQ Max 
Quercetin 20µM liverGS 15.215787 0.20352077 0.27069092 0.8289225 0.4340042 1.5831932
Quercetin 80µM liverGS 15.166507 0.149226 0.22141075 0.8577263 0.542042 1.3572644
 
MGS (24h)        
Sample Detector 
Avg delta 
Ct delta Ct SD 
delta delta 
Ct RQ RQ Min RQ Max 
Quercetin 20µM muscleGS 4.8368206 0.019563992
-
0.113061905 1.0815212 1.0183666 1.1485924
Quercetin 80µM muscleGS 5.414919 0.025599128 0.4650364 0.7244528 0.6696044 0.783794 
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 ▓ PAGE 25 ▓ 
Data to figure 46A: Effect of EGCG on MGS and LGS transcripts in HepG2 cells 
MGS (6h)        
Sample Detector 
Avg delta 
Ct delta Ct SD 
delta delta 
Ct RQ RQ Min RQ Max 
EGCG 1 µM muscleGS 6.327994 0.018181192 0.08902645 0.9401569 0.88903 0.9942242
EGCG 10 µM muscleGS 6.2068596 0.025802257 -0.03210783 1.0225049 0.9445007 1.1069514
        
LGS (6h)        
Sample Detector 
Avg delta 
Ct delta Ct SD 
delta delta 
Ct RQ RQ Min RQ Max 
EGCG 1 µM liverGS 13.80549 0.20075868 -0.29340744 1.2255313 0.6076539 2.471682 
EGCG 10 µM liverGS 14.021217 0.11866881 
-
0.077679634 1.0553193 0.7326259 1.5201467
 
MGS (24h)        
Sample Detector 
Avg delta 
Ct delta Ct SD 
delta delta 
Ct RQ RQ Min RQ Max 
EGCG 1 µM muscleGS 4.9944453 0.01665157 -0.4066887 1.3256397 1.2594606 1.3952961
EGCG 10 µM muscleGS 5.2582855 0.031757414 -0.1428485 1.104083 1.0013467 1.2173597
        
LGS (24h)        
Sample Detector 
Avg delta 
Ct delta Ct SD 
delta delta 
Ct RQ RQ Min RQ Max 
EGCG 1 µM liverGS 14.298144 0.25228915 -0.441968 1.3584561 0.588778 3.1342938
EGCG 10 µM liverGS 15.831564 0.19103956 1.0914516 0.46928895 0.2491705 0.8838612
 
Data to figure 46B: Effect of quercetin on MGS and LGS transcripts in HepG2 cells 
MGS (6h)        
Sample Detector 
Avg delta 
Ct delta Ct SD 
delta delta 
Ct RQ RQ Min RQ Max 
Quercetin 20 µM muscleGS 6.3117623 0.02093278 0.072794914 0.9507943 0.8915124 1.014018 
Quercetin 80 µM muscleGS 6.002098 0.022734378 -0.23686934 1.1784327 1.0988523 1.2637764
 
LGS (6h)        
Sample Detector 
Avg delta 
Ct delta Ct SD 
delta delta 
Ct RQ RQ Min RQ Max 
Quercetin 20 µM liverGS 14.218636 0.13220057 0.11973858 0.9203544 0.6128858 1.3820717
Quercetin 80 µM liverGS 14.376901 0.2432388 0.2780037 0.8247314 0.3805837 1.7872072
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 ▓ PAGE 26 ▓ 
MGS (24h)        
Sample Detector 
Avg delta 
Ct delta Ct SD 
delta delta 
Ct RQ RQ Min RQ Max 
Quercetin 20 µM muscleGS 5.581742 0.017435957 0.1806078 0.8823312 0.8362634 0.9309368
Quercetin 80 µM muscleGS 5.5280385 0.028761463 0.1269045 0.9157943 0.8382669 1.000492 
LGS (24h)        
Sample Detector 
Avg delta 
Ct delta Ct SD 
delta delta 
Ct RQ RQ Min RQ Max 
Quercetin 20 µM liverGS 16.65366 0.15158142 1.9135475 0.26543903 0.1562886 0.4508192
Quercetin 80 µM liverGS 13.183871 0.13352957 -1.556241 2.940866 1.9235283 4.4962645
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 ▓ PAGE 27 ▓ 
8.8 Effect on GP 
Data to figure 48: Effect of EGCG and SB216763 on GP activity 
EGCG 25 µM       
Date 0.5h 1h 3h 6h 12h 24h 
26.04.06           112.90 
04.05.06           77.90 
09.05.06 105.50     92.20 80.80   
17.05.06 105.20   93.30 86.90 93.90   
31.05.06     95.70 93.10 84.10 72.30 
27.06.06   116.00         
09.08.06   110.00         
19/09/2006 102.00 111.00 85.60       
01/11/2006           93.00 
03/11/2006           95.10 
08/11/2006           81.20 
10/11/2006           107.10 
15/11/2006           105.10 
22/11/2006 115.70   102.00 99.10   102.10 
MW 107.10 112.33 94.15 92.83 86.27 94.08 
SD 5.15 2.62 5.87 4.33 5.56 13.39 
n 4.00 3.00 4.00 4.00 3.00 9.00 
p 0.032787889 3.17618E-06 0.062614582 0.002175667 0.001729753 0.172773407
 
SB216763 10µM      
Date 0.5h 1h 3h 6h 12h 24h 
              
26.04.06           66.20 
04.05.06           88.80 
09.05.06       100.60 75.90   
17.05.06 106.40 106.00   75.10 103.80   
23.05.06 105.80 111.00 162.00 73.00     
31.05.06     102.90 87.00 83.00 91.60 
13.06.06   103.60 103.00       
20.06.06     148.00       
09.08.06 97.20 115.00         
19/09/2006 97.50 125.00         
01/11/2006           89.00 
22/11/2006   104.00         
MW 101.73 110.77 128.98 83.93 87.57 83.90 
SD 4.38 7.53 26.49 11.01 11.84 10.28 
n 4.00 6.00 4.00 4.00 3.00 4.00 
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Data to figure 49: Effect of EGCG and SB216763 on total GP 
GP 24h    
Date DMSO EGCG 1 µM EGCG 25 µM SB216763 10 µM 
91.30       16/11/2006 
108.70 121.45 113.50 100.50 
85.00       22/11/2006 
115.00   109.00 102.00 
64.00       29/11/2006 
136.00   81.00 115.00 
92.00       07/12/2006 
108.00 95.00 92.00 49.00 
60.00       04/01/2007 
140.00 108.00 54.00 92.00 
94.00       10/01/2007 
106.00 116.00 67.00 79.00 
35.00       11/01/2007 
165.00   96.00 47.00 
71.00       17/01/2007 
129.00   67.00 91.00 
96.00       20/01/2007 
104.00 133.00 110.00 77.70 
87.00       24/11/2007 
113.00 99.00 71.00 72.00 
MW 100.00 112.08 86.05 82.52 
SD 29.24 13.04 19.98 21.10 
n 20.00 6.00 10.00 10.00 
 
Data to figure 50B: Effect of EGCG on the transcripts of GP after 6h in HT29 cells 
BGP (6h)        
Sample Detector 
Avg delta 
Ct 
delta Ct 
SD 
delta delta 
Ct RQ RQ Min RQ Max 
DMSO brainGP 1.5282803 0.0420414 0 1 0.8541997 1.1706865
EGCG 1 µM brainGP 2.3345928 0.0142396 0.8063126 0.5718416 0.542119 0.6031938
EGCG 10 µM brainGP 2.4744892 0.0236198 0.946209 0.5189945 0.4750193 0.5670407
        
LGP (6h)        
Sample Detector 
Avg delta 
Ct 
delta Ct 
SD 
delta delta 
Ct RQ RQ Min RQ Max 
DMSO liverGP 5.684272 0.0598348 0 1 0.7990847 1.2514318
EGCG 1 µM liverGP 7.1598024 0.0727285 1.4755306 0.3596011 0.2737939 0.4723004
EGCG 10 µM liverGP 7.0273266 0.0448489 1.3430548 0.3941851 0.3331878 0.4663494
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Data to figure 50B: Effect of EGCG on the transcripts of GP after 24h in HT29 cells 
BGP (24h)        
Sample Detector Avg delta Ct delta Ct SD 
delta delta 
Ct RQ RQ Min RQ Max
DMSO brainGP 0.24593163 0.0347421 0 1 0.948377 1.054433
EGCG 10 µM brainGP 0.4859403 0.04648693 0.240009 0.84674 0.788769 0.908972
EGCG 25 µM brainGP 1.864591 0.014152023 1.618659 0.325638 0.318683 0.332745
SB216763 10 
µM brainGP 0.88783455 0.017612927 0.641903 0.640867 0.623876 0.658321
EGCG 1 µM brainGP 0.69029236 0.02696105 0.444361 0.73491 0.703141 0.768114
        
LGP (24h)        
Sample Detector Avg delta Ct delta Ct SD 
delta delta 
Ct RQ RQ Min RQ Max
DMSO control liverGP 5.6536994 0.04055208 0 1 0.940008 1.06382 
EGCG 10 µM liverGP 6.104302 0.055873822 0.450603 0.731737 0.671947 0.796847
EGCG 25 µM liverGP 5.169576 0.047945168 -0.48412 1.398736 1.300077 1.504881
SB216763 10 
µM liverGP 5.8124065 0.027000958 0.158707 0.895828 0.859676 0.9335 
EGCG 1 µM liverGP 6.1441517 0.042199347 0.490452 0.711802 0.664233 0.762777
        
MGP (24h)        
Sample Detector Avg delta Ct delta Ct SD 
delta delta 
Ct RQ RQ Min RQ Max
DMSO control muscleGP 13.826332 0.05944484 0 1 0.913301 1.094929
EGCG 10 µM muscleGP 13.610616 0.047892448 -0.21572 1.16128 1.079457 1.249306
EGCG 25 µM muscleGP 13.133941 0.026678054 -0.69239 1.61596 1.551511 1.683087
SB216763 10 
µM muscleGP 12.81324 0.03194128 -1.01309 2.018232 1.922242 2.119016
 
Data to figure 51: Effect of quercetin on the transcripts of GP in HT29 cells after 6h and 
24h 
BGP (6h)        
Sample Detector 
Avg delta 
Ct 
delta Ct 
SD 
delta delta 
Ct RQ RQ Min RQ Max 
DMSO brainGP 1.5282803 0.0420414 0 1 0.8541997 1.1706865
Quercetin 20 µM brainGP 2.0272703 0.0145153 0.4989901 0.707602 0.6701299 0.7471694
Quercetin 80 µM brainGP 2.1276217 0.0318624 0.5993414 0.6600552 0.5857474 0.7437896
        
LGP (6h)        
Sample Detector 
Avg delta 
Ct 
delta Ct 
SD 
delta delta 
Ct RQ RQ Min RQ Max 
DMSO liverGP 5.684272 0.0598348 0 1 0.7990847 1.2514318
Quercetin 20 µM liverGP 6.376072 0.0520099 0.6918001 0.6190809 0.5094232 0.7523434
Quercetin 80 µM liverGP 6.454685 0.0700565 0.7704134 0.5862495 0.4508531 0.7623069
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BGP (24h)        
Sample Detector 
Avg delta 
Ct 
delta Ct 
SD 
delta delta 
Ct RQ RQ Min RQ Max 
DMSO brainGP -0.6399727 0.1042912 0 1 0.7256079 1.3781548
Quercetin 20 µM brainGP -0.35392252 0.0212563 0.2860502 0.8201444 0.7682437 0.8755513
Quercetin 80 µM brainGP 0.68417484 0.0256467 1.3241475 0.3993851 0.3690937 0.4321626
        
LGP (24h)        
Sample Detector 
Avg delta 
Ct 
delta Ct 
SD 
delta delta 
Ct RQ RQ Min RQ Max 
DMSO liverGP 4.2677255 0.0856001 0 1 0.768541 1.3011668
Quercetin 20 µM liverGP 4.5688796 0.0333818 0.3011541 0.8116029 0.7324143 0.8993534
Quercetin 80 µM liverGP 4.9842224 0.0769121 0.7164969 0.6085733 0.4803793 0.7709774
 
Data to figure 52A: Effect of EGCG transcripts of GP after 6h and 24h in HepG2 cells 
BGP (6h)        
Sample Detector Avg delta Ct
delta Ct 
SD 
delta delta 
Ct RQ RQ Min RQ Max 
EGCG 1 µM brainGP 3.6636543 0.0138274 0.1404636 0.9072276 0.8694557 0.9466404
EGCG 10 µM brainGP 3.9738548 0.021393 0.450664 0.731706 0.6851138 0.7814667
        
LGP (6h)        
Sample Detector Avg delta Ct
delta Ct 
SD 
delta delta 
Ct RQ RQ Min RQ Max 
EGCG 1 µM liverGP 3.7452633 0.0436748 0.3037255 0.8101576 0.7083284 0.9266259
EGCG 10 µM liverGP 3.997619 0.0547063 0.5560811 0.6801472 0.5748224 0.8047707
 
BGP (24h)        
Sample Detector Avg delta Ct
delta Ct 
SD 
delta delta 
Ct RQ RQ Min RQ Max 
EGCG 1 µM brainGP 5.1508718 0.0207906 0.0103531 0.9928495 0.9313527 1.0584068
EGCG 10 µM brainGP 5.1525016 0.0145723 0.0119829 0.9917285 0.9482635 1.0371858
        
LGP (24h)        
Sample Detector Avg delta Ct
delta Ct 
SD 
delta delta 
Ct RQ RQ Min RQ Max 
EGCG 1 µM liverGP 4.5118995 0.059023 -0.0086336 1.0060023 0.8390042 1.2062403
EGCG 10 µM liverGP 4.889883 0.0422467 0.36935 0.7741312 0.6798095 0.8815399
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Data to figure 52B: Effect of quercetin transcripts of GP after 6h and 24h in HepG2 cells 
BGP (6h)        
Sample Detector 
Avg delta 
Ct 
delta Ct 
SD 
delta delta 
Ct RQ RQ Min RQ Max 
Quercetin 20 µM brainGP 3.6179874 0.0192113 0.0947967 0.9364042 0.8826805 0.9933978
Quercetin 80 µM brainGP 3.9213207 0.013254 0.3981299 0.7588413 0.7285311 0.7904125
        
LGP (6h)        
Sample Detector 
Avg delta 
Ct 
delta Ct 
SD 
delta delta 
Ct RQ RQ Min RQ Max 
Quercetin 20 µM liverGP 3.745807 0.0620275 0.3042691 0.8098524 0.6692033 0.9800624
Quercetin 80 µM liverGP 4.159971 0.0343441 0.7184334 0.607757 0.546837 0.6754639
 
BGP (24h)        
Sample Detector Avg delta Ct
delta Ct 
SD 
delta delta 
Ct RQ RQ Min RQ Max 
Quercetin 20 µM brainGP 5.1762433 0.0170076 0.0357246 0.9755417 0.9258259 1.027927 
Quercetin 80 µM brainGP 4.909824 0.0417644 -0.2306948 1.1733999 1.0319599 1.3342255
        
LGP (24h)        
Sample Detector Avg delta Ct
delta Ct 
SD 
delta delta 
Ct RQ RQ Min RQ Max 
Quercetin 20 µM liverGP 5.0131946 0.0528406 0.4926615 0.7107128 0.6041112 0.8361253
Quercetin 80 µM liverGP 6.0932884 0.0690807 1.5727553 0.3361658 0.2718222 0.4157402
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8.9 Effect on cellular Glycogen  
Data to figure 53: Effect of EGCG and SB216763 on total GS 
DMSO       
Date 0.5h 1h 3h 6h 12h 24h 
              
          97.80 27.04.06 
          102.20 
  99.65   95.00 87.13   11.05.06 
  100.35   105.00 112.87   
  85.00 90.00 95.00 112.00   18.05.06 
  115.00 110.00 105.00 88.00   
95.00 95.00 94.00       24.05.06 
105.00 105.00 106.00       
97.00 99.00 99.00 99.30 95.00 97.00 01.06.06 
103.00 101.00 101.00 100.70 105.00 103.00 
98.70 99.10 99.70 98.50   99.70 14.06.06 
102.30 100.90 100.30 101.50   100.30 
  92.00         21.06.06 
  108.00         
98.10 95.00         28.06.06 
100.90 105.00         
MW 100.00 100.00 100.00 100.00 100.00 100.00 
SD 3.15 6.98 5.85 3.63 10.56 2.15 
n 8.00 14.00 8.00 8.00 6.00 6.00 
 
EGCG 25 µM      
Date 0.5h 1h 3h 6h 12h 24h 
              
          47.40 27.04.06 
            
          67.30 05.05.06 
            
            11.05.06 
  94.10   94.90 79.70   
            18.05.06 
    88.50 72.00 81.60   
            01.06.06 
105.00 112.00 113.00 96.70 72.90 68.70 
            14.06.06 
98.50 82.00 91.10 115.00   85.50 
            21.06.06 
  108.00         
            28.06.06 
92.40 124.00         
MW 98.63 104.02 97.53 94.65 78.07 67.23 
SD 5.14 14.57 10.99 15.26 3.73 13.50 
n 3.00 5.00 3.00 4.00 3.00 4.00 
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SB216763 10µM      
Date 0.5h 1h 3h 6h 12h 24h 
              
            27.04.06 
          456.50 
            05.05.06 
          453.00 
      151.50 218.10   11.05.06 
            
  109.00 146.00 169.50 264.80   18.05.06 
            
112.80 109.20 174.00       24.05.06 
            
            01.06.06 
105.00 128.00 134.00   241.00 387.00 
            14.06.06 
106.00   159.00 214.00     
MW 107.93 115.40 153.25 178.33 241.30 432.17 
SD 3.47 8.91 14.89 26.27 19.07 31.97 
n 3.00 3.00 4.00 3.00 3.00 3.00 
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8.12 Formulae 
y-axis intercept   
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Square sum of error (S):   ( )∑
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Standard deviation ( )1−nσ :  ∑
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Nalimov outlier:   
11
*
−⋅
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nxxr
nσ       : Testvalue 
*x
Outlier criteria :x* = outlier when r >  1.409 at n = 3 
1.645 bei n = 4 
1.757 bei n = 5 
1.814 bei n = 6 
1.848 bei n = 7 
1.870 bei n = 8 
 
Comparative Ct method: 2–[delta][delta]Ct 
[delta][delta]Ct = [delta]Ct of sample - [delta]Ct of reference 
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